{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/olonok69/LLM_Notebooks/blob/main/langchain/langgraph/LangGraph_research_automation.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "e0a5763f-5f45-4b8f-b3e2-480f46c5721b",
      "metadata": {
        "id": "e0a5763f-5f45-4b8f-b3e2-480f46c5721b"
      },
      "source": [
        "# Research Assistant\n",
        "\n",
        "## Topics\n",
        "\n",
        "* Memory\n",
        "* Human-in-the-loop\n",
        "* Controllability\n",
        "\n",
        "### research automation.\n",
        "\n",
        "Research is often laborious work offloaded to analysts. AI has considerable potential to assist with this.\n",
        "\n",
        "However, research demands customization: raw LLM outputs are often poorly suited for real-world decision-making workflows.\n",
        "\n",
        "Customized, AI-based [research and report generation](https://jxnl.co/writing/2024/06/05/predictions-for-the-future-of-rag/#reports-over-rag) workflows are a promising way to address this.\n",
        "\n",
        "## Goal\n",
        "\n",
        "Our goal is to build a lightweight, multi-agent system around chat models that customizes the research process.\n",
        "\n",
        "`Source Selection`\n",
        "* Users can choose any set of input sources for their research.\n",
        "  \n",
        "`Planning`\n",
        "* Users provide a topic, and the system generates a team of AI analysts, each focusing on one sub-topic.\n",
        "* `Human-in-the-loop` will be used to refine these sub-topics before research begins.\n",
        "  \n",
        "`LLM Utilization`\n",
        "* Each analyst will conduct in-depth interviews with an expert AI using the selected sources.\n",
        "* The interview will be a multi-turn conversation to extract detailed insights as shown in the [STORM](https://github.com/langchain-ai/langgraph/blob/main/docs/docs/tutorials/storm/storm.ipynb) paper.\n",
        "* These interviews will be captured in a using `sub-graphs` with their internal state.\n",
        "   \n",
        "`Research Process`\n",
        "* Experts will gather information to answer analyst questions in `parallel`.\n",
        "* And all interviews will be conducted simultaneously through `map-reduce`.\n",
        "\n",
        "`Output Format`\n",
        "* The gathered insights from each interview will be synthesized into a final report.\n",
        "* We'll use customizable prompts for the report, allowing for a flexible output format.\n",
        "\n",
        "![Screenshot 2024-08-26 at 7.26.33 PM.png](https://cdn.prod.website-files.com/65b8cd72835ceeacd4449a53/66dbb164d61c93d48e604091_research-assistant1.png)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "f23991e9-51b3-4e9f-86a0-dec16aa7d1e6",
      "metadata": {
        "scrolled": true,
        "id": "f23991e9-51b3-4e9f-86a0-dec16aa7d1e6"
      },
      "outputs": [],
      "source": [
        "%%capture --no-stderr\n",
        "%pip install --quiet -U langgraph langchain_openai langchain_community langchain_core tavily-python wikipedia langchain-google-genai google-cloud-aiplatform"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install semanticscholar  xmltodict -q"
      ],
      "metadata": {
        "id": "Gd4eUKg6POo_"
      },
      "id": "Gd4eUKg6POo_",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "id": "99a1c01d-87e1-4723-b83e-ebcf937fe914",
      "metadata": {
        "id": "99a1c01d-87e1-4723-b83e-ebcf937fe914"
      },
      "source": [
        "## Setup"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "ba917800-10e4-4e2a-8e9e-30893b731e97",
      "metadata": {
        "id": "ba917800-10e4-4e2a-8e9e-30893b731e97"
      },
      "outputs": [],
      "source": [
        "import os, getpass\n",
        "from google.colab import userdata\n",
        "def _set_env(var: str):\n",
        "    if not os.environ.get(var):\n",
        "        os.environ[var] = getpass.getpass(f\"{var}: \")\n",
        "\n",
        "#_set_env(\"OPENAI_API_KEY\")"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "if \"GEMINI_API_KEY\" not in os.environ:\n",
        "    os.environ[\"GEMINI_API_KEY\"] = userdata.get('GEMINI_API_KEY')\n",
        "if \"OPENAI_API_KEY\" not in os.environ:\n",
        "    os.environ[\"OPENAI_API_KEY\"] = userdata.get('KEY_OPENAI')"
      ],
      "metadata": {
        "id": "SeTMeE0j1Yl1"
      },
      "id": "SeTMeE0j1Yl1",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "afe9ff57-0826-4669-b88b-4d0501a509f5",
      "metadata": {
        "id": "afe9ff57-0826-4669-b88b-4d0501a509f5"
      },
      "outputs": [],
      "source": [
        "from langchain_openai import ChatOpenAI\n",
        "llm = ChatOpenAI(model=\"gpt-4o\", temperature=0, max_completion_tokens=8092)"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain_google_genai import ChatGoogleGenerativeAI, GoogleGenerativeAIEmbeddings"
      ],
      "metadata": {
        "id": "Ck2Hm9sc17vK"
      },
      "id": "Ck2Hm9sc17vK",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "#llm = ChatGoogleGenerativeAI(model=\"gemini-1.5-flash-002\")"
      ],
      "metadata": {
        "id": "dfDropQx2EzB"
      },
      "id": "dfDropQx2EzB",
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "id": "3419257b-2c6b-4d68-ae38-4a266cc02982",
      "metadata": {
        "id": "3419257b-2c6b-4d68-ae38-4a266cc02982"
      },
      "source": [
        "We'll use [LangSmith](https://docs.smith.langchain.com/) for [tracing](https://docs.smith.langchain.com/concepts/tracing)."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "5102cf2e-0ca9-465b-9499-67abb8132e5d",
      "metadata": {
        "id": "5102cf2e-0ca9-465b-9499-67abb8132e5d"
      },
      "outputs": [],
      "source": [
        "#_set_env(\"LANGCHAIN_API_KEY\")\n",
        "if \"LANGCHAIN_API_KEY\" not in os.environ:\n",
        "    os.environ[\"LANGCHAIN_API_KEY\"] = userdata.get('LANGCHAIN_API_KEY')\n",
        "os.environ[\"LANGCHAIN_TRACING_V2\"] = \"true\"\n",
        "os.environ[\"LANGCHAIN_PROJECT\"] = \"langchain-research\""
      ]
    },
    {
      "cell_type": "markdown",
      "id": "f8fe5d93-e353-44bb-be3e-434654bcb7ea",
      "metadata": {
        "id": "f8fe5d93-e353-44bb-be3e-434654bcb7ea"
      },
      "source": [
        "## Generate Analysts: Human-In-The-Loop\n",
        "\n",
        "A single shared state makes the process easier to observe, interrupt and modify. Which is very important for complex LLM applications, where some amount of human supervision/approval/editing can be the difference between a toy and a deployment useful in the real world\n",
        "\n",
        "Create analysts and review them using human-in-the-loop.\n",
        "\n",
        "https://blog.langchain.dev/human-in-the-loop-with-opengpts-and-langgraph/\n",
        "\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "1eee8e60-e548-49b1-88ec-a4f3aef2174e",
      "metadata": {
        "id": "1eee8e60-e548-49b1-88ec-a4f3aef2174e"
      },
      "outputs": [],
      "source": [
        "from typing import List\n",
        "from typing_extensions import TypedDict\n",
        "from pydantic import BaseModel, Field\n",
        "\n",
        "class Analyst(BaseModel):\n",
        "    affiliation: str = Field(\n",
        "        description=\"Primary affiliation of the analyst.\",\n",
        "    )\n",
        "    name: str = Field(\n",
        "        description=\"Name of the analyst.\"\n",
        "    )\n",
        "    role: str = Field(\n",
        "        description=\"Role of the analyst in the context of the topic.\",\n",
        "    )\n",
        "    description: str = Field(\n",
        "        description=\"Description of the analyst focus, concerns, and motives.\",\n",
        "    )\n",
        "    @property\n",
        "    def persona(self) -> str:\n",
        "        return f\"Name: {self.name}\\nRole: {self.role}\\nAffiliation: {self.affiliation}\\nDescription: {self.description}\\n\"\n",
        "\n",
        "class Perspectives(BaseModel):\n",
        "    analysts: List[Analyst] = Field(\n",
        "        description=\"Comprehensive list of analysts with their roles and affiliations.\",\n",
        "    )\n",
        "\n",
        "class GenerateAnalystsState(TypedDict):\n",
        "    topic: str # Research topic\n",
        "    max_analysts: int # Number of analysts\n",
        "    human_analyst_feedback: str # Human feedback\n",
        "    analysts: List[Analyst] # Analyst asking questions"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 62,
      "id": "fd088ff5-4c75-412c-85f0-04afd0900bfc",
      "metadata": {
        "id": "fd088ff5-4c75-412c-85f0-04afd0900bfc",
        "outputId": "7e02ca53-40ee-425c-b0c4-4ed2885d2e7d",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 392
        }
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "image/png": "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\n",
            "text/plain": [
              "<IPython.core.display.Image object>"
            ]
          },
          "metadata": {}
        }
      ],
      "source": [
        "from IPython.display import Image, display\n",
        "from langgraph.graph import START, END, StateGraph\n",
        "from langgraph.checkpoint.memory import MemorySaver\n",
        "from langchain_core.messages import AIMessage, HumanMessage, SystemMessage\n",
        "\n",
        "analyst_instructions=\"\"\"You are tasked with creating a set of AI analyst personas. Follow these instructions carefully:\n",
        "\n",
        "1. First, review the research topic:\n",
        "{topic}\n",
        "\n",
        "2. Examine any editorial feedback that has been optionally provided to guide creation of the analysts:\n",
        "\n",
        "{human_analyst_feedback}\n",
        "\n",
        "3. Determine the most interesting themes based upon documents and / or feedback above.\n",
        "\n",
        "4. Pick the top {max_analysts} themes.\n",
        "\n",
        "5. Assign one analyst to each theme.\"\"\"\n",
        "\n",
        "def create_analysts(state: GenerateAnalystsState):\n",
        "\n",
        "    \"\"\" Create analysts \"\"\"\n",
        "\n",
        "    topic=state['topic']\n",
        "    max_analysts=state['max_analysts']\n",
        "    human_analyst_feedback=state.get('human_analyst_feedback', '')\n",
        "\n",
        "    # Enforce structured output\n",
        "    structured_llm = llm.with_structured_output(Perspectives)\n",
        "\n",
        "    # System message\n",
        "    system_message = analyst_instructions.format(topic=topic,\n",
        "                                                            human_analyst_feedback=human_analyst_feedback,\n",
        "                                                            max_analysts=max_analysts)\n",
        "\n",
        "    # Generate question\n",
        "    analysts = structured_llm.invoke([SystemMessage(content=system_message)]+[HumanMessage(content=\"Generate the set of analysts.\")])\n",
        "\n",
        "    # Write the list of analysis to state\n",
        "    return {\"analysts\": analysts.analysts}\n",
        "\n",
        "def human_feedback(state: GenerateAnalystsState):\n",
        "    \"\"\" No-op node that should be interrupted on \"\"\"\n",
        "    pass\n",
        "\n",
        "def should_continue(state: GenerateAnalystsState):\n",
        "    \"\"\" Return the next node to execute \"\"\"\n",
        "\n",
        "    # Check if human feedback\n",
        "    human_analyst_feedback=state.get('human_analyst_feedback', None)\n",
        "    if human_analyst_feedback:\n",
        "        return \"create_analysts\"\n",
        "\n",
        "    # Otherwise end\n",
        "    return END\n",
        "\n",
        "# Add nodes and edges\n",
        "builder = StateGraph(GenerateAnalystsState)\n",
        "builder.add_node(\"create_analysts\", create_analysts)\n",
        "builder.add_node(\"human_feedback\", human_feedback)\n",
        "builder.add_edge(START, \"create_analysts\")\n",
        "builder.add_edge(\"create_analysts\", \"human_feedback\")\n",
        "builder.add_conditional_edges(\"human_feedback\", should_continue, [\"create_analysts\", END])\n",
        "\n",
        "# Compile\n",
        "memory = MemorySaver()\n",
        "graph = builder.compile(interrupt_before=['human_feedback'], checkpointer=memory)\n",
        "\n",
        "# View\n",
        "display(Image(graph.get_graph(xray=1).draw_mermaid_png()))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 63,
      "id": "6c22cb05-c436-4358-8f7a-72d722f9b5cc",
      "metadata": {
        "id": "6c22cb05-c436-4358-8f7a-72d722f9b5cc",
        "outputId": "3cbb5f30-7ae6-41ea-df6d-d7a423c01530",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Name: Dr. Emily Carter\n",
            "Affiliation: Children's Rare Disease Research Institute\n",
            "Role: Pediatric Geneticist\n",
            "Description: Dr. Carter focuses on the genetic underpinnings of rare diseases in children. Her primary concern is identifying genetic markers that can lead to early diagnosis and potential treatment options. She is motivated by the potential to improve patient outcomes through personalized medicine and genetic counseling.\n",
            "--------------------------------------------------\n",
            "Name: Mr. John Thompson\n",
            "Affiliation: National Health Policy Center\n",
            "Role: Health Policy Analyst\n",
            "Description: Mr. Thompson analyzes the impact of health policies on the availability and accessibility of treatments for rare diseases in children. His focus is on advocating for policy changes that increase funding for research and support for affected families. He is driven by the need to address disparities in healthcare access and ensure equitable treatment options for all children.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Aisha Khan\n",
            "Affiliation: Global Pediatric Health Organization\n",
            "Role: Epidemiologist\n",
            "Description: Dr. Khan studies the prevalence and distribution of rare diseases in children globally. Her work involves identifying patterns and potential environmental or socio-economic factors contributing to these diseases. She aims to inform public health strategies and interventions that can mitigate the impact of rare diseases on children worldwide.\n",
            "--------------------------------------------------\n"
          ]
        }
      ],
      "source": [
        "# Input\n",
        "max_analysts = 3\n",
        "topic = \"Rare diseases in children\"#\"Prevention of cardiovascular conditions\"\n",
        "thread = {\"configurable\": {\"thread_id\": \"1\"}}\n",
        "\n",
        "# Run the graph until the first interruption\n",
        "for event in graph.stream({\"topic\":topic,\"max_analysts\":max_analysts,}, thread, stream_mode=\"values\"):\n",
        "    # Review\n",
        "    analysts = event.get('analysts', '')\n",
        "    if analysts:\n",
        "        for analyst in analysts:\n",
        "            print(f\"Name: {analyst.name}\")\n",
        "            print(f\"Affiliation: {analyst.affiliation}\")\n",
        "            print(f\"Role: {analyst.role}\")\n",
        "            print(f\"Description: {analyst.description}\")\n",
        "            print(\"-\" * 50)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 64,
      "id": "2f81ad23-5656-43e6-b50a-0d7a4f69a60a",
      "metadata": {
        "id": "2f81ad23-5656-43e6-b50a-0d7a4f69a60a",
        "outputId": "5235f40a-f8b8-4e6c-af0e-04d91e4aaa8f",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "('human_feedback',)"
            ]
          },
          "metadata": {},
          "execution_count": 64
        }
      ],
      "source": [
        "# Get state and look at next node\n",
        "state = graph.get_state(thread)\n",
        "state.next"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 65,
      "id": "72b2a402-fd10-4f26-9a32-3e3c0d4aaf76",
      "metadata": {
        "id": "72b2a402-fd10-4f26-9a32-3e3c0d4aaf76",
        "outputId": "205ee5b0-fdac-4684-d30f-4c2c9bde7d12",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'configurable': {'thread_id': '1',\n",
              "  'checkpoint_ns': '',\n",
              "  'checkpoint_id': '1efd903b-756c-692e-8002-3ff1beff9e37'}}"
            ]
          },
          "metadata": {},
          "execution_count": 65
        }
      ],
      "source": [
        "# We now update the state as if we are the human_feedback node\n",
        "graph.update_state(thread, {\"human_analyst_feedback\":\n",
        "                            \"Add in someone with a Pharmaceutical Research background\"}, as_node=\"human_feedback\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 66,
      "id": "b8816eb9-9906-441b-b552-be71107db14f",
      "metadata": {
        "id": "b8816eb9-9906-441b-b552-be71107db14f",
        "outputId": "521633cf-469f-400b-f7c9-b604219979f6",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Name: Dr. Emily Carter\n",
            "Affiliation: Children's Rare Disease Research Institute\n",
            "Role: Pediatric Geneticist\n",
            "Description: Dr. Carter focuses on the genetic underpinnings of rare diseases in children. Her primary concern is identifying genetic markers that can lead to early diagnosis and potential treatment options. She is motivated by the potential to improve patient outcomes through personalized medicine and genetic counseling.\n",
            "--------------------------------------------------\n",
            "Name: Mr. John Thompson\n",
            "Affiliation: National Health Policy Center\n",
            "Role: Health Policy Analyst\n",
            "Description: Mr. Thompson analyzes the impact of health policies on the availability and accessibility of treatments for rare diseases in children. His focus is on advocating for policy changes that increase funding for research and support for affected families. He is driven by the need to address disparities in healthcare access and ensure equitable treatment options for all children.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Aisha Khan\n",
            "Affiliation: Global Pediatric Health Organization\n",
            "Role: Epidemiologist\n",
            "Description: Dr. Khan studies the prevalence and distribution of rare diseases in children globally. Her work involves identifying patterns and potential environmental or socio-economic factors contributing to these diseases. She aims to inform public health strategies and interventions that can mitigate the impact of rare diseases on children worldwide.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Emily Carter\n",
            "Affiliation: Children's Hospital Research Institute\n",
            "Role: Pediatric Geneticist\n",
            "Description: Dr. Carter focuses on the genetic underpinnings of rare diseases in children. Her primary concern is understanding how genetic mutations contribute to these diseases and how early genetic screening can lead to better outcomes. She is motivated by the potential to develop targeted therapies that can address the root causes of these conditions.\n",
            "--------------------------------------------------\n",
            "Name: Mr. Raj Patel\n",
            "Affiliation: Global Health Policy Institute\n",
            "Role: Health Policy Analyst\n",
            "Description: Mr. Patel examines the policy implications of rare diseases in children, particularly in terms of access to care and funding for research. His concerns include the disparities in healthcare access for children with rare diseases and the need for international collaboration to improve treatment options. He is driven by the goal of influencing policy to ensure equitable healthcare solutions.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Lisa Nguyen\n",
            "Affiliation: PharmaGen Research Labs\n",
            "Role: Pharmaceutical Research Scientist\n",
            "Description: Dr. Nguyen is involved in the development of new drugs for rare pediatric diseases. Her focus is on the challenges of creating effective treatments given the small patient populations and the high costs associated with drug development. She is motivated by the potential to bring innovative therapies to market that can significantly improve the quality of life for affected children.\n",
            "--------------------------------------------------\n"
          ]
        }
      ],
      "source": [
        "# Continue the graph execution\n",
        "for event in graph.stream(None, thread, stream_mode=\"values\"):\n",
        "    # Review\n",
        "    analysts = event.get('analysts', '')\n",
        "    if analysts:\n",
        "        for analyst in analysts:\n",
        "            print(f\"Name: {analyst.name}\")\n",
        "            print(f\"Affiliation: {analyst.affiliation}\")\n",
        "            print(f\"Role: {analyst.role}\")\n",
        "            print(f\"Description: {analyst.description}\")\n",
        "            print(\"-\" * 50)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 67,
      "id": "a43ac322-5926-4932-8653-68206fec0d2c",
      "metadata": {
        "id": "a43ac322-5926-4932-8653-68206fec0d2c",
        "outputId": "845135bf-c4a8-4c9e-af01-92f8c16ac0d4",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'configurable': {'thread_id': '1',\n",
              "  'checkpoint_ns': '',\n",
              "  'checkpoint_id': '1efd903c-bf47-675e-8004-d6d5a9c275cf'}}"
            ]
          },
          "metadata": {},
          "execution_count": 67
        }
      ],
      "source": [
        "# If we are satisfied, then we simply supply no feedback\n",
        "further_feedack = None\n",
        "graph.update_state(thread, {\"human_analyst_feedback\":\n",
        "                            further_feedack}, as_node=\"human_feedback\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 68,
      "id": "ab034e65-aeee-4723-8d6d-74541b548425",
      "metadata": {
        "id": "ab034e65-aeee-4723-8d6d-74541b548425"
      },
      "outputs": [],
      "source": [
        "# Continue the graph execution to end\n",
        "for event in graph.stream(None, thread, stream_mode=\"updates\"):\n",
        "    print(\"--Node--\")\n",
        "    node_name = next(iter(event.keys()))\n",
        "    print(node_name)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 69,
      "id": "2f204e8a-285c-4e46-8223-a695caec7764",
      "metadata": {
        "id": "2f204e8a-285c-4e46-8223-a695caec7764"
      },
      "outputs": [],
      "source": [
        "final_state = graph.get_state(thread)\n",
        "analysts = final_state.values.get('analysts')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 70,
      "id": "59704086-cb3b-42e9-8395-37be6f0d44e9",
      "metadata": {
        "id": "59704086-cb3b-42e9-8395-37be6f0d44e9",
        "outputId": "f2a99bc3-bd74-43be-8859-1f187e4c1aa6",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "()"
            ]
          },
          "metadata": {},
          "execution_count": 70
        }
      ],
      "source": [
        "final_state.next"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "final_state.values"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "SUYnXG-GlBzh",
        "outputId": "b0a1fcd4-25b9-4798-e310-f91bd511dcb1"
      },
      "id": "SUYnXG-GlBzh",
      "execution_count": 71,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'topic': 'Rare diseases in children',\n",
              " 'max_analysts': 3,\n",
              " 'analysts': [Analyst(affiliation=\"Children's Hospital Research Institute\", name='Dr. Emily Carter', role='Pediatric Geneticist', description='Dr. Carter focuses on the genetic underpinnings of rare diseases in children. Her primary concern is understanding how genetic mutations contribute to these diseases and how early genetic screening can lead to better outcomes. She is motivated by the potential to develop targeted therapies that can address the root causes of these conditions.'),\n",
              "  Analyst(affiliation='Global Health Policy Institute', name='Mr. Raj Patel', role='Health Policy Analyst', description='Mr. Patel examines the policy implications of rare diseases in children, particularly in terms of access to care and funding for research. His concerns include the disparities in healthcare access for children with rare diseases and the need for international collaboration to improve treatment options. He is driven by the goal of influencing policy to ensure equitable healthcare solutions.'),\n",
              "  Analyst(affiliation='PharmaGen Research Labs', name='Dr. Lisa Nguyen', role='Pharmaceutical Research Scientist', description='Dr. Nguyen is involved in the development of new drugs for rare pediatric diseases. Her focus is on the challenges of creating effective treatments given the small patient populations and the high costs associated with drug development. She is motivated by the potential to bring innovative therapies to market that can significantly improve the quality of life for affected children.')]}"
            ]
          },
          "metadata": {},
          "execution_count": 71
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 72,
      "id": "95717ba3-aa00-48d6-bbb7-5fe4db5919bf",
      "metadata": {
        "id": "95717ba3-aa00-48d6-bbb7-5fe4db5919bf",
        "outputId": "83118381-2884-44c5-b9bf-82c65efe773c",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Name: Dr. Emily Carter\n",
            "Affiliation: Children's Hospital Research Institute\n",
            "Role: Pediatric Geneticist\n",
            "Description: Dr. Carter focuses on the genetic underpinnings of rare diseases in children. Her primary concern is understanding how genetic mutations contribute to these diseases and how early genetic screening can lead to better outcomes. She is motivated by the potential to develop targeted therapies that can address the root causes of these conditions.\n",
            "--------------------------------------------------\n",
            "Name: Mr. Raj Patel\n",
            "Affiliation: Global Health Policy Institute\n",
            "Role: Health Policy Analyst\n",
            "Description: Mr. Patel examines the policy implications of rare diseases in children, particularly in terms of access to care and funding for research. His concerns include the disparities in healthcare access for children with rare diseases and the need for international collaboration to improve treatment options. He is driven by the goal of influencing policy to ensure equitable healthcare solutions.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Lisa Nguyen\n",
            "Affiliation: PharmaGen Research Labs\n",
            "Role: Pharmaceutical Research Scientist\n",
            "Description: Dr. Nguyen is involved in the development of new drugs for rare pediatric diseases. Her focus is on the challenges of creating effective treatments given the small patient populations and the high costs associated with drug development. She is motivated by the potential to bring innovative therapies to market that can significantly improve the quality of life for affected children.\n",
            "--------------------------------------------------\n"
          ]
        }
      ],
      "source": [
        "for analyst in analysts:\n",
        "    print(f\"Name: {analyst.name}\")\n",
        "    print(f\"Affiliation: {analyst.affiliation}\")\n",
        "    print(f\"Role: {analyst.role}\")\n",
        "    print(f\"Description: {analyst.description}\")\n",
        "    print(\"-\" * 50)"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "7d2498e4-20ae-4503-9dd0-a4165132b7a7",
      "metadata": {
        "id": "7d2498e4-20ae-4503-9dd0-a4165132b7a7"
      },
      "source": [
        "## Conduct Interview\n",
        "\n",
        "### Generate Question\n",
        "\n",
        "The analyst will ask questions to the expert."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "e5d5f559-f42e-442b-87cd-dbf0a91abf9c",
      "metadata": {
        "id": "e5d5f559-f42e-442b-87cd-dbf0a91abf9c"
      },
      "outputs": [],
      "source": [
        "import operator\n",
        "from typing import  Annotated\n",
        "from langgraph.graph import MessagesState\n",
        "\n",
        "class InterviewState(MessagesState):\n",
        "    max_num_turns: int # Number turns of conversation\n",
        "    context: Annotated[list, operator.add] # Source docs\n",
        "    analyst: Analyst # Analyst asking questions\n",
        "    interview: str # Interview transcript\n",
        "    sections: list # Final key we duplicate in outer state for Send() API\n",
        "\n",
        "class SearchQuery(BaseModel):\n",
        "    search_query: str = Field(None, description=\"Search query for retrieval.\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "1c2e71eb-07ad-4bea-aabc-dbaf551408c0",
      "metadata": {
        "id": "1c2e71eb-07ad-4bea-aabc-dbaf551408c0"
      },
      "outputs": [],
      "source": [
        "question_instructions = \"\"\"You are an analyst tasked with interviewing an expert to learn about a specific topic.\n",
        "\n",
        "Your goal is boil down to interesting and specific insights related to your topic.\n",
        "\n",
        "1. Interesting: Insights that people will find surprising or non-obvious.\n",
        "\n",
        "2. Specific: Insights that avoid generalities and include specific examples from the expert.\n",
        "\n",
        "Here is your topic of focus and set of goals: {goals}\n",
        "\n",
        "Begin by introducing yourself using a name that fits your persona, and then ask your question.\n",
        "\n",
        "Continue to ask questions to drill down and refine your understanding of the topic.\n",
        "\n",
        "When you are satisfied with your understanding, complete the interview with: \"Thank you so much for your help!\"\n",
        "\n",
        "Remember to stay in character throughout your response, reflecting the persona and goals provided to you.\"\"\"\n",
        "\n",
        "def generate_question(state: InterviewState):\n",
        "    \"\"\" Node to generate a question \"\"\"\n",
        "\n",
        "    # Get state\n",
        "    analyst = state[\"analyst\"]\n",
        "    messages = state[\"messages\"]\n",
        "    print(\"### Generate Question ####\")\n",
        "    # Generate question\n",
        "    system_message = question_instructions.format(goals=analyst.persona)\n",
        "    question = llm.invoke([SystemMessage(content=system_message)]+messages)\n",
        "\n",
        "    print(f\"QUESTION: {question.content}\")\n",
        "\n",
        "    # Write messages to state\n",
        "    return {\"messages\": [question]}"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "be2ff33a-6232-4a79-8a82-882a645394f5",
      "metadata": {
        "id": "be2ff33a-6232-4a79-8a82-882a645394f5"
      },
      "source": [
        "### Generate Answer: Parallelization\n",
        "\n",
        "The expert will gather information from multiple sources in parallel to answer questions.\n",
        "\n",
        "For example, we can use:\n",
        "\n",
        "* Specific web sites e.g., via [`WebBaseLoader`](https://python.langchain.com/v0.2/docs/integrations/document_loaders/web_base/)\n",
        "* Indexed documents e.g., via [RAG](https://python.langchain.com/v0.2/docs/tutorials/rag/)\n",
        "* Web search\n",
        "* Wikipedia search\n",
        "\n",
        "You can try different web search tools, like [Tavily](https://tavily.com/)."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 73,
      "id": "606ea95b-e811-4299-8b66-835d4016c338",
      "metadata": {
        "id": "606ea95b-e811-4299-8b66-835d4016c338"
      },
      "outputs": [],
      "source": [
        "def _set_env(var: str):\n",
        "    if not os.environ.get(var):\n",
        "        os.environ[var] = userdata.get(f\"{var}\")\n",
        "\n",
        "os.environ[\"TAVILY_API_KEY\"]=  userdata.get(\"TAVILY_API_KEY\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 74,
      "id": "c61ae74a-f838-4e97-8bd5-48ccd15b7789",
      "metadata": {
        "id": "c61ae74a-f838-4e97-8bd5-48ccd15b7789"
      },
      "outputs": [],
      "source": [
        "# Web search tool\n",
        "from langchain_community.tools.tavily_search import TavilySearchResults\n",
        "tavily_search = TavilySearchResults(max_results=3)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 75,
      "id": "2d8f760b-5a1a-4fa9-a014-d3fb02bec51c",
      "metadata": {
        "id": "2d8f760b-5a1a-4fa9-a014-d3fb02bec51c"
      },
      "outputs": [],
      "source": [
        "# Wikipedia search tool\n",
        "from langchain_community.document_loaders import WikipediaLoader"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Semantic Scholar search tool\n",
        "\n",
        "The Semantic Scholar REST API allows you to find and explore scientific publication data about authors, papers, citations, venues, and more.\n",
        "\n",
        "\n",
        "- https://python.langchain.com/api_reference/community/utilities/langchain_community.utilities.semanticscholar.SemanticScholarAPIWrapper.html#langchain_community.utilities.semanticscholar.SemanticScholarAPIWrapper\n",
        "\n",
        "- https://api.semanticscholar.org/api-docs/graph#tag/Paper-Data/operation/get_graph_paper_relevance_search"
      ],
      "metadata": {
        "id": "n-1GvULNEJjA"
      },
      "id": "n-1GvULNEJjA"
    },
    {
      "cell_type": "code",
      "source": [
        "# Semantic Scholar search tool\n",
        "from langchain_community.utilities.semanticscholar import SemanticScholarAPIWrapper\n",
        "from langchain.output_parsers import PydanticOutputParser\n",
        "from langchain_core.prompts import PromptTemplate\n",
        "from langchain import hub\n",
        "from langchain.agents import AgentExecutor, create_openai_functions_agent\n",
        "from langchain_openai import ChatOpenAI\n",
        "from langchain_community.tools.semanticscholar.tool import SemanticScholarQueryRun\n",
        "\n",
        "os.environ[\"GOOGLE_API_KEY\"] = userdata.get(\"GOOGLE_API_KEY\")\n",
        "os.environ[\"GOOGLE_CSE_ID\"] = userdata.get(\"GOOGLE_CSE_ID\")\n",
        "os.environ[\"USER_AGENT\"] = 'Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/111.0.0.0 Safari/537.36'\n",
        "google_scholar = SemanticScholarAPIWrapper(\n",
        "                    doc_content_chars_max=10000, top_k_results=10\n",
        "                ) # top_k_results = 3, load_max_docs = 3"
      ],
      "metadata": {
        "id": "MknoGYkAOdJI"
      },
      "id": "MknoGYkAOdJI",
      "execution_count": 76,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "google_scholar = SemanticScholarAPIWrapper(\n",
        "                    top_k_results = 5, load_max_docs = 10\n",
        "                )"
      ],
      "metadata": {
        "id": "1Er4Z-u2rTZH"
      },
      "id": "1Er4Z-u2rTZH",
      "execution_count": 77,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "publications = google_scholar.run(topic)"
      ],
      "metadata": {
        "id": "hOim9tNVEAXp"
      },
      "id": "hOim9tNVEAXp",
      "execution_count": 78,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "publications"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 330
        },
        "id": "5EUoS1c845xq",
        "outputId": "126ad66b-0442-45cc-bfbf-bd1acdd99097"
      },
      "id": "5EUoS1c845xq",
      "execution_count": 79,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Published year: 2022\\nTitle: A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020\\nAuthors: Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu\\nAbstract: Objective To clarify the current state of methodology of clinical trials for rare neurological diseases in children, and to provide a basis for the further optimization of the trial design. Methods Data of clinical trials for the rare neurological diseases with childhood onset (searched through https://rarediseases.info.nih.gov/diseases and www.Orpha.net) registered on the Clinicaltrils.gov from January 2010 to June 2020 was collected. Analysis on the methodology of the clinical trials were performed, focusing on initiator of the studies, multi or single research center, study design, sample size, and the endpoint using in the trial. Results A total of 162 clinical trials were included, covering only 7.3% (61/835) of rare neurological diseases in children. 101 (62.3%) were initiated by pharmaceutical companies, and 61 (37.7%) by investigators. Most (95.4%) of global multicenter studies were initiated by pharmaceutical companies, whereas most (70.0%) of single-center studies were initiated by investigators (χ2\\u2009=\\u200961.635, P\\u2009<\\u20090.001). Of the 162 trials, 74 (45.7%) were open-label single-arm trials, 68 (42.0%) were randomized double-blind parallel controlled trials (RCT), 12 (7.4%) were randomized crossover trials. Most of RCTs (73.5%) and 54.1% of open-label single-arm trials were initiated by pharmaceutical companies. The proportion of RCTs in clinical trials for diseases with a prevalence of ≥1/10,000 (62.5%) was higher than that in diseases with prevalence ≤1/1,000,000 (12.0%) or 1/1,000,000~1/10,000 (43.1%) (χ2\\u2009=\\u200914.790, P\\u2009=\\u20090.001). The median expected sample size of the studies was 34 (4–500). 132 (132/162, 81.5%) studies enrolled fewer than 100 cases. Diseases with a prevalence of ≥1/10,000 had significantly larger sample sizes than other prevalence classes (P\\u2009<\\u20090.001, P\\u2009=\\u20090.003). Conclusions There were few clinical trials targeting on treatment of rare neurological diseases in children. Trials on rare diseases used fewer participants, and high-quality randomized controlled trials were less common. It is necessary to conduct global multicenter recruitment and choose optimal study designs to improve the level of evidence in clinical trials on rare diseases.\\n\\n\\nPublished year: 2021\\nTitle: An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation\\nAuthors: S. Y. Volgina, A. Sokolov\\nAbstract: Rare diseases continue to present numerous challenges for the medical field worldwide. Understanding innovative mechanisms of service provision for patients with rare conditions through shared communication across different healthcare systems should be encouraged. This study presents the organization of medical care for people with rare diseases in Russia, while also exploring the epidemiology of both life-threatening and chronic, progressive, rare diseases. Further, the regulation of medical care provision is examined, including the preferential provision of medicines in different Russian regions and potential role of compulsory medical insurance. The principles guiding patient referrals to appropriate specialist centres for rare diseases are outlined, including considering the increased role that public-patient organizations have in developing healthcare systems. In reviewing the specialized resources available for patients with rare diseases, medical genetics services offering diagnostics and counselling are discussed. Additionally, population-level preventive care necessitates significant investment, principally in diagnostic technology and screening programs. As seen elsewhere, these initiatives involve forming reference centres and tertiary-level pediatric departments staffed by multidisciplinary specialists in rare diseases. Numerous challenges are highlighted relating to Russian healthcare sy'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 79
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from typing import List, Optional\n",
        "from pydantic import BaseModel, Field\n",
        "class Output(BaseModel):\n",
        "    autors: str = Field(description=\"List of authors of this paper\")\n",
        "    title: str = Field(description=\"title of this paper\")\n",
        "    abstract: str = Field(description=\"abstract of this paper\")\n",
        "    url: Optional[str] = Field(description=\"url of this paper\")\n",
        "\n",
        "class Documents(BaseModel):\n",
        "    documents: List[Output] = Field(description=\"List of documents\")\n",
        "\n",
        "query = \"rare diseases in children\"\n",
        "\n",
        "# Set up a parser + inject instructions into the prompt template.\n",
        "parser = PydanticOutputParser(pydantic_object=Documents)\n",
        "\n",
        "prompt = PromptTemplate(\n",
        "    template=\"Format this text {publications} according to the model.\\n{format_instructions}\\n\",\n",
        "\n",
        "    partial_variables={\"format_instructions\": parser.get_format_instructions()},\n",
        ")\n",
        "\n",
        "chain2 = prompt | llm | parser\n",
        "\n",
        "docs = chain2.invoke({\"publications\":publications})"
      ],
      "metadata": {
        "id": "d7bgc0178wx0"
      },
      "id": "d7bgc0178wx0",
      "execution_count": 80,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "docs\n"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "uGZKcCas2lo5",
        "outputId": "23902efd-f2b1-4dfb-ccc0-fed5aa335e28"
      },
      "id": "uGZKcCas2lo5",
      "execution_count": 81,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Documents(documents=[Output(autors='Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu', title='A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020', abstract='Objective To clarify the current state of methodology of clinical trials for rare neurological diseases in children, and to provide a basis for the further optimization of the trial design. Methods Data of clinical trials for the rare neurological diseases with childhood onset (searched through https://rarediseases.info.nih.gov/diseases and www.Orpha.net) registered on the Clinicaltrils.gov from January 2010 to June 2020 was collected. Analysis on the methodology of the clinical trials were performed, focusing on initiator of the studies, multi or single research center, study design, sample size, and the endpoint using in the trial. Results A total of 162 clinical trials were included, covering only 7.3% (61/835) of rare neurological diseases in children. 101 (62.3%) were initiated by pharmaceutical companies, and 61 (37.7%) by investigators. Most (95.4%) of global multicenter studies were initiated by pharmaceutical companies, whereas most (70.0%) of single-center studies were initiated by investigators (χ2\\u2009=\\u200961.635, P\\u2009<\\u20090.001). Of the 162 trials, 74 (45.7%) were open-label single-arm trials, 68 (42.0%) were randomized double-blind parallel controlled trials (RCT), 12 (7.4%) were randomized crossover trials. Most of RCTs (73.5%) and 54.1% of open-label single-arm trials were initiated by pharmaceutical companies. The proportion of RCTs in clinical trials for diseases with a prevalence of ≥1/10,000 (62.5%) was higher than that in diseases with prevalence ≤1/1,000,000 (12.0%) or 1/1,000,000~1/10,000 (43.1%) (χ2\\u2009=\\u200914.790, P\\u2009=\\u20090.001). The median expected sample size of the studies was 34 (4–500). 132 (132/162, 81.5%) studies enrolled fewer than 100 cases. Diseases with a prevalence of ≥1/10,000 had significantly larger sample sizes than other prevalence classes (P\\u2009<\\u20090.001, P\\u2009=\\u20090.003). Conclusions There were few clinical trials targeting on treatment of rare neurological diseases in children. Trials on rare diseases used fewer participants, and high-quality randomized controlled trials were less common. It is necessary to conduct global multicenter recruitment and choose optimal study designs to improve the level of evidence in clinical trials on rare diseases.', url=None), Output(autors='S. Y. Volgina, A. Sokolov', title='An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation', abstract='Rare diseases continue to present numerous challenges for the medical field worldwide. Understanding innovative mechanisms of service provision for patients with rare conditions through shared communication across different healthcare systems should be encouraged. This study presents the organization of medical care for people with rare diseases in Russia, while also exploring the epidemiology of both life-threatening and chronic, progressive, rare diseases. Further, the regulation of medical care provision is examined, including the preferential provision of medicines in different Russian regions and potential role of compulsory medical insurance. The principles guiding patient referrals to appropriate specialist centres for rare diseases are outlined, including considering the increased role that public-patient organizations have in developing healthcare systems. In reviewing the specialized resources available for patients with rare diseases, medical genetics services offering diagnostics and counselling are discussed. Additionally, population-level preventive care necessitates significant investment, principally in diagnostic technology and screening programs. As seen elsewhere, these initiatives involve forming reference centres and tertiary-level pediatric departments staffed by multidisciplinary specialists in rare diseases. Numerous challenges are highlighted relating to Russian healthcare sy according to the model.', url=None)])"
            ]
          },
          "metadata": {},
          "execution_count": 81
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "for doc in docs.documents:\n",
        "  print(f\"Author: {doc.autors}\")\n",
        "  print(f\"Title: {doc.title}\")\n",
        "  print(f\"Abstract: {doc.abstract}\")\n",
        "  print(f\"URL: {doc.url}\")\n",
        "  print(\"-\"*50)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5V91QzIq-YZf",
        "outputId": "4e213d84-fc42-47ce-8480-867b4af2453b"
      },
      "id": "5V91QzIq-YZf",
      "execution_count": 82,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Author: Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu\n",
            "Title: A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020\n",
            "Abstract: Objective To clarify the current state of methodology of clinical trials for rare neurological diseases in children, and to provide a basis for the further optimization of the trial design. Methods Data of clinical trials for the rare neurological diseases with childhood onset (searched through https://rarediseases.info.nih.gov/diseases and www.Orpha.net) registered on the Clinicaltrils.gov from January 2010 to June 2020 was collected. Analysis on the methodology of the clinical trials were performed, focusing on initiator of the studies, multi or single research center, study design, sample size, and the endpoint using in the trial. Results A total of 162 clinical trials were included, covering only 7.3% (61/835) of rare neurological diseases in children. 101 (62.3%) were initiated by pharmaceutical companies, and 61 (37.7%) by investigators. Most (95.4%) of global multicenter studies were initiated by pharmaceutical companies, whereas most (70.0%) of single-center studies were initiated by investigators (χ2 = 61.635, P < 0.001). Of the 162 trials, 74 (45.7%) were open-label single-arm trials, 68 (42.0%) were randomized double-blind parallel controlled trials (RCT), 12 (7.4%) were randomized crossover trials. Most of RCTs (73.5%) and 54.1% of open-label single-arm trials were initiated by pharmaceutical companies. The proportion of RCTs in clinical trials for diseases with a prevalence of ≥1/10,000 (62.5%) was higher than that in diseases with prevalence ≤1/1,000,000 (12.0%) or 1/1,000,000~1/10,000 (43.1%) (χ2 = 14.790, P = 0.001). The median expected sample size of the studies was 34 (4–500). 132 (132/162, 81.5%) studies enrolled fewer than 100 cases. Diseases with a prevalence of ≥1/10,000 had significantly larger sample sizes than other prevalence classes (P < 0.001, P = 0.003). Conclusions There were few clinical trials targeting on treatment of rare neurological diseases in children. Trials on rare diseases used fewer participants, and high-quality randomized controlled trials were less common. It is necessary to conduct global multicenter recruitment and choose optimal study designs to improve the level of evidence in clinical trials on rare diseases.\n",
            "URL: None\n",
            "--------------------------------------------------\n",
            "Author: S. Y. Volgina, A. Sokolov\n",
            "Title: An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation\n",
            "Abstract: Rare diseases continue to present numerous challenges for the medical field worldwide. Understanding innovative mechanisms of service provision for patients with rare conditions through shared communication across different healthcare systems should be encouraged. This study presents the organization of medical care for people with rare diseases in Russia, while also exploring the epidemiology of both life-threatening and chronic, progressive, rare diseases. Further, the regulation of medical care provision is examined, including the preferential provision of medicines in different Russian regions and potential role of compulsory medical insurance. The principles guiding patient referrals to appropriate specialist centres for rare diseases are outlined, including considering the increased role that public-patient organizations have in developing healthcare systems. In reviewing the specialized resources available for patients with rare diseases, medical genetics services offering diagnostics and counselling are discussed. Additionally, population-level preventive care necessitates significant investment, principally in diagnostic technology and screening programs. As seen elsewhere, these initiatives involve forming reference centres and tertiary-level pediatric departments staffed by multidisciplinary specialists in rare diseases. Numerous challenges are highlighted relating to Russian healthcare sy according to the model.\n",
            "URL: None\n",
            "--------------------------------------------------\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "i = 0\n",
        "docums= []\n",
        "for item in docs.documents:\n",
        "\n",
        "\n",
        "  doc = f'<Document source=\"{item.title}\"\\n Abstract=\"{item.abstract}\",\\n authors: {item.autors}\\n</Document>'\n",
        "  docums.append(doc)\n",
        "\n",
        "text = \"\\n\\n---\\n\\n\".join(\n",
        "        [\n",
        "\n",
        "           str(doc) for doc in docums\n",
        "        ]\n",
        " )\n",
        "print(text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "gSJkGPCkA-nV",
        "outputId": "77a42993-f7e4-405c-f581-21b97793e8d5"
      },
      "id": "gSJkGPCkA-nV",
      "execution_count": 83,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<Document source=\"A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020\"\n",
            " Abstract=\"Objective To clarify the current state of methodology of clinical trials for rare neurological diseases in children, and to provide a basis for the further optimization of the trial design. Methods Data of clinical trials for the rare neurological diseases with childhood onset (searched through https://rarediseases.info.nih.gov/diseases and www.Orpha.net) registered on the Clinicaltrils.gov from January 2010 to June 2020 was collected. Analysis on the methodology of the clinical trials were performed, focusing on initiator of the studies, multi or single research center, study design, sample size, and the endpoint using in the trial. Results A total of 162 clinical trials were included, covering only 7.3% (61/835) of rare neurological diseases in children. 101 (62.3%) were initiated by pharmaceutical companies, and 61 (37.7%) by investigators. Most (95.4%) of global multicenter studies were initiated by pharmaceutical companies, whereas most (70.0%) of single-center studies were initiated by investigators (χ2 = 61.635, P < 0.001). Of the 162 trials, 74 (45.7%) were open-label single-arm trials, 68 (42.0%) were randomized double-blind parallel controlled trials (RCT), 12 (7.4%) were randomized crossover trials. Most of RCTs (73.5%) and 54.1% of open-label single-arm trials were initiated by pharmaceutical companies. The proportion of RCTs in clinical trials for diseases with a prevalence of ≥1/10,000 (62.5%) was higher than that in diseases with prevalence ≤1/1,000,000 (12.0%) or 1/1,000,000~1/10,000 (43.1%) (χ2 = 14.790, P = 0.001). The median expected sample size of the studies was 34 (4–500). 132 (132/162, 81.5%) studies enrolled fewer than 100 cases. Diseases with a prevalence of ≥1/10,000 had significantly larger sample sizes than other prevalence classes (P < 0.001, P = 0.003). Conclusions There were few clinical trials targeting on treatment of rare neurological diseases in children. Trials on rare diseases used fewer participants, and high-quality randomized controlled trials were less common. It is necessary to conduct global multicenter recruitment and choose optimal study designs to improve the level of evidence in clinical trials on rare diseases.\",\n",
            " authors: Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu\n",
            "</Document>\n",
            "\n",
            "---\n",
            "\n",
            "<Document source=\"An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation\"\n",
            " Abstract=\"Rare diseases continue to present numerous challenges for the medical field worldwide. Understanding innovative mechanisms of service provision for patients with rare conditions through shared communication across different healthcare systems should be encouraged. This study presents the organization of medical care for people with rare diseases in Russia, while also exploring the epidemiology of both life-threatening and chronic, progressive, rare diseases. Further, the regulation of medical care provision is examined, including the preferential provision of medicines in different Russian regions and potential role of compulsory medical insurance. The principles guiding patient referrals to appropriate specialist centres for rare diseases are outlined, including considering the increased role that public-patient organizations have in developing healthcare systems. In reviewing the specialized resources available for patients with rare diseases, medical genetics services offering diagnostics and counselling are discussed. Additionally, population-level preventive care necessitates significant investment, principally in diagnostic technology and screening programs. As seen elsewhere, these initiatives involve forming reference centres and tertiary-level pediatric departments staffed by multidisciplinary specialists in rare diseases. Numerous challenges are highlighted relating to Russian healthcare sy according to the model.\",\n",
            " authors: S. Y. Volgina, A. Sokolov\n",
            "</Document>\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# SemanticScholarQueryRun\n",
        "\n",
        "https://python.langchain.com/docs/integrations/tools/semanticscholar/"
      ],
      "metadata": {
        "id": "JfAdnmCTAsvR"
      },
      "id": "JfAdnmCTAsvR"
    },
    {
      "cell_type": "code",
      "source": [
        "instructions = \"\"\"You are an expert researcher. provide title , abstract and authors of the documents you use to provide an answer\"\"\"\n",
        "base_prompt = hub.pull(\"langchain-ai/openai-functions-template\")\n",
        "prompt = base_prompt.partial(instructions=instructions)"
      ],
      "metadata": {
        "id": "qkbNBkwD2vT2"
      },
      "id": "qkbNBkwD2vT2",
      "execution_count": 84,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain_community.tools.semanticscholar.tool import SemanticScholarQueryRun\n",
        "\n",
        "tools = [SemanticScholarQueryRun()]\n",
        "agent = create_openai_functions_agent(llm, tools, prompt)\n",
        "agent_executor = AgentExecutor(\n",
        "    agent=agent,\n",
        "    tools=tools,\n",
        "    verbose=True,\n",
        "    return_intermediate_steps=True,\n",
        ")"
      ],
      "metadata": {
        "id": "fHP2IRPq7VFU"
      },
      "id": "fHP2IRPq7VFU",
      "execution_count": 85,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "documents = agent_executor.invoke(\n",
        "    {\n",
        "        \"input\": topic\n",
        "    }\n",
        ")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "Vg50wSyL8CHV",
        "outputId": "6035e147-f8f9-473a-fc77-3c0da72950d6"
      },
      "id": "Vg50wSyL8CHV",
      "execution_count": 86,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "\n",
            "\u001b[1m> Entering new AgentExecutor chain...\u001b[0m\n",
            "\u001b[32;1m\u001b[1;3m\n",
            "Invoking: `semanticscholar` with `{'query': 'Rare diseases in children'}`\n",
            "\n",
            "\n",
            "\u001b[0m\u001b[36;1m\u001b[1;3mPublished year: 2022\n",
            "Title: A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020\n",
            "Authors: Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu\n",
            "Abstract: Objective To clarify the current state of methodology of clinical trials for rare neurological diseases in children, and to provide a basis for the further optimization of the trial design. Methods Data of clinical trials for the rare neurological diseases with childhood onset (searched through https://rarediseases.info.nih.gov/diseases and www.Orpha.net) registered on the Clinicaltrils.gov from January 2010 to June 2020 was collected. Analysis on the methodology of the clinical trials were performed, focusing on initiator of the studies, multi or single research center, study design, sample size, and the endpoint using in the trial. Results A total of 162 clinical trials were included, covering only 7.3% (61/835) of rare neurological diseases in children. 101 (62.3%) were initiated by pharmaceutical companies, and 61 (37.7%) by investigators. Most (95.4%) of global multicenter studies were initiated by pharmaceutical companies, whereas most (70.0%) of single-center studies were initiated by investigators (χ2 = 61.635, P < 0.001). Of the 162 trials, 74 (45.7%) were open-label single-arm trials, 68 (42.0%) were randomized double-blind parallel controlled trials (RCT), 12 (7.4%) were randomized crossover trials. Most of RCTs (73.5%) and 54.1% of open-label single-arm trials were initiated by pharmaceutical companies. The proportion of RCTs in clinical trials for diseases with a prevalence of ≥1/10,000 (62.5%) was higher than that in diseases with prevalence ≤1/1,000,000 (12.0%) or 1/1,000,000~1/10,000 (43.1%) (χ2 = 14.790, P = 0.001). The median expected sample size of the studies was 34 (4–500). 132 (132/162, 81.5%) studies enrolled fewer than 100 cases. Diseases with a prevalence of ≥1/10,000 had significantly larger sample sizes than other prevalence classes (P < 0.001, P = 0.003). Conclusions There were few clinical trials targeting on treatment of rare neurological diseases in children. Trials on rare diseases used fewer participants, and high-quality randomized controlled trials were less common. It is necessary to conduct global multicenter recruitment and choose optimal study designs to improve the level of evidence in clinical trials on rare diseases.\n",
            "\n",
            "\n",
            "Published year: 2021\n",
            "Title: An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation\n",
            "Authors: S. Y. Volgina, A. Sokolov\n",
            "Abstract: Rare diseases continue to present numerous challenges for the medical field worldwide. Understanding innovative mechanisms of service provision for patients with rare conditions through shared communication across different healthcare systems should be encouraged. This study presents the organization of medical care for people with rare diseases in Russia, while also exploring the epidemiology of both life-threatening and chronic, progressive, rare diseases. Further, the regulation of medical care provision is examined, including the preferential provision of medicines in different Russian regions and potential role of compulsory medical insurance. The principles guiding patient referrals to appropriate specialist centres for rare diseases are outlined, including considering the increased role that public-patient organizations have in developing healthcare systems. In reviewing the specialized resources available for patients with rare diseases, medical genetics services offering diagnostics and counselling are discussed. Additionally, population-level preventive care necessitates significant investment, principally in diagnostic technology and screening programs. As seen elsewhere, these initiatives involve forming reference centres and tertiary-level pediatric departments staffed by multidisciplinary specialists in rare diseases. Numerous challenges are highlighted relating to Russian healthcare sy\u001b[0m\u001b[32;1m\u001b[1;3mHere are two research papers related to rare diseases in children:\n",
            "\n",
            "1. **Title**: A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020  \n",
            "   **Authors**: Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu  \n",
            "   **Abstract**: This study aims to clarify the current state of clinical trial methodologies for rare neurological diseases in children and provide a basis for optimizing trial design. It analyzes data from clinical trials registered between 2010 and 2020, focusing on study initiators, design, sample size, and endpoints. The study found that few clinical trials target rare neurological diseases in children, with most trials initiated by pharmaceutical companies and involving fewer participants. The study suggests the need for global multicenter recruitment and optimal study designs to improve evidence levels in clinical trials for rare diseases.\n",
            "\n",
            "2. **Title**: An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation  \n",
            "   **Authors**: S. Y. Volgina, A. Sokolov  \n",
            "   **Abstract**: This paper discusses the challenges and organization of medical care for children with rare diseases in Russia. It explores the epidemiology of rare diseases, regulation of medical care, and the role of compulsory medical insurance. The study highlights the importance of specialized resources, such as medical genetics services, and the need for investment in diagnostic technology and screening programs. It also emphasizes the role of public-patient organizations in developing healthcare systems for rare diseases.\u001b[0m\n",
            "\n",
            "\u001b[1m> Finished chain.\u001b[0m\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "documents.keys()"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ONwEqK4treTB",
        "outputId": "8a05ffdf-c3e5-4efc-9d20-e18d115223f5"
      },
      "id": "ONwEqK4treTB",
      "execution_count": 87,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "dict_keys(['input', 'output', 'intermediate_steps'])"
            ]
          },
          "metadata": {},
          "execution_count": 87
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(documents['output'])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "FnLvvUEM5LmV",
        "outputId": "5c186325-8489-4c94-ba83-ab3aaf94a607"
      },
      "id": "FnLvvUEM5LmV",
      "execution_count": 88,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Here are two research papers related to rare diseases in children:\n",
            "\n",
            "1. **Title**: A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020  \n",
            "   **Authors**: Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu  \n",
            "   **Abstract**: This study aims to clarify the current state of clinical trial methodologies for rare neurological diseases in children and provide a basis for optimizing trial design. It analyzes data from clinical trials registered between 2010 and 2020, focusing on study initiators, design, sample size, and endpoints. The study found that few clinical trials target rare neurological diseases in children, with most trials initiated by pharmaceutical companies and involving fewer participants. The study suggests the need for global multicenter recruitment and optimal study designs to improve evidence levels in clinical trials for rare diseases.\n",
            "\n",
            "2. **Title**: An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation  \n",
            "   **Authors**: S. Y. Volgina, A. Sokolov  \n",
            "   **Abstract**: This paper discusses the challenges and organization of medical care for children with rare diseases in Russia. It explores the epidemiology of rare diseases, regulation of medical care, and the role of compulsory medical insurance. The study highlights the importance of specialized resources, such as medical genetics services, and the need for investment in diagnostic technology and screening programs. It also emphasizes the role of public-patient organizations in developing healthcare systems for rare diseases.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(documents['intermediate_steps'])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "T45rHy2h3Ljj",
        "outputId": "17b169f6-e0b6-4df9-be7c-081d010c4411"
      },
      "id": "T45rHy2h3Ljj",
      "execution_count": 89,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "[(AgentActionMessageLog(tool='semanticscholar', tool_input={'query': 'Rare diseases in children'}, log=\"\\nInvoking: `semanticscholar` with `{'query': 'Rare diseases in children'}`\\n\\n\\n\", message_log=[AIMessageChunk(content='', additional_kwargs={'function_call': {'arguments': '{\"query\":\"Rare diseases in children\"}', 'name': 'semanticscholar'}}, response_metadata={'finish_reason': 'function_call', 'model_name': 'gpt-4o-2024-08-06', 'system_fingerprint': 'fp_50cad350e4'}, id='run-cb4501d6-0e7e-4ca0-9fc2-a27752b8bd5f')]), 'Published year: 2022\\nTitle: A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020\\nAuthors: Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu\\nAbstract: Objective To clarify the current state of methodology of clinical trials for rare neurological diseases in children, and to provide a basis for the further optimization of the trial design. Methods Data of clinical trials for the rare neurological diseases with childhood onset (searched through https://rarediseases.info.nih.gov/diseases and www.Orpha.net) registered on the Clinicaltrils.gov from January 2010 to June 2020 was collected. Analysis on the methodology of the clinical trials were performed, focusing on initiator of the studies, multi or single research center, study design, sample size, and the endpoint using in the trial. Results A total of 162 clinical trials were included, covering only 7.3% (61/835) of rare neurological diseases in children. 101 (62.3%) were initiated by pharmaceutical companies, and 61 (37.7%) by investigators. Most (95.4%) of global multicenter studies were initiated by pharmaceutical companies, whereas most (70.0%) of single-center studies were initiated by investigators (χ2\\u2009=\\u200961.635, P\\u2009<\\u20090.001). Of the 162 trials, 74 (45.7%) were open-label single-arm trials, 68 (42.0%) were randomized double-blind parallel controlled trials (RCT), 12 (7.4%) were randomized crossover trials. Most of RCTs (73.5%) and 54.1% of open-label single-arm trials were initiated by pharmaceutical companies. The proportion of RCTs in clinical trials for diseases with a prevalence of ≥1/10,000 (62.5%) was higher than that in diseases with prevalence ≤1/1,000,000 (12.0%) or 1/1,000,000~1/10,000 (43.1%) (χ2\\u2009=\\u200914.790, P\\u2009=\\u20090.001). The median expected sample size of the studies was 34 (4–500). 132 (132/162, 81.5%) studies enrolled fewer than 100 cases. Diseases with a prevalence of ≥1/10,000 had significantly larger sample sizes than other prevalence classes (P\\u2009<\\u20090.001, P\\u2009=\\u20090.003). Conclusions There were few clinical trials targeting on treatment of rare neurological diseases in children. Trials on rare diseases used fewer participants, and high-quality randomized controlled trials were less common. It is necessary to conduct global multicenter recruitment and choose optimal study designs to improve the level of evidence in clinical trials on rare diseases.\\n\\n\\nPublished year: 2021\\nTitle: An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation\\nAuthors: S. Y. Volgina, A. Sokolov\\nAbstract: Rare diseases continue to present numerous challenges for the medical field worldwide. Understanding innovative mechanisms of service provision for patients with rare conditions through shared communication across different healthcare systems should be encouraged. This study presents the organization of medical care for people with rare diseases in Russia, while also exploring the epidemiology of both life-threatening and chronic, progressive, rare diseases. Further, the regulation of medical care provision is examined, including the preferential provision of medicines in different Russian regions and potential role of compulsory medical insurance. The principles guiding patient referrals to appropriate specialist centres for rare diseases are outlined, including considering the increased role that public-patient organizations have in developing healthcare systems. In reviewing the specialized resources available for patients with rare diseases, medical genetics services offering diagnostics and counselling are discussed. Additionally, population-level preventive care necessitates significant investment, principally in diagnostic technology and screening programs. As seen elsewhere, these initiatives involve forming reference centres and tertiary-level pediatric departments staffed by multidisciplinary specialists in rare diseases. Numerous challenges are highlighted relating to Russian healthcare sy')]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Using Semantic Sholar Library\n",
        "\n",
        "\n",
        "https://api.semanticscholar.org/api-docs/graph#tag/Paper-Data/operation/get_graph_paper_relevance_search\n",
        "\n",
        "\n",
        "https://github.com/danielnsilva/semanticscholar\n"
      ],
      "metadata": {
        "id": "OGYO1OOr8qML"
      },
      "id": "OGYO1OOr8qML"
    },
    {
      "cell_type": "code",
      "source": [
        "from semanticscholar import SemanticScholar\n",
        "sch = SemanticScholar()\n",
        "results = sch.search_paper('Rare diseases in children', fields_of_study=['Medicine'], limit=10) #, fields=['title','year'])\n",
        "\n"
      ],
      "metadata": {
        "id": "vnlFc7nm7EYO"
      },
      "id": "vnlFc7nm7EYO",
      "execution_count": 90,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "i = 0\n",
        "docs= []\n",
        "for item in results:\n",
        "\n",
        "  autor_names = \"\".join(f\"{autor.name}, \" for autor in item.authors )\n",
        "  doc = f'<Document source=\"{item.url}\" page=\"{item.title}\"/>\\n{item.abstract}, authors: {autor_names}\\n</Document>'\n",
        "  docs.append(doc)\n",
        "  i=i+1\n",
        "  if i > 10:\n",
        "    break\n"
      ],
      "metadata": {
        "id": "L5qmV3IM8xD9"
      },
      "id": "L5qmV3IM8xD9",
      "execution_count": 91,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "\"\\n\\n---\\n\\n\".join(\n",
        "        [\n",
        "\n",
        "           str(doc) for doc in docs\n",
        "        ]\n",
        " )"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "RFoyBQWa1IrY",
        "outputId": "e59010a2-c4c4-4c23-8214-7c34e6f25133"
      },
      "id": "RFoyBQWa1IrY",
      "execution_count": 92,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'<Document source=\"https://www.semanticscholar.org/paper/d2964573b4e8f5bf5a04e05c48791d1e8da5000e\" page=\"A survey of registered pharmacological clinical trials on rare neurological diseases in children in 2010–2020\"/>\\nObjective To clarify the current state of methodology of clinical trials for rare neurological diseases in children, and to provide a basis for the further optimization of the trial design. Methods Data of clinical trials for the rare neurological diseases with childhood onset (searched through https://rarediseases.info.nih.gov/diseases and www.Orpha.net) registered on the Clinicaltrils.gov from January 2010 to June 2020 was collected. Analysis on the methodology of the clinical trials were performed, focusing on initiator of the studies, multi or single research center, study design, sample size, and the endpoint using in the trial. Results A total of 162 clinical trials were included, covering only 7.3% (61/835) of rare neurological diseases in children. 101 (62.3%) were initiated by pharmaceutical companies, and 61 (37.7%) by investigators. Most (95.4%) of global multicenter studies were initiated by pharmaceutical companies, whereas most (70.0%) of single-center studies were initiated by investigators (χ2\\u2009=\\u200961.635, P\\u2009<\\u20090.001). Of the 162 trials, 74 (45.7%) were open-label single-arm trials, 68 (42.0%) were randomized double-blind parallel controlled trials (RCT), 12 (7.4%) were randomized crossover trials. Most of RCTs (73.5%) and 54.1% of open-label single-arm trials were initiated by pharmaceutical companies. The proportion of RCTs in clinical trials for diseases with a prevalence of ≥1/10,000 (62.5%) was higher than that in diseases with prevalence ≤1/1,000,000 (12.0%) or 1/1,000,000~1/10,000 (43.1%) (χ2\\u2009=\\u200914.790, P\\u2009=\\u20090.001). The median expected sample size of the studies was 34 (4–500). 132 (132/162, 81.5%) studies enrolled fewer than 100 cases. Diseases with a prevalence of ≥1/10,000 had significantly larger sample sizes than other prevalence classes (P\\u2009<\\u20090.001, P\\u2009=\\u20090.003). Conclusions There were few clinical trials targeting on treatment of rare neurological diseases in children. Trials on rare diseases used fewer participants, and high-quality randomized controlled trials were less common. It is necessary to conduct global multicenter recruitment and choose optimal study designs to improve the level of evidence in clinical trials on rare diseases., authors: Xuting Chang, Jie Zhang, Yuwu Jiang, M. Shang, Ye Wu, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/968cddb006195beddb1e7c007f5b7d3b55e610a2\" page=\"An Analysis of Medical Care Services for Children With Rare Diseases in the Russian Federation\"/>\\nRare diseases continue to present numerous challenges for the medical field worldwide. Understanding innovative mechanisms of service provision for patients with rare conditions through shared communication across different healthcare systems should be encouraged. This study presents the organization of medical care for people with rare diseases in Russia, while also exploring the epidemiology of both life-threatening and chronic, progressive, rare diseases. Further, the regulation of medical care provision is examined, including the preferential provision of medicines in different Russian regions and potential role of compulsory medical insurance. The principles guiding patient referrals to appropriate specialist centres for rare diseases are outlined, including considering the increased role that public-patient organizations have in developing healthcare systems. In reviewing the specialized resources available for patients with rare diseases, medical genetics services offering diagnostics and counselling are discussed. Additionally, population-level preventive care necessitates significant investment, principally in diagnostic technology and screening programs. As seen elsewhere, these initiatives involve forming reference centres and tertiary-level pediatric departments staffed by multidisciplinary specialists in rare diseases. Numerous challenges are highlighted relating to Russian healthcare systems, including the financing of expensive treatments and ensuring equitable access to medical care for those patients with rare diseases outside of State-subsidized programs. Recommendations are made on creating international registries for knowledge sharing, quality appraisal, newborn screening, diagnostic challenges, available treatments and rehabilitation services. Given the high cost of rare diseases, cost-effective interventions are advisable, particularly developing preventive programs and targeting the most common and severe mutations in patients planning pregnancies., authors: S. Y. Volgina, A. Sokolov, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/0771cb6ed338d9f4b8ef1f5bb9a7214491712431\" page=\"The Caregiving Experiences of Fathers and Mothers of Children With Rare Diseases in Italy: Challenges and Social Support Perceptions\"/>\\nFamily caregiving is a growing phenomenon with the increased prevalence of chronic illness and shorter hospitalizations. Rare diseases pose significant challenges not only to patients living with these kinds of pathologies but also to those who care for these patients. The caregiving role has specific characteristics. The present work aims to increase knowledge of the challenges that are common or specific to fathers and mothers of children diagnosed with a rare disease. Moreover, the paper analyses the kinds of social support they experience according to gender. A descriptive study was conducted using grounded theory methodology. A semi-structured interview with open-ended questions was conducted with 15 parents of children with a rare disease. The interview was organized into three main areas: personal experiences in caring for a child with a rare disease, family changes and perceived social support. The transcriptions were analyzed using NVivo 11 software. From data analysis, themes emerged regarding the challenges shared by fathers and mothers, but some aspects also emerged that were gender-specific. The analyses of differences between mothers’ and fathers’ narratives showed that there is a specific experience of the impact that caregiving has on parents’ relationships with their jobs and on their worries. Self-help group is the main source of social support for all respondents. We discuss these findings in relation to possible appropriate specific interventions and support for family caregiving., authors: P. Cardinali, L. Migliorini, N. Rania, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/27f08b2846a068d7171ae3bba1e587530c1fb0bf\" page=\"New Drugs for Rare Diseases in Children.\"/>\\nNone, authors: K. Rose, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/fe18a9fb7d98481972806c7377e06a03d5f78cf2\" page=\"Undiagnosed and Rare Diseases in Children\"/>\\nNone, authors: R. Kliegman, B. Bordini, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/e244ea298fb0d0482fa8e2da49cccfcb05a5bbd4\" page=\"Healthcare access, satisfaction, and health-related quality of life among children and adults with rare diseases\"/>\\nNone, authors: Kathleen R. Bogart, Amanda R. Hemmesch, Erica Barnes, Thomas Blissenbach, A. Beisang, Patti A. Engel, Jakub Tim Lisa Nicole Kelly Tony Matt Julia Karl Rae Kar Tolar Schacker Schimmenti Brown Morrison Albright , J. Tolar, Tim Schacker, Lisa A Schimmenti, Nicole Brown, K. Morrison, Tony Albright, Matt Klein, Julia Coleman, Karlee Nelsen, Rae Blaylark, Karri LaFond, S. Berkowitz, K. A. Schultz, Kerry Hansen, S. Beiraghi, B. Joers, D. Tilstra, A. Gaviglio, Lee A. Jones, Ab Miller, Jackie Foster, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/ef1592bd9839987c74aad515f167e99141797325\" page=\"Gender Differences in Caring for Children with Genetic or Rare Diseases: A Mixed-Methods Study\"/>\\nAs a factor in parenting stress, gender differences in caring for children with genetic or rare diseases warrant research attention; therefore, this study explored gender differences in parenting stress, health outcomes, and illness perceptions among caregivers of pediatric genetic or rare disease populations to improve the understanding of such gender differences. Applying a concurrent triangulation mixed-methods design, we conducted a questionnaire survey to assess study measures for 100 family caregivers (42 men and 58 women), which included a free-text response item to probe caregivers’ subjective perceptions of the children’s illness. The gender differences hypothesis was tested with statistics and the qualitative data about illness perception was analyzed by directed content analysis. Most female caregivers served as the primary caregivers and provided more caregiving, while they experienced significantly increased levels of parenting stress and depressive symptoms compared with male caregivers. Female caregivers perceived the conditions of their children’s diseases to be highly symptomatic, with negative consequences and requiring disease control. By contrast, male caregivers had stronger perceptions regarding the negative effects of the disease on the children’s quality of life. The gender discrepancy in viewpoints of illness perception sequence may contribute to female caregivers’ higher levels of stress and depressive symptoms than males., authors: Shao-Yin Chu, Chin-Chen Wen, Chun-Ying Weng, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/a0dacf7752fe8e559518c36141229984a36939e1\" page=\"Being the Pillar for Children with Rare Diseases—A Systematic Review on Parental Quality of Life\"/>\\nParents caring for children with rare diseases fear the long-term progression of the child’s disease. The current study aims to systematically investigate the quality of life (QoL) in parents of children with different rare diseases. We performed a systematic literature search including quantitative studies on QoL of parents caring for children and adolescents with rare diseases in five databases (APA PsycArticles, APA PsycInfo, MEDLINE, PSYNDEXplus, and PubMed) published between 2000–2020. Of the 3985 titles identified, 31 studies met the inclusion criteria and were selected for narrative review. Studies were included if they investigated predictors of parental QoL or reported QoL compared to normative samples, parents of healthy children, or children with other chronic diseases. We used the Newcastle–Ottawa Scale to assess methodological quality. The systematic review revealed that parents of children with rare diseases experience reduced QoL compared to parents with healthy children and norm values. Psychosocial factors, beyond disease-specific predictors, were shown to influence parental QoL substantially and may thus present an essential aspect within interventions for this highly burdened group. Health care professionals should consider and address the impairment of parental QoL due to the child’s rare disease. We discuss insights into existing research gaps and improvements for subsequent work., authors: Johannes Boettcher, Michael Boettcher, S. Wiegand-Grefe, H. Zapf, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/b778bfd2ab03ee4ccf910b79928debda7309001c\" page=\"Influence of schooling on the health-related quality of life of children with rare diseases\"/>\\nNone, authors: Berta Paz-Lourido, Francisca Negre, Begoña de la Iglesia, Sebastià Verger, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/5e5aa1558ed9700af05e6c6022316202629bcc98\" page=\"Quality of Life and Mental Health in Mothers and Fathers Caring for Children and Adolescents with Rare Diseases Requiring Long-Term Mechanical Ventilation\"/>\\n(1) Parents caring for children and adolescents with rare diseases fear the long-term progression of the child’s disease and the loss of their parental role. The aim of this study was to examine the quality of life, mental health and associated protective factors of mothers and fathers caring for children with rare diseases requiring mechanical long-term ventilation. (2) In a cross-sectional design, data on quality of life, mental health, coping mechanisms, social support and family functioning from n = 75 affected families were collected using standardized psychometric questionnaires. (3) Mothers compared to fathers were significantly more impaired in their quality of life and mental health. Protective factors significantly associated with the respective outcomes for mothers were coping mechanisms, social support and family functioning, whereas for fathers solely the latter was found to be significant. Multiple regression analyses showed that family functioning may be the most important predictor of quality of life and mental health. (4) The results support the need for family-oriented care in parents of children with rare diseases. To reach optimal efficiency, health care providers should not only screen parents for psychosocial impairment but also provide interventions that consider gender-specific differences in psychological health., authors: Johannes Boettcher, J. Denecke, C. Barkmann, S. Wiegand-Grefe, \\n</Document>\\n\\n---\\n\\n<Document source=\"https://www.semanticscholar.org/paper/bf11968ec7cbf5373a1e1b364f83235c8ad58930\" page=\"Navigating the U.S. health insurance landscape for children with rare diseases: a qualitative study of parents’ experiences\"/>\\nNone, authors: Tai L. S. Pasquini, Sarah L. Goff, J. Whitehill, \\n</Document>'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 92
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "# Pubmed\n",
        "PubMed® comprises more than 37 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites.\n",
        "\n",
        "- https://python.langchain.com/api_reference/community/retrievers/langchain_community.retrievers.pubmed.PubMedRetriever.html\n",
        "\n",
        "- https://www.ncbi.nlm.nih.gov/"
      ],
      "metadata": {
        "id": "3zOfpjCTQnQV"
      },
      "id": "3zOfpjCTQnQV"
    },
    {
      "cell_type": "code",
      "source": [
        "from langchain_community.retrievers import PubMedRetriever"
      ],
      "metadata": {
        "id": "hzaczdOCOlez"
      },
      "id": "hzaczdOCOlez",
      "execution_count": 93,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import userdata\n",
        "pubmed_key =userdata.get('PUBMED_KEY')"
      ],
      "metadata": {
        "id": "gYpzdbgWlqKe"
      },
      "id": "gYpzdbgWlqKe",
      "execution_count": 94,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "retriever = PubMedRetriever(api_key=pubmed_key, top_k_results=5 )"
      ],
      "metadata": {
        "id": "grMc_aR0Onl-"
      },
      "id": "grMc_aR0Onl-",
      "execution_count": 95,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pubmed_docs = retriever.invoke(topic)"
      ],
      "metadata": {
        "id": "nHdyBzQ2O0Nc"
      },
      "id": "nHdyBzQ2O0Nc",
      "execution_count": 96,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "len(pubmed_docs)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2cQMkKrYO9Qj",
        "outputId": "cc3752a7-2011-40c4-e883-87f8a99886c4"
      },
      "id": "2cQMkKrYO9Qj",
      "execution_count": 97,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "5"
            ]
          },
          "metadata": {},
          "execution_count": 97
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "for doc in pubmed_docs:\n",
        "  print(doc.page_content)\n",
        "  print(doc.metadata)\n",
        "  print(\"-\"*50)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "HLKIOM4wPBpZ",
        "outputId": "ae65b268-cfc9-4dd1-ea76-91951e6d92b3"
      },
      "id": "HLKIOM4wPBpZ",
      "execution_count": 98,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Pediatric cholestatic liver diseases are rare conditions that can result from multiple specific underlying etiologies. Among the most common etiologies of pediatric cholestatic liver diseases are biliary atresia, Alagille syndrome (ALGS), and inherited disorders of bile acid transport. These diseases are characterized by episodic or chronic unremitting cholestasis. Due to the chronicity of these conditions, it is imperative to optimize medical management to improve patient quality of life, provide nutritional support, and reduce bile acid toxicity in efforts to slow disease progression. Cholestatic liver diseases remain the leading cause of pediatric liver transplantation, as many underlying disease etiologies have no curative medical therapies. In the present review, we provide an update on the nutritional, medical, and surgical management of pediatric cholestatic liver diseases. As recent advances have occurred in the field with the addition of ileal bile acid transporter (IBAT) inhibitors, we also review the results from prospective clinical trials, including their strengths and limitations. While recent clinical trials have demonstrated improved pruritus using IBAT inhibitors in ALGS and progressive familial intrahepatic cholestasis, establishing medical therapies proven to slow disease progression remains an area of unmet need.\n",
            "{'uid': '39840645', 'Title': 'Recent advances in the management of pediatric cholestatic liver diseases.', 'Published': '2025-01-22', 'Copyright Information': '© 2025 European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.'}\n",
            "--------------------------------------------------\n",
            "Congenital orofacial cleft, the most common birth defect in the maxillofacial region, exhibits a wide range of prognosis depending on the severity of deformity and underlying etiology. Non-syndromic congenital orofacial clefts typically present with milder deformities and more favorable treatment outcomes, whereas syndromic congenital orofacial clefts often manifest with concomitant organ abnormalities, which pose greater challenges for treatment and result in poorer prognosis. This consensus provides an elaborate classification system for varying degrees of orofacial clefts along with corresponding diagnostic and therapeutic guidelines. Results serve as a crucial resource for families to navigate prenatal screening results or make informed decisions regarding treatment options while also contributing significantly to preventing serious birth defects within the development of population.\n",
            "{'uid': '39840621', 'Title': 'Expert consensus on classification and diagnosis of congenital orofacial cleft.', 'Published': '--', 'Copyright Information': ''}\n",
            "--------------------------------------------------\n",
            "BACKGROUND: Early onset hypocalcemia, occurring within 3 days of birth, is prevalent among preterm infants. A central line is required to deliver calcium (Ca). The prediction of hypocalcemia is therefore clinically important when the requirement for initial intravascular calcium administration is anticipated.\n",
            "METHODS: This retrospective study included preterm infants born between 2019 and 2023 with a birthweight <1500 g or a gestational age (GA) <32 weeks in a single tertiary center. Hypocalcemia was defined as serum Ca <7 mg/dL or ionized calcium (iCa) <0.8 mmol/L within 72 h after birth. Perinatal factors and laboratory test results associated with hypocalcemia were collected and analyzed.\n",
            "RESULTS: Of the 348 infants, 20 died within 7 postnatal days, 22 were transferred to other hospitals, and eight were transferred from other hospitals and were thus excluded. Of 298 enrolled infants, 20 were diagnosed with hypocalcemia. In multivariate analysis, male sex, elevated day 1 phosphorus (d1P), magnesium (d1Mg) levels, and maternal premature rupture of membranes (PROM) were significant risk factors for early onset hypocalcemia. These factors, along with birthweight, a widely recognized risk factor, were used to develop predictive models for early onset hypocalcemia. Among the six suggested models, logistic regression exhibited the highest accuracy. Conversely, the random forest model outperformed others in the Youden index and area under the receiver operating characteristic curve.\n",
            "CONCLUSIONS: In our cohort, early onset hypocalcemia was linked to male sex, lower GA, higher d1P and d1Mg, and maternal PROM. Notably, higher d1P has not been previously reported as a risk factor.\n",
            "{'uid': '39840584', 'Title': 'Factors associated with early onset hypocalcemia: A retrospective cohort study.', 'Published': '--', 'Copyright Information': '© 2025 Japan Pediatric Society.'}\n",
            "--------------------------------------------------\n",
            "OBJECTIVE: To study and correlate the clinicopathological findings of Solitary Rectal Ulcer Syndrome (SRUS) in 10 pediatric patients.\n",
            "MATERIAL AND METHODS: This study is a retrospective study of patients from January 2017 to June 2024. The clinical records were reviewed for details of the clinical presentation, colonoscopic findings, associated local and systemic diseases, and other investigations.\n",
            "RESULTS: The mean age of presentation was 10±1 years, and the youngest child was 6 years old. The most common clinical presentation was rectal bleeding and a single ulcer on endoscopy. Histological findings included crypt distortion, crypt branching, and fibromuscular obliteration of the lamina propria. Immunohistochemistry (IHC) for Smooth Muscle Actin (SMA) and special staining with Masson Trichrome (MT) were used to highlight fibromuscular areas whenever in doubt.\n",
            "CONCLUSION: The pathogenesis of SRUS is not well understood. It may be associated with chronic mucosal and hypoperfusion-induced ischemic injury to the rectal mucosa due to trauma or increased rectal pressure during straining. Solitary rectal ulcer is a misnomer, as the patient may present with multiple or no ulcers. Endoscopy and histopathology help to diagnose SRUS. Timely and correct diagnosis reduces the morbidity associated with this entity.\n",
            "{'uid': '39840514', 'Title': 'Solitary Rectal Ulcer Syndrome - A Rare Entity in the Pediatric Population.', 'Published': '2025-01-22', 'Copyright Information': ''}\n",
            "--------------------------------------------------\n",
            "BACKGROUND: Labial adhesion (LA) is a total or partial labial fusion mostly seen in pre-pubertal children and is rare in premenopausal and postmenopausal periods. This review aimed to evaluate risk factors for labial fusion and the recurrence rate following surgical intervention in postmenopausal women.\n",
            "METHODS: According to PRISMA guidelines, international databases including Embase, World Cat, Web of Science, Scopus, Dimension, Open Grey, Cochrane, Google Scholar, and also PubMed gateway for PMC and MEDLINE were searched. The included studies were in English and published from 1985 until December 2023 with the keywords including vulvar diseases, agglutination, menopause, postmenopause, and recurrence. All studies that evaluated the clinical course and recurrence of LAs following surgical treatment in postmenopausal women were included. The inclusion criteria were the risk factors of LA recurrence rate, and the exclusion criteria were studies with missing required data, letters to editors, and conference studies.\n",
            "RESULTS: Thirty-four case reports were enrolled. In total, 54 patients were evaluated. The most common risk factors for LA included hypoestrogenism, virginity, sexual inactivity, cervical cancer, hysterectomy, urinary tract infections, and lichen sclerosis. Only one study reported a recurrence of labial fusion following surgical intervention in a one-year follow-up.\n",
            "CONCLUSION: The most common risk factors for LA were hypoestrogenism, virginity, sexual inactivity, cervical cancer, hysterectomy, urinary tract infections, and lichen sclerosis. The low recurrence rate following surgical release of labial fusion has made it an effective and safe method in postmenopausal women with negligible medium-term recurrence rates.\n",
            "{'uid': '39840303', 'Title': 'The Labial Adhesion in Postmenopausal Women: A Systematic Review.', 'Published': '2024-12-01', 'Copyright Information': 'Copyright: © Iranian Journal of Medical Sciences.'}\n",
            "--------------------------------------------------\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "doc.metadata"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "oKkkv0tePNGy",
        "outputId": "a8d0ed9f-13ed-4038-c5c6-b0a6e1193635"
      },
      "id": "oKkkv0tePNGy",
      "execution_count": 99,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'uid': '39840303',\n",
              " 'Title': 'The Labial Adhesion in Postmenopausal Women: A Systematic Review.',\n",
              " 'Published': '2024-12-01',\n",
              " 'Copyright Information': 'Copyright: © Iranian Journal of Medical Sciences.'}"
            ]
          },
          "metadata": {},
          "execution_count": 99
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "docs_pubmed= []\n",
        "for item in pubmed_docs:\n",
        "\n",
        "\n",
        "  doc = f'<Document source Pubmed=\"{item.metadata.get(\"uid\")}\" \\n Title :\"{item.metadata.get(\"Title\")}\"/>\\n, Abstract: {item.page_content}\\n</Document>'\n",
        "  docs_pubmed.append(doc)\n",
        "\n"
      ],
      "metadata": {
        "id": "G-EwOMJ6PdnE"
      },
      "id": "G-EwOMJ6PdnE",
      "execution_count": 100,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "texto = \"\\n\\n---\\n\\n\".join(\n",
        "        [\n",
        "\n",
        "           str(doc) for doc in docs_pubmed\n",
        "        ]\n",
        " )\n",
        "\n",
        "print(texto)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "hdo2BWz5QcXL",
        "outputId": "93299384-cb69-4767-9736-edad17786f7f"
      },
      "id": "hdo2BWz5QcXL",
      "execution_count": 101,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "<Document source Pubmed=\"39840645\" \n",
            " Title :\"Recent advances in the management of pediatric cholestatic liver diseases.\"/>\n",
            ", Abstract: Pediatric cholestatic liver diseases are rare conditions that can result from multiple specific underlying etiologies. Among the most common etiologies of pediatric cholestatic liver diseases are biliary atresia, Alagille syndrome (ALGS), and inherited disorders of bile acid transport. These diseases are characterized by episodic or chronic unremitting cholestasis. Due to the chronicity of these conditions, it is imperative to optimize medical management to improve patient quality of life, provide nutritional support, and reduce bile acid toxicity in efforts to slow disease progression. Cholestatic liver diseases remain the leading cause of pediatric liver transplantation, as many underlying disease etiologies have no curative medical therapies. In the present review, we provide an update on the nutritional, medical, and surgical management of pediatric cholestatic liver diseases. As recent advances have occurred in the field with the addition of ileal bile acid transporter (IBAT) inhibitors, we also review the results from prospective clinical trials, including their strengths and limitations. While recent clinical trials have demonstrated improved pruritus using IBAT inhibitors in ALGS and progressive familial intrahepatic cholestasis, establishing medical therapies proven to slow disease progression remains an area of unmet need.\n",
            "</Document>\n",
            "\n",
            "---\n",
            "\n",
            "<Document source Pubmed=\"39840621\" \n",
            " Title :\"Expert consensus on classification and diagnosis of congenital orofacial cleft.\"/>\n",
            ", Abstract: Congenital orofacial cleft, the most common birth defect in the maxillofacial region, exhibits a wide range of prognosis depending on the severity of deformity and underlying etiology. Non-syndromic congenital orofacial clefts typically present with milder deformities and more favorable treatment outcomes, whereas syndromic congenital orofacial clefts often manifest with concomitant organ abnormalities, which pose greater challenges for treatment and result in poorer prognosis. This consensus provides an elaborate classification system for varying degrees of orofacial clefts along with corresponding diagnostic and therapeutic guidelines. Results serve as a crucial resource for families to navigate prenatal screening results or make informed decisions regarding treatment options while also contributing significantly to preventing serious birth defects within the development of population.\n",
            "</Document>\n",
            "\n",
            "---\n",
            "\n",
            "<Document source Pubmed=\"39840584\" \n",
            " Title :\"Factors associated with early onset hypocalcemia: A retrospective cohort study.\"/>\n",
            ", Abstract: BACKGROUND: Early onset hypocalcemia, occurring within 3 days of birth, is prevalent among preterm infants. A central line is required to deliver calcium (Ca). The prediction of hypocalcemia is therefore clinically important when the requirement for initial intravascular calcium administration is anticipated.\n",
            "METHODS: This retrospective study included preterm infants born between 2019 and 2023 with a birthweight <1500 g or a gestational age (GA) <32 weeks in a single tertiary center. Hypocalcemia was defined as serum Ca <7 mg/dL or ionized calcium (iCa) <0.8 mmol/L within 72 h after birth. Perinatal factors and laboratory test results associated with hypocalcemia were collected and analyzed.\n",
            "RESULTS: Of the 348 infants, 20 died within 7 postnatal days, 22 were transferred to other hospitals, and eight were transferred from other hospitals and were thus excluded. Of 298 enrolled infants, 20 were diagnosed with hypocalcemia. In multivariate analysis, male sex, elevated day 1 phosphorus (d1P), magnesium (d1Mg) levels, and maternal premature rupture of membranes (PROM) were significant risk factors for early onset hypocalcemia. These factors, along with birthweight, a widely recognized risk factor, were used to develop predictive models for early onset hypocalcemia. Among the six suggested models, logistic regression exhibited the highest accuracy. Conversely, the random forest model outperformed others in the Youden index and area under the receiver operating characteristic curve.\n",
            "CONCLUSIONS: In our cohort, early onset hypocalcemia was linked to male sex, lower GA, higher d1P and d1Mg, and maternal PROM. Notably, higher d1P has not been previously reported as a risk factor.\n",
            "</Document>\n",
            "\n",
            "---\n",
            "\n",
            "<Document source Pubmed=\"39840514\" \n",
            " Title :\"Solitary Rectal Ulcer Syndrome - A Rare Entity in the Pediatric Population.\"/>\n",
            ", Abstract: OBJECTIVE: To study and correlate the clinicopathological findings of Solitary Rectal Ulcer Syndrome (SRUS) in 10 pediatric patients.\n",
            "MATERIAL AND METHODS: This study is a retrospective study of patients from January 2017 to June 2024. The clinical records were reviewed for details of the clinical presentation, colonoscopic findings, associated local and systemic diseases, and other investigations.\n",
            "RESULTS: The mean age of presentation was 10±1 years, and the youngest child was 6 years old. The most common clinical presentation was rectal bleeding and a single ulcer on endoscopy. Histological findings included crypt distortion, crypt branching, and fibromuscular obliteration of the lamina propria. Immunohistochemistry (IHC) for Smooth Muscle Actin (SMA) and special staining with Masson Trichrome (MT) were used to highlight fibromuscular areas whenever in doubt.\n",
            "CONCLUSION: The pathogenesis of SRUS is not well understood. It may be associated with chronic mucosal and hypoperfusion-induced ischemic injury to the rectal mucosa due to trauma or increased rectal pressure during straining. Solitary rectal ulcer is a misnomer, as the patient may present with multiple or no ulcers. Endoscopy and histopathology help to diagnose SRUS. Timely and correct diagnosis reduces the morbidity associated with this entity.\n",
            "</Document>\n",
            "\n",
            "---\n",
            "\n",
            "<Document source Pubmed=\"39840303\" \n",
            " Title :\"The Labial Adhesion in Postmenopausal Women: A Systematic Review.\"/>\n",
            ", Abstract: BACKGROUND: Labial adhesion (LA) is a total or partial labial fusion mostly seen in pre-pubertal children and is rare in premenopausal and postmenopausal periods. This review aimed to evaluate risk factors for labial fusion and the recurrence rate following surgical intervention in postmenopausal women.\n",
            "METHODS: According to PRISMA guidelines, international databases including Embase, World Cat, Web of Science, Scopus, Dimension, Open Grey, Cochrane, Google Scholar, and also PubMed gateway for PMC and MEDLINE were searched. The included studies were in English and published from 1985 until December 2023 with the keywords including vulvar diseases, agglutination, menopause, postmenopause, and recurrence. All studies that evaluated the clinical course and recurrence of LAs following surgical treatment in postmenopausal women were included. The inclusion criteria were the risk factors of LA recurrence rate, and the exclusion criteria were studies with missing required data, letters to editors, and conference studies.\n",
            "RESULTS: Thirty-four case reports were enrolled. In total, 54 patients were evaluated. The most common risk factors for LA included hypoestrogenism, virginity, sexual inactivity, cervical cancer, hysterectomy, urinary tract infections, and lichen sclerosis. Only one study reported a recurrence of labial fusion following surgical intervention in a one-year follow-up.\n",
            "CONCLUSION: The most common risk factors for LA were hypoestrogenism, virginity, sexual inactivity, cervical cancer, hysterectomy, urinary tract infections, and lichen sclerosis. The low recurrence rate following surgical release of labial fusion has made it an effective and safe method in postmenopausal women with negligible medium-term recurrence rates.\n",
            "</Document>\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "id": "06cb1603",
      "metadata": {
        "id": "06cb1603"
      },
      "source": [
        "Now, we create nodes to search the web and wikipedia and Semantic Scholar\n",
        "\n",
        "We'll also create a node to answer analyst questions.\n",
        "\n",
        "Finally, we'll create nodes to save the full interview and to write a summary (\"section\") of the interview."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 102,
      "id": "9c863768-2278-415b-aef1-96fd18c1b1cb",
      "metadata": {
        "id": "9c863768-2278-415b-aef1-96fd18c1b1cb",
        "outputId": "0afd1671-c175-4f03-c9a8-fc179796bf70",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 647
        }
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "image/png": "iVBORw0KGgoAAAANSUhEUgAAAusAAAJ2CAIAAABpY1v3AAAAAXNSR0IArs4c6QAAIABJREFUeJzs3WdYE9nbBvATCJ3QO6E3EamiIiCggAqCDSxr72XV1bW76trLuu7asGN3xbJWbFhQkC4oKyhFEBSQAKElIYTU98Ps5vUPiKjATMjz++AVMpPJQxhn7pxz5gxJJBIhAAAAAACJIoN3AQAAAAAAXw0SDAAAAAAkDyQYAAAAAEgeSDAAAAAAkDyQYAAAAAAgeSDBAAAAAEDykPEuAAAAOgybKaytaGpg8BvqBQK+UMDHu6B2kJFBZHkZZTVZFTWypp68iros3hUBIBlIMB8MAEDS1dN5BZmsd9kNIhGSkyMpq8uqqJFV1Ml8rhDv0r5MlkxqZAkaGAI2gy8UID5PaNFLxdqFoqknh3dpABAaJBgAgARrYguToumNDQJNPXmLXioG5op4V/S9Kkua3mWx6qp4ZDKpf6iOiho0yQDQOkgwAABJlRlX/zym2jNUx6G/Gt61dLzc58yk23TnARq9AzTxrgUAIoIEAwCQSPdP0wzMlVz81PEupHNlJzGKslmhc4zwLgQAwoFrkQAAkufK3lJrF9VuH18QQr081Zy8Nc5te493IQAQDrTBAAAkzIXfPniP0DHtoYx3IV2n4j3n3mnatA3meBcCAIFAggEASJKYczQLBxVbNwrehXS14jfsrMS60NnQnQTAvyDBAAAkxqtn9QK+yHWgBt6F4CM7idHUKOjtDwN7AUAwDgYAIDEEfFHCTbrUxhdsTEzm0zo2U4B3IQAQAiQYAIBkSIqu9grVxrsKnHmF6iRF0/GuAgBCgAQDAJAAbIaQUc1z9u2iBpjs7Oympia8Xt6GHn0pfJ6orpLXGRsHQLJAggEASIDCLKaKRhfdxy06OnratGmNjY24vPyL1HXkCl+xOmnjAEgQSDAAAAlQlN1g4aDSNe/1zc0n2IURndT6ImbhoPIuu6FT3wIAiQD3pgYAEJ2AjxpZAjP7jp8AhsPh7Ny5Mz4+HiHk6uq6fPny9PT0nTt3IoQCAgIQQhs2bAgNDa2oqDh06FBiYiKLxTIzM5s+ffrQoUMRQnV1dQEBAYsXL87Ly3v69GmPHj1GjBjR8uUdW7OBuaKsLKmRKVCiwC2TgFSDBAMAILp6OpfP65R5H06dOnX79u158+bp6Ojcvn1bSUnJy8tr0qRJ58+f37t3r6qqqqmpKUKIz+e/fv06PDxcQ0MjNjZ23bp1JiYmDg4O2EZOnDgxZsyYI0eOyMrK6uvrt3x5hxMKRXV0HiQYIOUgwQAAiK6BIVBR75Sz9cePH5WUlKZNm0Ymk0eOHIk9SaVSEUK9evXS0Ph34LCxsfGVK1dIJBJCaMSIEQEBAU+fPhUnGEdHxwULFoi32fLlHU5FndzA4HfSxgGQFDAOBgBAdA0Mvopap3zdCgoK4nA4ixYtKigoaHvN/Pz8pUuXDh06dNSoUQKBoLq6Wryob9++nVFbG1TUZNkMmBUGSDtIMAAAwhMhOYVOOVh5enru27evurp6/PjxW7du5fNbb9h4/vz51KlTuVzuhg0bdu3apa6uLhQKxUuVlJQ6o7Y2yMnLwGzqAEAvEgCA6JRUZRnVnTUDiqenp4eHR1RU1J49ewwNDWfOnIk9/+kdVyIjI6lU6t69e8lkcjsjS6fesIVRw9MxUui87QMgEaANBgBAdCpqZHbnDPvgcrkIIRkZmYkTJ+rq6ubm5ooDSlVVlXi1uro6W1tbLL5wuVw2m/1pG0wzLV/e4RoYAmU1GMYLpB20wQAAiE5Vk9xJ42AuXrwYFxcXHBxcVVVVVVXVs2dPhJCzs7OsrOzu3buHDx/e1NQUFhbm7u4eHR198+ZNdXX1v/76i8FgFBYWfq6VpeXLO7xsRWUZiqZch28WAMkCbTAAAKJTVJbhNgnLizgdvmUqlcrlcvfs2XPjxo3x48dPnjwZe3Lt2rXv37/fvXv3w4cPEULz58/v37//77//vmvXrn79+v322290Oj09Pf1z22z28o5VQ+PWVfHUtOH7J5B2pE7trAUAgA6R8bi2iS30lPo7OyKEMh7VcjnC/iHwUQBpBykeACABLHqppt2rbmOFxsbGoKCgVhdRqdTS0tKWz/v6+m7atKnjamxdRETE33//3fJ5BQWFVu8/QKVSz58/38YGayt5vTzVOrRGACQStMEAACRDzBmapZOqjatqq0tFIlF5eXmri0ik1g90SkpKmpqaHV1mc/X19Q0NrdzGiMvlysvLt3yeTCbr6el9bmsfctmZT+uGzzPq6DIBkDyQYAAAkoFZw78WUTr1V3O8C8HTxd8/BEww0DFuJfoAIG1gJC8AQDJQtMg9+qjlZzDxLgQ377IaTGxVIL4AgIEEAwCQGP2CtDLj6io/tDJ8pNurq+IlRdO9RsAAXgD+BQkGACBJxi41+Xt/qYAvdd3fF3a+n7DKDO8qACAQGAcDAJAwQoHo5IbisEXGmvpS0Z/CrOVf2v1h+kYLWTkS3rUAQCCQYAAAkkckRBd2vfcM0bXopYx3LZ2r9G3jowsVE1ebdtK9LQGQXJBgAACSKv4avaqM4xWqY2CuiHctHa+qtCkpmq6uI+83RhfvWgAgIkgwAAAJ9vEdJymarmeioG+maNlLVU5B4vtZBDzRu+yGig+csoJGzxBtE7tu3sgEwDeDBAMAkHjFb9j5L5hFWSxzBxVFFVlliqyyGllZVVYgkIDjm6ysTGMDn80QsJn8pkZhQSbLspeKjRvF0lEF79IAIDRIMACA7qP0bWMNjctm8tlMAUKoqVHYsdtPS0tzd3eXkenIISlkORkZWaRMkVVRI2vpy1NtlTpw4wB0Y5BgAACgvTw9PZ88eaKgoIB3IQAAmA8GAAAAABIIEgwAAAAAJA8kGAAAaC8HBwcSSeIvdwKge4AEAwAA7fX69WsYOwgAQUCCAQCA9tLU1IQ2GAAIAhIMAAC0V21tLbTBAEAQkGAAAKC9qFQqtMEAQBCQYAAAoL1KS0uhDQYAgoAEAwAA7eXs7Ix3CQCAf0GCAQCA9vrnn3/wLgEA8C9IMAAAAACQPJBgAACgvbS1tWEkLwAEAQkGAADaq7q6GkbyAkAQkGAAAKC99PT0oA0GAIKABAMAAO1VWVkJbTAAEAQkGAAAAABIHkgwAADQXra2ttCLBABBQIIBAID2ys/Ph14kAAgCEgwAAAAAJA8kGAAAaC9HR0e8SwAA/AsSDAAAtFdWVhbeJQAA/gUJBgAAAACSBxIMAAC0F9ybGgDigAQDAADtBfemBoA4IMEAAAAAQPJAggEAgPZycHCAGe0AIAhIMAAA0F6vX7+GGe0AIAhIMAAAAACQPJBgAACgvTQ1NaEXCQCCgAQDAADtVVtbC71IABAEJBgAAGgvOzs7aIMBgCAgwQAAQHvl5eVBGwwABAEJBgAAAACSBxIMAAC0l6GhIfQiAUAQkGAAAKC9ysvLoRcJAIKABAMAAO3l5OSEdwkAgH9BggEAgPZ69eoV3iUAAP4FCQYAANrLxcUF7xIAAP+CBAMAAO2VmZmJdwkAgH9BggEAgPYyMzODa5EAIAgSjKsHAIC2BQUFycnJkUikyspKHR0dEokkEAiMjY2PHTuGd2kASC8y3gUAAADRycrKfvz4EXtcXl6OEFJXV588eTLedQEg1aAXCQAAvsDR0bHZMzY2NgMGDMCpHAAAggQDAABfNn78eENDQ/GPampqU6ZMwbUiAAAkGAAA+BJnZ2c7OzvxqEE7OztPT0+8iwJA2kGCAQCAL5s4caKOjg7WADNx4kS8ywEAQIIBAIB2cHV17dmzJ0LI1tbW29sb73IAAHAtEgAAVyIRqq3g1lXxhEKiz+wQ7DujpkQ+dNDYgn9YeNfyBTIkkpqOnJa+vIws3qUA0GlgPhgAAG7yXzCzEhmNLIGRlVIDQ4B3Od2HsiqZ9p4tryjj0E+tp4ca3uUA0CmgDQYAgI+3L1k5aazAScYk6M3uHCIRSrhWIRIiB08IMaAbgiMHAAAHRdkNr5OZg34whPjSeUgkNCBMv+gNOy+diXctAHQ8OHgAAHCQGVfvOUIP7yqkgudwvewkBowXAN0PJBgAQFfjNgorSzhKqjDKtCvIKcgwanisOj7ehQDQwSDBAAC6GqOGr2+mhHcVUkSPqsSo5uJdBQAdDBIMAKDriRoZPLxrkCIcNh8hEt5VANDBIMEAAAAAQPJAggEAAACA5IEEAwAAAADJAwkGAAAAAJIHEgwAAAAAJA8kGAAAAABIHkgwAAAAAJA8kGAAAAAAIHkgwQAAAABA8kCCAQAAAIDkgQQDAAAAAMkDCQYA0N2s+3XZ3HmT8K6iORaLlf8299Nn7t67OXJ0QEUFDb+iAJBgkGAAAKArzJoz/t69m58+Iy+voKKiKiMDx2EAvgUZ7wIAAEAqcLncZs8E+A8N8B+KUzkASDxIMAAACZCVlXnufGRWdiZCqIedw7x5S+xs7RFCHA5n7/6dSUnxCCEnJ9eFPy43MDD89IX37t/a9fvm9eu2Dxo4uI3tczicEycPPXn6oLGR7ebaV1tbh8Go/3X9jhMnD126fO7B/WRstdy8N/N/nLJzx/5+fT0RQi8z049HRhQW5mtqarm69Jk1c4G2tg5C6ELU6Rs3LzOZDGtru2lT5/Z26zt+Qkhtbc2Nm1du3Lyir29w8cLtnbs2xsTcRgg9jEkhk8kIoTc52UeO7s3Le6OoqOTZ32f+/J/VKGoIodARfksWr0lIeJKSmqCiohoaEjZ1yuxO/rwBkADQegkAkAA02scmbtPkSbOmTplDo31cveYnDoeDELoQdSom5nZ42IS5c35iMOqVlJQ+fVVBQf6+/b+NCZ/YdnwRCoVr1/189VrUAO+BS35ara9vGH372hdLyniRtnLVQnMzy+XL1o8Nn/Tq1Yuly+dxOJyMF2nHIyOcnNyWLvnFQN+wkc1GCG3csItCURvgPXD/3siNG3YhhEaPGh8YGCzeWnHxu2XL5/F4vJUrNkydPDsh4cmmTavES3f+tsHa2m7vnuOBAcGnzxxNSUn4xs8RgG4E2mAAABIgICBIfL63s+u5dNm8rOzMPu4e5bSPSkpKE36YRiaThwWP/PQlLBZr4+ZVPXo4zJm9qO2Np6QkvHj5fO6cn8aPm4IQCgwMzniR+sWSDkT8Hhoy+qdFK7Ef3d09pk4Pf56ezGDUI4RGjRjr4OAkrrmHXU8ymaytrePo6II9Y2vTw9zMUry183+dkJGR2fVbBEWVghCiUNS27/z1n39eODu7IYSCg0ZMnDAdIWRtZXvn7o209GQPD++v/AgB6G4gwQAAJACJRHqW8OTylfPv3xcpKysjhGprqhFCAf5Bjx/fX7V60YIfl1laWn/6kt93by4rK/llzRasj6YNGS/TEEKhIWHtr4dGK3//vqisrOT2neufPl9ZWeHnG0ChqG3fsX7RwhXtzxmZ/2S4uvbB4gtCqE+f/gihvPw3WIJRVPy3bUlWVlZXV6+aXtX+UgHoriDBAAAkwNlzkadOHwkb/cOcWYuqa+ibNq8WioQIoX59PXds33fk6N6Zs8cPCx65ZPFqLK8UFOaX0z7q6elHRZ3esnl32xtnMhmqqqoqKirtr6e2thohNHXKHJ8Bgz59XktLR1VVNWL/yYOH/1yzdkmvXs6/rtuhq6v3xQ02NLA01DXFP1IoagghemtJhSxLFggF7S8VgO4KEgwAgOj4fP6FqFPDgkcuXLAMa+f4dGm/vp593D2uXos6dHiPvr7h5EkzEUJycnLbt+6prqFv3LQqPSPVvXe/Nravo63LYrEaGxubDaPB2n5afYmqKgUh1NTEMTU1b7nU1NT8tx37X7x8/uuG5b/t2rj790PY8yKR6LM16Ohh3U+Y2toa8bsAAFoFI3kBAETX1NTU1NRka2uP/VjPqMOG34ovUZaRkRkTPlFHR/ftf1PGmZla9Orl7Ovj7+rifiDidz6f38b2sS3fvXuj5SJ1dU0ej1f/X7ag0T5iD6hUU319g3v3bzU2NmLP8Pl8Ho+HPcaqcnPt4+ExQDyLnZKiUnU1/XM1ODg4Zf6TgQ1PRgjFxz9GCIkHzQAAWoI2GAAA0amoqFhaWl+7flFLS7uBxTpz9piMjMy7dwUIoWvXLyYmxQUGBFdXV9HpVXZ2PZu9duGC5bPnTrh+49KY8Imf277PgEHm5paHjuwpKy+1s7EvKi4sKyuxMLdCCLn37kcikSIO7g4Pm1BcVHj0+H7sJSQSacGPy37dsGLBomnDQ8OFAkHMg9uBgcHhYRNycl9v2rxq5IixSkrKaWlJPf4rydHR9XHs/QtRpykUNYeeTs1G7UyaMCM2NmbVmkWhIWGVlbQzZ4+5uri7OPfuhI8TgG4C2mAAABJg/drtSopKm7esuXTl3Pz5P0+eNDMmJprH4xkZUXlc7uEje+7cvTF69PhxYyc3e6GlpfWI4eFnzh6rqan+3MZlZGR2bt/v2d/n/v1bEQd3l5Z9UFfXwBaZmVmsXrkx503W4iWzHsfenzv7J/GrBngP3LFtrxxZ7uChP86ej9TXN3RyckMIycvJm5laXLhwKjIywsnJdfmy9dj6c+f85Orifu585IULp8o+ljSrgUo13bUzgsfj7fp906XL5wIDgjdv2v25PiwAAEKI1Ea/LAAAdAZ6WdPD8xUh80zxLuSzps8ca2Fu9ev6HXgX0jEenCnzCNYytm4+ygcAiQa9SAAAqfDTkllFRQUtn/f09F2zahMeFQEAvgskGABA1xGJRKWlpflZ5UKRfhe/9a/rdvD4vJbPKylKY8tEfn5+RkbG/fv3z5w5g3ctAHwjSDAAgE7BYrHKyspK/1d5eTmVSrWiurgaT+vienR0dNu/8qkTlzuzFtxkZGSkpKQkJibW1dXR6XSBAOaVARIMEgwA4HtVVVWVlpY2yys8Hs/Y2JhKpVKpVHt7+8DAQCqVamRkJB4Hg3fV0uXMmTOpr+41NDTU1dUJhUIZGRls1hy86wLg20GCAQC0l0AgEAeUT/OKmpoa9T/e3t7YAw0NDbzrBf8vPz+/tLQUu7gJiy8IIQoFZswDEgwSDACgFSwWq7SFyspKcVIxNjbu3bs39lhBQQHvesEXrFmz5uhZlJGR0dDQIH6yvr4+ICDg0aNHLBYrKiqqZ8+eXl5euJYJwFeABAOAtKusrPw0pmCNKwKBQBxWHBwchgwZQqVSDQ0N8S4WfCNVVdU///zz7NmzUVFRVVVV2KjqtLQ0bKmcnJxAIHj27JmXl1dxcfHq1au9vb0XLlzIZDJra2tNTYl73TuQZpBgAJAWfD6/ZbNKWVmZhoaGOKz4+vpig1egD6hbmjJlirOz85YtW4qLiz+dLk9BQWHevHnYY3Nz861bt1ZUVGCNNIsXL9bV1T127FhhYeHTp0/79u3r6OiI328AwP+DBANAN8RgMLCAQqfTCwsLscfV1dXiobVUKrVfv35YZ5C8vDze9YKu4+zs/Pfff69fv/7JkyefW8fa2tra2hohRKVSr1+/jl2ypKGh0dTUlJaW5ujoGBcXd/To0VGjRo0ZM6aiooLH41Gp1K79PQCAOXkBkHA0Gq1lywqJRMJiio2NjZaWFvbYwMAA72L/Rfw5ebuZmNOl7oPVzO3VOnCbeXl5bDbb1dX1+fPnW7du9fLyWrlyZWpqak5Ojo+Pj6WlZQe+FwCtgjYYACQDl8ttmVRKS0vd3d2FQiGWUfz9/bEHBL/G5MOHD0IRNPx0HaFItGTJEh0TmX79+vXr18/Jyen7t2lnZ4c96NOnz82bN7G7fxsYGDx//vz169eWlpanT59+9OjRnDlzfHx8ioqKFBUVYRwV6FjQBgMA4Yj7gEpLSxsaGl69elVaWlpXV0dtjaysLN71tguHw0lMTExOTk5MTDTUsh3U6+cRP5rjXZS0wO6LVMXKS0lJSU1Nffv2rYeHR79+/Tw8PExMTDrpTQUCQX5+PplMtrGxuXbt2smTJ5csWRIQEBAVFSUQCIKDg7W0tDrprYGUgAQDAJ4qKytLSkqaNatg4w8wVlZWenp6VCpVT08P72K/RV5eXlJSUlJSUk5Ojud/ZHjq0IvUlZrd2bGxsTE1NTUlJSUlJUUgEGBRpl+/fp3ddCcQCGRlZdPS0pKSkgYNGuTk5LR+/fqSkpKNGzeam5tnZ2fr6+vr6n7F1MlAykGCAaCLYOkEyyslJSUlJSWqqqo0Gs3ExKRZs4qaWkeOV+h6LBYLa2tJTk7W1tbGUoubm5t4hZoKXtItuu9Y6FPoIgnXK9wGauibtTJtz8ePH1NTU7FAY2JigqUZd3f3rimMy+Xm5+cbGBjo6Ojs2rUrNjZ23759dnZ2586dk5OTCwsLg1mDQRsgwQDQwXg8njimiP8tLS39NKOY/Kc7HaDfvHmDNbcUFhb279/fy8urf//+Ojo6ra58aHnBxF+sZGRJrS4FHevclsK5Oy1lyV/4tN+8eYOlmRcvXmAjZjw8PLCLkroM1k4TFxeXlpY2d+5cFRWVoUOHuru779ixg8ViFRcX29rawtVzAAMJBoBv19jYWPIfcRNLdXU11qwi/hd7gHexnYLJZCYmJmLBxdDQEGtucXZ2/uILYy9VGttQjKyk8b7QXazyA6fwn/rBk77iZuACgSD1PzU1NYGBgfb29h4eHp/Lo52qpqampKTE2dmZTqcvW7aMRCKdPn26tLT05s2brq6unp6eXV8SIAhIMAC0C4vF+vDhQ0VFBTa9ChZZGhoaxK0p4shCnIuWO092djYWXBQVFXV1dbEWl6+dBO/42nfD55spUyRjJLKE4nKEtw5/mLTGTE7hG5u7qqurX7x4kZCQkJKSoqGhIW6bwXcIOZPJvHLlCpvNXrhwYWlp6bJly5ycnNauXcvj8WpqavT1vyKuAckFCQaA5phM5ocPH0r+F5/PNzExcXZ2VlFREY9cweUrKV5qa2vFFxOZm5tjzS29evX65g3ymkTnthU7+WqrqJM1dOVFQjgWdRiSDGLQeax6QcbDqinrzRWVZTpkswUFBeJBM25ubn5+fs7Ozvb29h2y8e8s7MOHD4MGDWIymePGjTM2Nj5+/HhJSUl6erqbm5uZmRneBYJOAQkGSDUsrJSWlr5//14cVgQCgampqcknTE1NpXaW/VevXiUmJpaUlKSlpWFDW7y8vDrwopWMR3Vl79hIRKqr5HbUNjsPk8mkUFQRIvrwHTVtOZIMMrJU6jNYs5PeIj09PTs7+9GjR+Xl5R4eHh4eHm0Me+piDQ0NKioqlZWVx44dU1dXX7RoUVxc3N27d0NCQgYMGIAtxbtG0AEgwQBpwWKxSkpKPnz4gEUWrJWFz+ebmppaWFgYGRlhSQVuCYTdDQfrJEpISLCwsPDy8vLx8bG1tcW7Lvx5eno+efIE7sX9qbq6upT/qKur9+/fHws0eNf1PxoaGpKTk8lksp+f3/3793fu3Dlv3rzx48cXFRU1Njb26NFDRqZjmqlAV4IEA7ohNpuNxZTi4mJszMqHDx+4XC7WsoLFFFNTU2luWWlVTk5OQkJCYmLihw8fvP5D8Ol9uxgkmLYVFBSI00xISIi1tbWnpycB7zDAYrFqampMTU3T09P37dvn4OCwevXqFy9eYLdE6LxZ/kDHggQDJBuPx/vQApvNNjMzs7KyMjAwwMasmJqawgSgreJyuQkJCc+ePUtISLCxsXFycvL29v6e0S3dGySY9nv+/HlCQkJSUhKbze7fvz82cEpRURHvuj6rpKTkypUrZmZmYWFhUVFRGRkZU6dOdXR0ZDKZkOOJCRIMkCQlJSVlZWXv3r0ThxU6nW7aAkE644mspKQESy0vX7709vYeMGCAt7c3hLwvmj9//t69eyHBfBUajZacnJyUlJScnNyjRw8syvTo0QPvutrCZDLT09O1tLScnZ0jIiJu3LixdetWDw+P7OxsTU1NY2NjvAsECBIMIC46nV5cXIzFlPfv32P/UqnU3r17Kysri8MK3Cvuq2Bfi589eyYUCrHU0q9fP7yLkiTQBvOdXr58iUUZGo02bNiwnj17ent7E39cbW1tLZ/P19XVvXDhwsWLF1euXOnt7X3r1i0lJSUfHx/YH/ACCQbgj8VilZaWFhUVYUkFCysqKipmZmampqbYv9gDEono14AQEIfDiY+Pj4uLS09Pt7CwwFpc4PrSbzN9+vSjR4/CnLDfr7a2NiMjIzY2NiEhwdbW1tvb28vLy8bGBu+62oXP55PJ5EePHj169GjSpEm9evXavXu3vLz8tGnTJP2WIJIFEgzoaiUlJe/fvy8uLn7/Hw6H4+vrKxQKP40sysrKeFcq2SoqKuLi4uLi4jIzM318fHx9ff38/Ig8CkEiQBtMZ8jMzExISEhISGAwGF5eXt7e3t7e3pJy03VMbm5uamqqv78/lUqdPXu2srLy5s2b1dXV6+rq4HKBzgMJBnQiBoMhTirFxcXYY2NjY3Nzc7NPwLCVDpSXlxcXFxcfH19TU+Pr6+vr60u061ol2ty5cw8cOABtMJ2koqIiMTERSzN9+/bF2gslbtAJg8F49eqVk5OTmpraxIkT6+rqLl++rKKikpmZ2bNnT9h5OhAkGNBhysrKioqKij/Rs2dPJpNpZmaGRRbsX5h3oTO8fPkyNjb2/fv3dDodCy4EHykpoaANpsukpKQkJCRkZ2ez2Wxsl5bQS+RoNJq2tracnNyCBQtevHiRnJzM5XLv37/v7OwMnbnfCRIM+BZNTU3FxcXN8oqenp6FhYX5JzQ1O2s+UIBJSUl58uTJ48ePzc3NBw0a5O/vD3eE6VTTpk07duwYfI3uSoWFhViz4sePH318fPz8/Ly9vfEu6rvw+fxt27aVlpYeP36cRqPduHHDy8vL0dER77okDyQY8GVMJvPdu3dF/2lqasrKyjI3N2+WV+Tk5PCuVFrEx8fHxsbGxsY6OjoOHDjQ398fwmLXgDYYHFVXV2Nj0hMTE7FWGR8fH3V1dbzr+i7JD92qAAAgAElEQVQcDuf8+fMMBmPp0qWZmZm3b98OCAiAnt92ggQDmquursaSiji1NDU1WVpaWvwHmykO7zKlUVxc3P3792NjYz09Pf39/QcOHEj8y1C7GUgwRCAUCuPj458+fRofH+/r62tjY9M9Wh/ZbHZMTExDQ8OkSZNSUlIuX74cGho6cOBAvOsiLkgw0o5OpxcWFhYVFRUWFvL5/KdPn8rJyVlaWpqbm4tTC4y0xdezZ89iYmIePHgQHh7u4uIyaNAgMpmMd1FSasaMGUeOHIFeJOLIysp68ODB48ePdXV1/f39/f39JW7kb6v4fH5iYiKTyQwJCXnw4MGlS5cmTZo0cOBA7EJuvKsjCkgw0oVOp7/7RGFhoYKCguV/bG1tTU1NYT4DgkhNTX3w4EFMTIy7u/uQIUMGDx4sWdeXdkvQBkNY2dnZjx8/fvz4MYVCwaJMdxonm5mZ2dDQ4OXlFRUVdefOnYULF3p4eHA4HCmfHwESTHfGYDAKCwsLCgpoNNo///zz7t07rH3FysoK6wyytLSEvEI0mZmZWIuLnZ3d4MGDhwwZoqSkhHdR4F+QYIgvNzcXizJycnL+/v4BAQEEvLXk98jJyREIBL169dqzZ09aWtqWLVusra3ZbLYUzqEFCab74PP5BQUFWGTBcDgcKysra2trBwcHKpVqaWkp6aPeurHS0tLo6Oi3b9/W19djLS4wERYBBQQE3L17F3qRJEJBQcHjx4/fv39fVFQUFBQUHBzc/TrE8/PzlZWVqVTqvHnzGAxGRESElpaW9PQ0QYKRYDQaLT8///37969fvy4oKCgpKbG2tsYiC0ZPTw/vGsEXCIXC6Ojo6Ojoqqqq0NDQ4cOHw1+NyKANRhLl5+ffu3fv3r175ubmQ4cODQ4O7pYZNC8vz9DQEJtGT1FR8ffff+/292qFBCMxhEJh/n/evn2bl5enqqpqY2Pj7OxMpVKtra3Nzc3xrhF8hfT09Ojo6Lt374aGhoaGhrq6uuJdEfiykJCQa9eudcvznzRIT0+/d+/e3bt3BwwYEBQU1I0v88nMzDQzM9PU1Bw3bpyxsfH27du75YgZSDDExWKxcnNzi4uLMzMz3759++7dOzs7OxsbG1tbWxsbGzs7OwqFgneN4KvV1NTcuXPn0qVLVCo1JCQkJCQE74rAV4A2mO7h8ePH9+7dS0lJmThxop+fn729Pd4VdRYul5ucnOzu7q6iojJmzBhfX9+FCxfiXVSHgQRDIAwGIycnJzc3F/u3trbW3t6+T58+RkZGNjY21tbWeBcIvktmZualS5fS09OnT58+aNAgmFNHEkGC6U44HM6TJ0/++usvEokUFhY2cuRIvCvqXB8+fHjx4sXIkSNzcnIOHz48adKkvn374l3Ud4EEg6eGhobXr18XFRVlZGTk5uYymUx7e/sePXrY29vb29tTqVS8CwQd4/bt2xcvXlRQUBg3btzgwYPxLgd8u/Hjx589exZ6kbqZN2/eXLt27ebNm2FhYWFhYTY2NnhX1OkSExNra2tDQkKioqLq6urGjx8vifN6Q4Lparm5udnZ2W/fvs3IyKisrHRwcOjXr5+JiUmPHj26x0RMQKympubixYsXL14cNGjQ+PHj4VaL3QC0wXRjQqHw2rVrf//9t6KiYlhYWGhoKN4VdQU6nX7jxg1LS8tBgwbdvn3bwMDA3d0d76LaCxJMp6urq8MGsqSmpmZnZ1tbW/fq1cvZ2dne3h7G3nZXNBotMjKyvLzczc1t/PjxMPd/twEJRhpkZWVdvXo1OTl53LhxU6dOlZ6ZJFNTU0+dOjVv3jwXF5eMjIzevXvjXdEXQILpFKWlpS9fviwoKIiPj2cymc7Ozn379rW1tXV0dJSSy/SlVmVl5aFDh9LT02fNmtXtu9Wl0PTp048ePQq9SNKAzWafOnXqzJkzc+fOnTBhgvRMLIlNJ7Nx48bHjx/HxcWJRCLCZjhIMB2mtLQ0PT09PT09KysLIeTq6urh4dGzZ09TU1O8SwNdgc/n7927Ny4ubu7cuXCFUXcFbTBS6Nq1a3/++efYsWPnzZsnVeGVzWYrKSlxudyQkJDJkydPmTIF74qagwTzXWpra1NTU1NTU7H5+93d3d3d3Xv37q2rq4t3aaBLRUVFRUZGzpo164cffsC7FtCJIMFIrTNnzty7d2/o0KHTpk3Du5auVlNTk5CQMHz48NTU1NLS0tDQUIIkOUgw3+Lly5cJCQlJSUnq6uo6Ojp9+/bt27cvXBwrnXJycjZu3NinT5/ly5fjXQvodPPnz9+7dy8kGKkVERFx586ddevWeXl54V0LDlgs1tmzZ8lk8pw5c96/f4/7vTMhwbQXm81OSUl5+PDhs2fPBg0aZGlp6enpaWtri3ddAE8HDx6srKycPHkyzNYjJaANBlRWVp49e7aiomLLli3dcqLbdvr777/Pnz9/8OBBHK+ihQTzBbW1tbGxsY8ePcrOzg4PD7e3t/fx8ZHmvRZgmEzm1q1b7ezsZsyYgXctoOtAggGY2NjY/fv3L1iwIDAwEO9acFNSUsLn8y0sLCIiIsLDw7u+IwISTOuampru3buXlZUVFxcXFBQ0YMAASZ+7EHSgtLS0lStXnj59Gq6HlzZwLRL41OrVq3V0dKAH+caNG1iTDJvNVlZW7rL3hQTT3MuXL69evVpTU2NoaBgSEgL32wPN3L59Oysra82aNXgXAnAAbTCgmTt37ly8ePHcuXN4F0II+fn5+/fvX7t2raGhYRe8HcxN8v+uXbt27tw5d3d3b2/voUOH4l0OIKKCgoIHDx7s378f70IAPrS0tEgkEt5VAAIZNmyYhYXFokWLDhw4gHct+LO1tZ04cWJiYmJ4eHhpaWln3xsH2mAQj8c7fvz4w4cPhw4dGhQUBNO3gM+B1hcAbTCgVUwmc+bMmZcvX8a7EAL5448/qqqqtm/fLiMj00lvIe1tMFFRUXfv3vXz87t27Rp8tQJtyMzMvHHjRmRkJN6FAAAIh0Kh7NixY8SIETdv3sS7FqJYtmzZw4cP6+vreTyenp5eZ7xFZyUj4ktOTl64cKFQKDx37tzMmTMhvoA2iESibdu2HT16FO9CAM4cHBzgWAFaZWVl9fPPP2/duhXvQggkMDBQU1NTVlbWz8+voKCgw7cvpQnm+PHj8fHx27ZtmzhxIt61AAkQERExe/Zswt4cBHSZ169fQ887+Bw/Pz8VFZUnT57gXQixaGtrR0dHv3v3DiHE5XI7cMvSmGCOHDliYGCwatUqdXV1vGsBEqCsrKykpGTw4MF4FwLw5+TkhHcJgNCmTp1669YtvKsgHAqFgh1CFy5cmJKS0lGblboEs3PnTl1d3dDQULwLARLj4cOH/fr1w7sKQAivXr3CuwRAaFpaWqampnFxcXgXQlDHjh17/vx5R21NuhLM5cuXzczMwsLC8C4ESJKcnBw3Nze8qwCE4OjoiHcJgOhcXV1fvHiBdxXEtWjRIuymBDU1Nd+5KelKMM+ePQsPD8e7CiBJuFwug8GwsLDAuxBACFlZWXiXAIjOysqKRqPhXQXRBQUFjRs3rrGx8Xs2IkUJ5tWrV8bGxnJycngXAiQJnU7vykmyAcFBGwz4IkNDw9raWryrIDoVFZWHDx8yGIySkpJv3kj3n9Fu3LhxDAYDIcThcHg8HoVCwb5YP378GO/SAHFNmzaNRqORSCQej9fQ0KCuro49fvToEd6lARwMHjxYVlaWRCLR6XQNDQ3sqjQqlXr8+HG8SwMEIt5PqqurNTQ0sJncLC0tDx48iHdpxJWTk/P8+fMpU6Z8w2u7/4x2vXr1un79unhOQA6HgxAyMTHBuy5AaD4+PseOHePz+diPdDodIdT1d14FBFFdXS2eBgbrvFdWVh45ciTedQFiodPp4nNNdXU1QkhdXR32k7bZ29s/ePCAz+eTyV8dSLp/L1J4eLiZmVmzJ+HKWNC2MWPGNLujh0gkgtt8Si03N7dmzdXm5ubDhg3DryJARC4uLs32E0tLy8DAQPwqkgyLFy8WCAQ8Hu9rX9j9E4y9vX3v3r0/fcbExGTcuHH4VQQkAIVCGTZs2KffCQwMDCZMmIBrUQA3kydP1tDQEP+ooqICxxDQ0sSJEzU1NcU/qqurw37STgoKCps3b7579+5Xvar7JxiEUFhYmJGRkfjHIUOGaGlp4VoRkAAjR44U3+ZTJBK5uLjY29vjXRTAh4+Pj6WlpfjrtampKTTAgJb8/f0/bbs1NTUNCAjAtSJJsmXLFjab/VWXcUlFgrG3t3dxccEem5qajh07Fu+KgATQ1NQcOnQo1gxjaGgIN6CQchMnTsSaYaABBrRh4sSJKioq2H4C55qvFR4e/lXDDaUiwWB7lb6+PolEGjx4MDTAgHYKCwvDBn07OTn17NkT73IAnvz8/KysrLBu6JCQELzLAQQVGBiITR9lZmYWFBSEdzmS58WLFxs2bGjnyu0a+svjitgM/vdVhTMDbUt3Z5+cnJzgwPB6+lcPFyIUWbKMqoaE3WKwvoqHJPKGvspD/UffunUrbPhkCd1tyHIyKuqwt3SMsOGTS95Vjx01jZg7g0iENHQlbL4rNkPA4wrxrqKDhY+YQi8/Mm70dGLuJ99DTl5GWa1zjydubm75+fmJiYleXl5fXPkL88HkpDL+ia+vq+IqqXb/664lhYaefGVJo11vNZ/ROnjX8gWMGn7y7erCV0wTO9Wa8ia8y5FGatpyNbQmO3c17xHaeNfyBbUV3NT7NYWvWFQblbrKjryBrZRQ05Eve9tg4ajaJ1BTz0QB73K+IOl2TW5avZqOfEOdZH89lioqGmQGnWvfV71/CCG6MtpKMM9jaqvKuS6+WhQtCcv13V4TW0Ar5qQ/oE9eaypLJuTXVYTqKvnXD5YO/MFQU09eRpagRUqDRpagvJCdk1Y39mcTGaI2x1SVce+dKvcba6ihK0+Sls7tTiBCdXTus6sVfmN0jSwV8a6mdSIhun6ozNRe1cROVZlC1D0SfAabKSjJZX3IYY1aYNx5/1UzMzOrq6v9/f3bXu2zCSb1Xg2jTuARrNs55YEOUFvBfXqpfMr65rPdEAGjhn91X2n4UnO8CwH/ohU1pj+k/7CCiHM50su4907TRi40xbuQ7uP2sRLf0bpGVkQMMVcPlNm5a5j1VMG7EPDtPrxpyE2vC1tk3HlvERgYeOnSpbbHrbaeoGorefSPXIgvBKepL2/vofHySR3ehbQi5U71wB+M2rEi6CIGFkoWvShZCfV4F9KKtJiaQRMM8a6iWwmYYJTxmIi35sl9ztQzVYL4IulMe6romyrlPmd23ltERUUxmV/YfusJhv6xqbvfLqmbUFEnlxZ81709O0nBP0xNPeh8JBZliuzHd4TbW4QCUfEblhp0VXcoRVXZig+cRpYA70KaoxVzlFSg56g7UFSRpRVzOm/7Ojo6LefTb6b1BMOs5etSidj8CJrR1FMgEe+yjfoqnomdKox9IRpNfQWhkHB/lJoKnrkDBe8quiFTO+XqCsINiOZxhZr6RB9lDNpDy0Ce29S515Ht3r37/v37bazQeoLhNwm5nO52hVu3JBSJaiuId40PCdXSiFeV1BMKRPWVxPu7iAhZleRj1vJJxGtKZ9byhULilQW+noCPWLWdex3ZoEGDHj582MYKcI00AAAAAAjHzc3Nzc2tjRXgskUAAAAAEFFdXV1j42dH70GCAQAAAAAR3b9/PyIi4nNLIcEAAAAAgIjc3d3r6j47YwgkGAAAAAAQkbW19bZt2z63FBIMAAAAAAgqPz+/qan1yxUhwQAAAACAoPbt2/fy5ctWF0GCAQAAAABB9enTh89vfeIZmA8GAAAAAAQ1bdq0zy2CNhgAAAAAEFRVVVVZWVmriyDBAAAAAICgkpOTIyMjW10kqQnmbUHeQH/35ORnnf1Gf1+9MNDfnc1md/YbIYRKy0oG+rs/jo3pgvcCoSP8Dh/Z20kb/7b9c/rMsZu3rOmkksD36NS9paUuO76BljrvmL/zt43z5k/GHn9uj+Lz+ZOmjOrAne3T00qHb7xrGBsb6+nptboIxsEAAAAAnU5ZRUVZWaXtdUgkEoWipqio2BkFdOrGO0/v3r179+7d6iJCJxiRSEQikfCuAkgqadh/pOF37BrwSUoVXP7cPy1c8cV1ZGVlDx8800kFdOrGOw+LxaqoqLCysmq5qMMSzIWo0zduXmYyGdbWdtOmzu3t1hchVE77eOjQnxkvUuXlFWxtesyY8WMPu54IoayszHPnI7OyMxFCPewc5s1bYmdrjxB6Gvdo0+bVWzbtvnTlXG7u6x/GT50xfT6Hwzl3PvLJkwdV9Ep9fcPBgcMmTpiOvWlRceHFy2fz8t5QqaaLF61ydHRpu8jQEX497BwaOY0FBXnq6hpDBodMmTybTCanZ6SuWLng4IFTPXs6YmsGDfMeNXLcnNmLsB8jT0TEP4ttbGS79/b4cf5SfX0DrLEx/lns4MBhZ84eq6+vs7KynTnjx0eP7iUmPiXLyQ0OHDZn9iJZWVmEEIfDiTxx8HHsfS63yYRqNnbs5EEDB2NbrqurPXjoj8SkOHl5BVcX9476c0iclJSEY5EHPn4sNTAwGh4aPnrUuDY+t8rKihOnDqWmJjY0sExMzCb8MD3Afyi2nekzx1qYW5mbW127frGpiXPl0n1VVdWsrMwzZ4+9yclCCDk7954+bZ6tTQ+EEIvF3LZjfWLiU3U1jfHjp44YHv5tRX7t/vkmJ/vI0b15eW8UFZU8+/vMn/+zGkWt2Xtxudyz547HxsZUVlVoa+sMDhw2bepcbHdq9jtG33xKJhP6q0iHI/7eEnXxzLHjBy5F3dHT00cIZWf/Exf/eMGPS7Gle/buSE1LvHjhNkLo5q2/L185T6dXGhgY+Q8aOm7sZAUFBWy12KcPjhzbR6N9tLa2mzv7Jycn187/aAmHw+Hs3b8zKSkeIeTk5Lrwx+UGBoYIoZeZ6ccjIwoL8zU1tVxd+syauUBbWwchdO/+rRs3Lr8rKlBSUu7bp//CBcs1NDQRQvv2/xYX/3j50nWHjuwpKyvZ/fuh3m59KypokScPPn+ezGY3WFnZjh0zaaBfIPa+z57FXrh4uqqqwrGXy/Jl63V1W+/FQAjxeLzRYYG+vgHLl63DnlmzdsnqlRvV1TUQQtXV9DHjglau+PX0maMVFbRevZwP7DvRbAs7ftuQmPj0yKFzsmTyhInDEUKTJs6YOePHtwV5c+ZOHDx42Js3WRUV5VSq6ad779eeVsppHz/deBtHGKLJyck5ceLEkSNHWi7qmANfxou045ER/v5D+/XxTHue1MhmY3+5RT/NMDY2WbhgOYlEevDgzuIls44cOmdhYUWjfWziNk2eNEtGRubmzSur1/wU9Ve0uGlr34HfZs1YMGP6fKqxqUAg+GXtkqzszNGjxltb2Ra/f1dS+l78KZ//68TYMZODhg6/EHV67fqlF87fUlVVbbvUDyXF8+f9rKOtm5zy7K8Lp1gs5k+LVn7xF6yqqpw9c+G7ooLrNy7l5b85fiyKokrBohhZlrzx198qKml//Ll1xcoFoSGjd+8+nJKScPrMUVNT82HBI4VC4dp1P9NoHydOmK6hoZWZmb5l6y8cTmNw0Agul7t85Y9lZSVjx0wyMDC6efNKR/w1JE9TU9PGzavMzSyXLV1XVFRQXV2FEGrjc+ML+Lm5r0cMD1dX04hPiN22fZ2xsYl9Dwdsa8+fJ3OaONu37mE3slVVVZ+np6z5ZbGVpc28uUuEQmFycrzgv6kF7t2/NWRwyM9Lfol9ErN3304Lc6s2ThJsNrtlkd+wfxYXv1u2fJ65udXKFRvq62pPnT5SWUn7Y/fhZm8nKyubkZHa39PHyJBaUJB3/q+TFIra2DGTWv6O0hZfJGJv8fUNOHb8QGJS3KiRY7HXJiQ+nT1roby8vFAofJbwJDAgGCF0+syxK3+fHz1qvJmZZUlJ8aXLZ0vLPvyyejO2keKiwvCwCSwW8+q1qGUr5u/bc1z8FUt6XIg6FRNze/q0edraOjEPbispKWFnnNVrfgoMCB41chyTUX/1WtTS5fOOHj6vqKj45k2Wqal5YGBwbW3NtesXG9gNO7b9O+yjoYF14tShJYtXcziNbq59qqvpCxZNEwgE48dN0dTQepX1kk6vFL/v2XPHx46d3NTEOXvu+I6dv/75RyunT4ycnJynl29ScrxQKJSRkamooKWmJt6PiR43djJCKC7+saysrKenr7a27vHjB1q+PPr2tQcP7mzZtJtKNeVwOFs27960efWnK9BoH5f+/Aufz7916+9t29eRyWQ/34BvOK1oamh9uvG2jzCEQqFQWm2A6bAEQ6N9RAiNGjHWwcEpMDAYe/Lc+UhNDa0/fj+MHWEDA4InTRl5++71RQuWBwQEiVezs+u5dNm8rOzMPu4e2DOjRo4bMiQEexz75MHLzPQVy9cHB41o+b6LF63C1jQztfhx4bSMF6m+Pv5tl+rnG+jnG4AQ6tXLmcGoj759berUuV/8Bdes3qysrIwQcnHu/cu6n69duzh1ymxs0a/rd2hoaDo4OKU9T0pJSfh5yRoSiWRna//gwe0XL9KGBY+Mfxb7Kutl1F/ROjq6CKEA/6GNjeyr16KCg0bcuHm5sPDt77sOuvfuhxBy6Ok0dfoXmgG6JTa7oampacCAQYEBQeIn2/jcjAyNT5+8gjUCBwWNGBUWkJj4VHxOkiWT16/djh3pEEIRB3cbGBgd2H9SXl4eITRyxBjxWwwOHLZq5QaE0ADvgWPHBT2Ne9jGOam2rqZlkXHxj792/zz/1wkZGZldv0VgIZhCUdu+89d//nnh7Oz26WtlZWUPHTwjbuj+WF4a/yxWfHxp9jtKFRaLSfy9xcjQ2NamR1JS3KiRYxsbG5/GPWSz2fHPYgP8h/7z6kVtbY2vbwCdXvXXhZPr1m4TH7W0tXX37N2xcMFy7McZ0+f37z8AO3hOmxEeeeJgG+fR7qqc9lFJSWnCD9PIZPKw4JHYkwcifg8NGS3+8unu7jF1evjz9OQB3gOX/vyL+H8NmUw+/9fJpqYmrFmLy+UuX7rO3r4XtvTsueN1dbUnIy+ZmpojhMQnHcwfu49gjT18Pv94ZER9fR3WptIqP5+ABw/uvHmT1auX8/2YaJFIdPvO9f8SzCM3t75qFLU+7h5Xrpxv5DR++sL8t7kRB3dPmjjD29sPIaSoqOjt5dese2v82ClYO0pvt77TZ46Nijrt5xvwDaeVZhtv+whDKD169OjRo0erizomwXj086ZQ1LbvWL9o4QoPD2/sydTUxMqqiuCQAeLVeDxeVWUFNp7oWcKTy1fOv39fhCWD2ppq8Wpubn3Fj9OeJykoKAwZHIJao6amjj0wN7dCCFVVVXxV2X37et6+c/3t29z2v6R//wEG+oaZmeniBCMv/2+Tr7ycvJycnHiH0NHVq6+vw1q8+Xz+hEnDxRsRCAQqKqoIoWcJTywtrbH9DCEkQ8gWvC6ARcDzf51QVFQKDRmNnTza+NwQQgWF+afPHM3Le4M9X/PJ/mNv30t8QiqnffzwoXjWzAXYNpsRH5IUFRWNjKiVbe4/RobGLYv8hv0z858MV9c+WHxBCPXp0x8hlJf/plmCQQjV1tacPXf8eXoKk8lACIlf0ux3lDZaWtrE31uwZphTp4+wWKyExCfYOebOnesB/kPj4h7p6xv0tO8VE3Obz+dv275u2/Z/ex9EIhFCiF5V2WxTOjq63l4DHz2+J4WDdQL8gx4/vr9q9aIFPy6ztLRGCNFo5e/fF5WVldy+c/3TNSsrK7CzzLXrFx8+ultZSVNQUBQKhXV1tVi/v6Kioji+IIRS0xLdXPtg8aUl8X9eSwtrhFBlVUUbCcbd3UNVVTUh8amDg1NMTPSw4JH37t/KzMwwMTHLyspcueLXVl/FYjE3bVolLy8/ZfLs9nwUMjIy7u4e169f4vF4HXJaaeMIQygNDQ3l5eXW1tYtF3VMgtHW1onYf/Lg4T/XrF3Sq5fzr+t26Orq1dRW9+8/YM6sRZ+uiX3EZ89Fnjp9JGz0D3NmLaquoW/avFooEorXUVZSFj+uranW0db9YuecjIwM9if8qrJVVSkIocZGttIn7/hFOrp6DQ2sL65GIpGw41FtbbW2ts6fu//ny5MsmYwQqqyk2di0Hi2lColE2rl9f+SJiCNH9175+/yaVZudnd3a+NxevHy+avUiVxf3lSs2qCir/Lpxxaf7j5Li/5/a62prEEJ6uvpfrEFGVrbt/af1Ir9+/2xoYGmoa4oXUShqCCE6varZS2pqqufMm6ikpDxj+nwjI+rJk4dKSt+3+jtKG4nYW7AEczwyIiU14e69m4EBwSHDRs+eO+HDh+L4Z7FYF1J1DR0htH3b3mbvaGRELSoubLY1XV09gUAgEAikrdOwX1/PHdv3HTm6d+bs8cOCRy5ZvLq2thohNHXKHJ8Bgz5dU0tLRyQS/bJ2SV7+m6lT5vTs6fTsWezFS2fFf+5mx/na2prebv2+WACpHScXOTm5/v19EpPi+vb1rKyqmDplTn193Z2713v2dMK6kFp91f2YaFNTc3YFOzr66ujR49vzaVBUKSKRqJHT+P2nlbaPMISSm5t79OjRY8eOtVzUYf8ZTE3Nf9ux/8XL579uWP7bro27fz9EoajV19e1TLhNTU0Xok4NCx65cMEycXD+HFVVSk1tdRsrfA/su46urn57EolYbW2NsRG1/etTKGp1dbX6+obiAXpiGuqatbU17d9UN6aqqrpk8eqxYyev/3XZuvVLL12828bndu5cpJERdfu2vdjRvI3TOZaYO2oXalnkN+yfOjp6DEa9+EdsB1Bt8e3nVvTV2tqagwdOY18f9fQMCHt86XoSsbcYG1FtbXpcvXohN+/N4kWrrKxs7O17/fb7JqwLSRxesdhR14MAACAASURBVIPnF7dWW1ujqKgobfEF06+vZx93j6vXog4d3qOvb4gNA2hq4rT83DIzMzJepK39ZSs23LWs9EMbm+3Yk4ufT8DDh3ePR0Z49vfR1dULDQ1bt37p+/dFWBdSqy8xMDDa88fRs+eOnzp9ZNCgIdiI47ZVVVUqKiqqUdS+/7QiQUcYVVXVVhtgOnJGOy6XixByc+3j4TEg/20u1hmUnf1PXn6OeJ3GxkaEEIfT2NTUZGtrjz1Zz6jDBuK1ullX1z6NjY2fTvL2uTs8fS2RSHTv/i2KKsXM1EJTQwshRK/+93twdTWdx+O1+qq3BXllZSWf9nN9kZtbX4FAcCv6b/Ez2OeAELKx6ZGX96akhKD7TVfCbp5uZGg8etR4VgOLRvvYxudWz6iztrLFjuZcLpfdyP7c/mNiYqarqxfz4LZ4txGJRJ9b+RuK/Ib908HBKfOfDA6Hg/0YH/8YIYRdpiQvJ4815yKEGIw6DQ1N7OCC/cpYkx6QlL0Fa4bJzXvj4OBkZWWDEBoRGv7mTRbWhYQd3Egk0vUbl1rW3AyHw0lJTXCRymsVsTOLjIzMmPCJOjq6b9/mUqmm+voG9+7fEn9cfD4fO2JjZxPb/1og2j65uLn2efEirZz2UfzM95xc3N09VFRUcnNfh4aGIYT6uHvo6eq/LcgTX9zUkreXn4aG5rRp82RkZSNPHPziWzBZzGfPYns5OHfIaUWCjjB2dnYrV7Z+wU3HJPqc3NebNq8aOWKskpJyWloSdsn01ClzUlISVqxcMHbMJE1NrbS0JIFQsHXzH+rqGpaW1teuX9TS0m5gsc6cPSYjI/PuXUGrWw4MCL5x8/LO3zbk5r62trJ9V1SQ8SL12JG/vrnUJ08faGvrKCgoxsU9epmZPnfOT0pKSqam5vr6BufPn9DU0GI3sk+cONhsp9+2Y52P96By2sfrNy4ZGRqHDBvd/ncMDAiOvn3tyNF95bSPtjY9CgryExKfnD75t6Ki4g8/THvw8M7in2eHh03Q1tJ5HHv/m38vicbn86dOD/PzDbQwt7p584qqiqqREdXExOxzn5uLi3tMTPTdezfVKOpXrv7FZDKKiwpbHSJAIpHmzP5p2/Z1CxZOGzIkVEZG5sHDO6NGjBUPJG8/Ho/XskhjY5Ov3T8nTZgRGxuzas2i0JCwykrambPHXF3cXZx7I4Ssre3u3rt58NCfc2YvcnFxv37j8slThx0cnJ89i01NTRQKhW0PJ5QSErG3YLCOpBGh/w7P9/MLPHj4T1+fAOxHqrHJ6FHjr16L+mXdz95eftXV9Bs3L+/Yvk98Ao48ebCmtprNbrgfE81g1E9rxzUH3c+16xcTk+ICA4Krq6vo9Co7u54kEmnBj8t+3bBiwaJpw0PDhQJBzIPbgYHB4WETeto7ysvLH4+MGDZs1Lt3by9EnUIIFb0raLXVfPKkWUnJ8QsXTR89aryWlnZ6eoqSkrL4iuivJS8v37+/z5s3WdgAFBKJFBIy+sTJQ5/rQhJTo6jNmD5/3/7fQkJGY6fOZs5fOEmvrmpsZN+69XcDu2H6tHkdclqRoCMMi8Wi0WitNsN0TBuMvJy8manFhQunIiMjnJxcly9bjzWiRuw/6eDg9NeFkwcP/VFXXxvg/++1A+vXbldSVNq8Zc2lK+fmz/958qSZMTHRrTZ7KCgo/LH7yJDBIQ8f3d27f2fa8ySfAf7fk5R1dPRiHtw+eOiPykravLmLx4+bgg1Z37hhlyyZvGLVgmPH90+ZPPvTprmBfoFKSsoHD/959eqF3m599/x5TEXlC/MqfkpOTu733w6GDBsVGxvz557tL16mDQ8Nx74RGhtRf9t5QFdH7/SZo+fOR1pa2nzz7yXReDyeq0ufR4/v7d2/kywnt33bXkVFxTY+txnT5vdx738g4vf9Ebt6u/Xb+Otv1TX0l5nprW48wH/ols27RSLR4SN7zv91QkND05hq+g1FNnIaWxb5DfsnlWq6a2cEj8fb9fumS5fPBQYEb960Gzubzpq5YID3wPv3bzU1NfkMGDRl8qwbN69s27aWx+cdjDhtamr+6fd1qcXlcom/t2CMjai93fpifUbY0Sxo6HDxjwihBT8unT9vSdG7gj17d9y5e32A90BdnX/nHTE1Nff28jt3PvLEyUOqqpQ/dx+x+6/dWqoYGVF5XO7hI3vu3L0xevR47AKfAd4Dd2zbK0eWO3joj7PnI/X1DZ2c3LDRQuvWbntbkLtx08qMjNQ//zjq4eF97frFVrdsamp+YN9Jayvb83+dOHx4D62i/Dtbufx8AoaHhomTcdDQ4R79vD/XhfSp0JDRVpY2ByJ+b7UVRFWVcuHCqcgTB1VVKdu27sGuqP/+04oEHWGys7P37m39TgikVj+ytPs1TRzkMlCr82vrUqEj/IKDRs6ftwTvQjoMo4YX+9fHyevM8C7kf9TTeTcPfxz1E7GqAjXlTcm3Ksav/PZTcmeglzU9PF8RMo9YVXUDD86UeQRrGVsTa9D3tYgyxwFaBubEqoqYsBnttm/dg11UTzS0osasZzWjFxl39htlZWXFxsYuXry45aLuNi7seGTEp12DYmoU9b/O38SjIiBJUlIStu1ovRk5Yv8pMzOLLq8IEBfsLVLlpyWziopaGe3g6em7ZtUmPCqSFo6Ojo6Orc/l2N0SzNixk0NCWhmkIkOS1Ltwg67k4uJ+7OiFVheJm/cBwMDeIlV+XbeDx29lqIM0T23QNWpqalgslqlpK8203S3BqKupq/83E1FL0Tefdm05QMIoKioaGhjhXQWQDLC3SBVs9tuuZGNt9+Rx6wO2pMq9e/cqKiqWLl3achG0TAAAAACAoFRUVGxtbVtd1N3aYAAAAADQbYwcOfJzi6ANBgAAAAAEVVBQUF9f3+oiSDAAAAAAIKjly5czGIxWF0GCAQAAAABBmZiYmJiYtLoIEgwAAAAACOrAgQOfWwQJBgAAAABE9PHjx9zc3M8thQQDAAAAACI6ePBgcXHx55ZCggEAAAAAEWlqanp7e39uKcwHAwAAAAAiWr58eRtLW2+DkVeSkVeC5hkJIEMiaRko4F1FCyKSliHxqpJ6JFkZDT3i/V1kSBr6xKtK8lG05GRkSHhX0ZyalpwMnFu6BRKZpKYt16lv8fz586ysrDZWaH1XomjKVb5v7LSqQIepoTUhkgjvKppT1yWX5jfwuYQrTMrVlHNkiNfqqm0gX/iKiXcV3VDxa5aWoTzeVTQnp0CqLufiXQXoADUfm+QUOjcir1ixwtzcvI0VWk8w+iYKJMJld9AKVh3PxFYZ7ypaYeNGqalowrsK8D8aGHyqNeH2FhIJ2ThTaitauesv+GbMWr6xtZIC8ZrSja2UOCw+3lWADsBp4BtbdeJ9uSsqKvbu3UuhUNpYp/X9W1WTTLVRiv+7otNqAx2gJI9dlM10GvDZe3HjyHuEzqPzH/GuAvy/wkxmZTG7p0dbhwO8eA7XfnS+FO8qupVH58o8grXxrqIV1i6qjBpuTmrrk8QDSZGTWs+o5lq7qHbeW+jr67u4uLS9Dkkk+mxTf04qMy+D6eynraErT5aHNhkCqaviVpVw3r6sH/uzCWFbyxqZgjNbigf9YKSmLaeiTrzeC6lRV8mlFbPL37GHzzFCRN1bWHX8qF0f/MYaqenIKVNk8S5HUjWyBMwaXvzftFELjTV0O3eMwveIOVtB0ZY3tlbRMiBcPxdoWw2N+/FtA6OGO2SKfue9S3p6+pMnT1asWNH2am0lGITQ+zfszLi68qJGwp4m208kEolEIhnJH0WmY6zAYQttXFX7DtHCu5Yv4HNFCbfoRdkN6jpyVSUcvMv5FiIREomEkrvbaBko8LhC294U9wBNvGv5Ag5bmHybXvS6QV1bnl5G0L1FIBDKyMgQ83ioaSDPrOGb91TpF6SlqkH07wyZT+tynjMQQgx6N+xAFPxfe/cdFsXVcAH8bqH3XgWkCQKKCChNREAFUbArUaOJsbeoSYz6ptpiJYlJNGJi7MaoqKCiAoogxYaKCgiIiBTpReou+/0xuuGzrgaYmeX8njw+u8Pu7Fk0y+HeOzPCVh6PrR8ab6CqLUuIyNZF1XGgeoe+UGho6KZNmwwMDN78sLc0GLGWJtavyrx06dLp06fXrFlDd5D/isvj8Jj+6fQi9v77yc/P//LLL/ft20d3kPfE43O4bBvRaGkUMXasyNfX99SpU3JyTDx4SiQisvJM/ca9hqiVCFrY+uHwBgMGDIiPj6c7Rfvjy3A4TCpmkv4k7Oglx52Ay29tJc1S8EbYiL3fdp6MSCjq8CX30JYMg38MC1obZeQ4+PfQXjhcFn84vEGLsEEq31cnaGxsPH369MiRIyV5MJPaFAAAAHRhU6dOdXBwkPDBbJuN+A/4fL6mJtMXjgDTcDic113YHboga2trDjNXwQCT2Nra0h2BlcrKyrZt26auLukimy40BsPhcGRlse4d3hkzFz0ALbKysiRcOwhdmYJCB54oRVpVVFTU19dLXl+6VoNRV1evr6+nOwWwjJycnFAopDsFMEXv3r3pjgBM19TUxOd3ofmNdnHp0qXvvvvOxMTknZ7VhRqMnZ1dYSHOsQbvRllZubGRoUf2Que7efMm3RGA6aqqquTl5elOwSaVlZWGhoZhYWHv+sQu1GAIIQ4ODmfPnqU7BbCJsrIyj8errsYpRIFgDAYkUVhYiDWXkouNja2trbWwsHiP53atBvPRRx/t2bOH7hTAMlpaWllZWXSnAEbAGAy8VWZmprGxMd0p2KGwsPD06dPvOnkk1rUajKKi4pw5c6ZNm0Z3EGATKyury5cv050CGEFdXR3HIsGbxcbGOjk50Z2CBWpraxsaGjZs2PDee+haDYYQ4ubm9u2333766ad0BwHW8PPzO336NN0pgBGqqqpwLBK8waNHj548edKrVy+6gzBaY2PjhAkT+Hz++00eiXW5BkMIMTExCQ4OnjNnTllZGd1ZgAV0dHQ8PT2TkpLoDgIATBcZGYlh/rcKDw///vvv//sx512xwRBCBg4c+Omnn37wwQcRERF0ZwEWGD169KlTp+hOAfRzdHSkOwIwV1lZWUZGRnBwMN1BmOubb74hhMybN8/Kyuq/762LNhhqcUN0dHReXl5oaGhmZibdcYDRbG1t+Xz+iRMn6A4CNEtLS6M7AjDXypUrJ0+eTHcK5lq2bNnAgQPbcYeSXptaimVmZu7evbuhoWHGjBk2NjZ0xwHmGjRo0KlTp3Cmh67M3d09Li4Op2mGl+3fv7+iomLevHl0B2GcBw8exMXFffTRR+2+5647BiPWo0eP1atXBwcHf//99999993169fpTgQMtXXr1nXr1tGdAuhkYWGBY5HgZTdu3MjNzUV9eVl5eflnn33m4+PTETvHGMz/k5CQ8Ndff9XV1U2cOHHEiBF0xwHGOXPmTGRk5NatW+kOAvTAGAy8LCEhYevWrQcPHqQ7CLP8+eef06ZNq62tVVFR6aCXQIN5haysrAMHDhQVFVlaWg4fPrxHjx50JwIGycrKOnr06LJly+gOAjRAg4EXXL169cCBA5s2baI7CLNMnTp1wIABHTFz1BYazGvV19efOHHixIkTIpFo+PDhQUFBqqqqdIcCRvjnn38yMjJWrlxJdxDobAEBAcePH8dV7oHy999/p6SkoL5QhEJheHi4lpbWmDFjhEIhj8fr6FdEg3m7rKyskydP3r17l8/n+/r6+vr6amlp0R0KaHb27NlDhw7t3LmT7iDQqTAGA2I//PADIeSLL76gOwj9SktLdXR0Dh06VF1dPX36dC63k5bYosG8g6tXr8bExMTExJiYmAQFBTk7O+PiF13Z3bt3p0yZsm3bNmdnZ7qzQCfx9PSMjY3FGEwXd+fOnaVLl86fPz8wMJDuLDRrbW1dvHixvLw8LUc5oMG8j7S0tNTU1FOnTvF4PE9PT09PTxcXF7pDAT1mzZrVq1evOXPm0B0EOgPGYGDnzp0XL17cuHGjrq4u3VloU19ff/jw4eDgYGVl5aSkJC8vL1pi4Gjq9+Ho6DhjxoyIiIhNmzbp6Ojs3LnT3d39888/j4iIKCgooDsddKpt27ZpaGgMHToU5zoDkG5xcXEDBw5UVlbevXt3l60vJSUl1AxadXW1iooKn8+nq75gDKbdNDU1JSQkXLlyJTk5WSAQuLi4uLq6uri4aGtr0x0NOkNZWdlvv/1WW1v7+eef4y9digUHB//9998Yg+lq0tPTf/zxR11d3WXLlnXcscEMl5KS8uWXX65bt87V1ZXuLM+gwbS/oqKiK1eupKamXrlyRUVFZfDgwaampo6Ojnp6enRHg44VExOzYcOGiRMnjh8/HqfulUqYRepqcnNzt2/fXlxcvHDhQicnJ7rjdLaGhoa9e/eKRKIZM2akp6d369ZNTU2N7lD/QoPpWA8ePEhPT09KSkpLS+PxeI7P/cdLigOTHT58+Mcffxw9evT06dO77K9r0goNpuu4evXq7t27S0tLP/74Yz8/P7rjdKqCgoKrV6+GhIQkJSXdvHlz7NixzDwCFw2m8xQWFqY99+TJE19fX0NDQ3t7e3t7eyUlJbrTQTvbu3dveHj4sGHDpk+frqGhQXccaB9Tp079/fffcSySdIuOjt6zZ4+ysvLkyZM9PDzojtN5srKyrKysGhoaQkNDx48fP3HiRLoTvQUaDD1qa2tv376dlpaWnp6enp6uq6trb29vZ2dnb29va2tLdzpoNwcPHgwPDx80aNDUqVMNDQ3pjgP/FcZgpNvBgwd3797t6Og4efLkrvNRXFdXp6ysPG7cOB6Pt2/fPpFI1Akno2sXaDCMkJeXl/5cVlaWnZ2dq6trt27dbG1tMd8kBY4cOXL8+HFVVdWxY8d6e3vTHQfeHxqMVLp7925EREROTo6tre3kyZO7wprFxsZGeXn5o0ePbt68edeuXZaWlsXFxfr6+nTnejdoMIwjFArv3Llz//79W7du3bt379GjRzY2Nra2tra2tjY2NlZWVnQHhPeUlJR0+PDhe/fujR07duzYsVgiw0azZ88OCwtDg5EOzc3NERERERERPB4vJCQkJCSELWMP/0VGRsbatWu9vb0/+uijO3fumJubKygo0B3qPaHBMF1zc3NGRsa9e/fu3buXkZHx4MEDGxsbd3d3HR0da2tra2trTMmzy5MnTw4fPnz48GEPD4+xY8c6OjrSnQjeAcZgpMO1a9ciIiLOnz9PFRepv3xvWVnZli1buFzu999/n5GRIRAI7O3t6Q7VDtBgWEYgEGRkZOTl5d28eTMrKysrK8vIyMjKyqpHjx5UocHJSNjizJkzJ06cKCkpCQoKGjZsWJc9QRa7oMGw2qNHj6Kjoy9duiQnJxcSEiLd1wSorq7esWNHdXX1999/n5ubm5WV5e3tzd7hlldCg2G9vLw8qspkZmbev39fKBRaW1s7ODiYmJhYWlpaWFh0hXFR9srLy4uMjIyKijIzMxs2bFhQUBDdieBNcG1qNiorKztz5kx0dHRtbe3QoUOHDRvWrVs3ukN1iIaGhj///LOmpmbZsmUPHjxISUkZMGCAFB9DgAYjbSoqKrKysnJzc+/du5ednZ2Tk0NVGTFcjZKZUlNTo6KioqKiqB6DK20xE8ZgWKSuri46Ojo6Ojo/P3/IkCFDhgzp2bMn3aE6xB9//HHr1q2wsLDCwsLTp0/7+PiYm5vTHaozoMFIvwcPHmRnZ1NtJjs7u7S0lKoyNjY2JiYmFhYWmHhilMjIyMjISAUFBRMTE39/f+mYrpYaWMnLfA0NDYmJiSdPnkxLS6OKS9++fekO1Z5EIhGHwzl8+PC5c+dWrVqlq6sbHh7u7OzcBRfVocF0OY2NjVShefz48Z07d3Jzc5uamiwsLCwsLMzNzak/NTU16Y7Z1ZWWlkZHR587d66iomLw4MH+/v42NjZ0hwKMwTBXZWVlbGxsXFxcWlra6NGjXVxcPD096Q7VbgQCAZ/PP3bs2PHjx5cuXWpvb//PP/90795dysrZu0KDAVJTU5OTk5OTk5Obm5ubm5uTkyMSiag2Y2FhYWVlZWJigrPK0qWwsPDs2bPnzp2rr6+nqoylpSXdobqu0NDQXbt2YR0McxQXF8fGxsbGxubl5Q0aNGjQoEH9+/enO1T7qK+vV1RUPHz48MGDB7/88ktnZ+fz58/r6ek5ODjQHY0p0GDgFaqqqsSdpqmp6dKlS4SQ7t27m5ubd+/enbqho6NDd8yuJT8/n6oy5ubm3bp18/Hx6TrnDGUOjMEwxIMHD+Li4mJjY6uqqnx8fHx9faVgDkUgEFRVVWlra+/fv/+PP/5Ys2aNq6trSkqKnp6emZkZ3emYCA0GJFJVVUWN0OTl5VE3GhsbzczMzM3NqVpjbm5uYGBAd8wuIS8vLyYmJi4urqKiwsfHx8fHx9nZme5QXcX48eP37NmDMRi6pKamxsfHX7p0SU1NrV+/foMGDWJ7jy8oKKivr7e2tj506NCWLVvWrFkzaNCgjIwMfX19dXV1utMxHRoMvKe6uroHDx7k5uZSf3I4nNTUVLOX4LfVjlNSUhIXF3fhwoWMjIyBz9EdSsphDKbz1dbWUq3l0qVLvXr1GjBggJeXF3uPqRQIBFevXm1pafHy8oqIiPjzzz/nzp07ePDg0tJSDGy/KzQYaDfNzc15L9HU1Hyh0+DQp3ZXV1d34cKFuLi4uro6JSUl6iNeS0uL7lxSaNasWT/++CMaTCfIzs6+cuVKTExMdnY29U/ay8tLXl6e7lzvo66uLjIyUigUfvDBB7GxsUePHh0zZszAgQObmprwb+m/QIOBjlVUVPTw4UNxoVFQULh+/brpc1SnMTU1lZGRoTuplLh48eKlS5fi4+MNDAy8vLwGDBhgbW1NdyjpgTGYDtXU1HT58uXExMTLly+rqKj4+vq6urqydIFLRUXFb7/9JhKJVq5cefv27ejoaF9f3z59+tCdS6qgwUBnq6ure/hcXl4e9aeOjg5VZag/u3fvjqGa/yg9PZ2qMrW1tV5eXt7e3lJzjEbnEx+zyuFwqBNy8Hi82bNnT5s2je5o0iA7O5tqLbdv33Z3d/fw8HB3d2fXBaIfPnxoampaXl6+ePFioVC4d+/ex48fp6SkuLi4SOv5f5kADQYYobCwkGozVKGpra2lPhFMTEyoP6kbuJ7zeyguLo6Pj79y5UpcXJznc/r6+nTnYpOxY8c+ePCg7RZTU9O9e/dK2VVmOtPTp0+TkpLu3Llz5swZNTU1d3d3d3d3Fq1Jp66zGxAQUFlZGRAQ0L9//7CwMOqDq2fPnlwul+6AXQIaDDBUQ0PDw4cP8/Pz8/PzqRsPHz7k8/niWiNuNpiBkpBIJEpISEhMTExISFBUVKSqjJOTE925WCAiImLDhg1NTU3UXR6PN3/+/EmTJtGdi31u376dlJSUlJSUk5Pj5uY2YMAAFxcXtlzW9NixY3fu3Fm5cmVDQ8Mnn3zSp0+fJUuWtLS0cDgcPp9Pd7quCA0G2KSyslLcZqgbsrKyVVVVVJvp1q0bVW4wbPtWOTk5CQkJ165du3btGjVu7+bmxq5x+042YcKE7Oxs6rapqemePXsUFRXpDsUOxcXF169fj4+PT0pK6t69u5ubm5ubW69evejO9SYVFRXy8vKKiopbtmxJTEzcvn27lpbW5s2bzc3NQ0JC6E4Hz6DBAOtRi4Xz8/MfPXpElZuCggKT56haY2Zmhh/Pr9TY2Hj5ORUVFXd3dy8vLwzMvOzo0aMbN25sbm7m8Xhz586dMmUK3YkYraGhISUlJTk5OTU1tbm52c/Pz97evn///srKynRHe7XCwsI7d+64urqqqal98skneXl5u3fvNjAwSExMNDIywgnlmAkNBqSTeAaKqjUKCgqJiYlUm+n2nImJCZaDtJWdnX358uW8vLxTp065P2doaPi6xwcEBGzdutXCwqJzY9KGGoYxMTHZu3cvBmBe6ebNm0lJSSkpKffv3+/fv3+/fv1cXV1NTU3pzvUioVDI4/FiYmJSUlKmTJlibGy8YMECRUXF5cuXq6qqVlZW4joqrIAGA11FS0sL1WYKCgqoZvPo0aOysrJubXTv3t3Q0BAnF25paREPzMjJybm5uXl4eLxwKNPIkSMfPXpkbGz89ddfd5FjRP/555/NmzfPnDnzww8/pDtLJxGJRKGhoQcOHHjDY/Ly8pKTk1NSUlJSUlxdXe3s7Pr168e0SaK8vDw5OTkDA4Pw8PCIiIhVq1Y5Ojru2rVLRUVl2LBhLD3NDKDBQJcmEAjEbebRo0dCoTA5Obm0tLRbt27GxsZtyw17zwH6H+Xl5VFVJjk5WTwwY2JiEhAQUFpaSgjR19dfvHjxoEGD2j7rWkxV3p06Hp9b8rCBvuztTyAQ8Hh8DofuHO1H11RB0NJqZqvkMvjFUYfS0tI5c+bk5uYaGBhERka2/VJVVVXKcwoKCv2eY86Zcqh/t6amph4eHr/++mtMTMzy5cv79u2bnp6upaWF31KkAxoMwIsEAkFBQcGjNgoKCgoKCqgqY2FhoaenZ2xsTFUcHo9Hd95OIhKJxAMzIpHo0aNHnOc/yXV0dKZPnz569Gjq7sENjyz7qKrrymrpyxMp+mEvlUSEVBY3VZe1pCdUTF5pKi5n9+7dW758+aNHjwghSkpKFy9epC5LRA23FBcXi1sL7VOxjY2NjY2N6urqUVFRJ0+eHDVq1ODBgw8cOFBYWBgcHGxpaUnNGdEbEjoCGgyApKjRmqKiory8PHHF0dPTaztgQzUbqR+ULigoeOGIDC0trQkTJkybNu3ghkf2npqmPZXoSwfvo+RhY2JE8YdfmRFCLl26tGnTpoKCAupLIpHIzc0tOTnZxcWFWt1iY2NDY9Tq6urk5GRtbe2+fftu3759z54969at8/T0TE5O5vF4vXr1Ys5QEHQoVoqAnAAAIABJREFUNBiA/6SwsJAapGn7p5mZmYKCgrjQUNTU1OgO226Cg4MfP378wkZFRcVxg5f16+9p46JKUy74T7LTalsaBQVP43bt2lVYWNj2S1u3bu3Xrx+Hjvmz4uJifX394uLiLVu2qKurf/nll2fOnImPjx83bpyjo2N1dbU0/Z8F7wQNBqD9lZWVtZ1+orS2trbtNCYmJoaGhiw9xtvDw6OxsVEkEqmoqCgpKcnJyenr65uZmVkqfNB7oJaeKc5Uy0oVxU1n9+Xsi59TW1v7QlnR09OLiorqhAwCgSAxMbGysjIkJCQzM3Py5MlBQUFfffVVcXFxenq6g4MDS/+XgY6A0wgCtD9tbW1tbe0XjtCpra0Vd5qbN29eunTp7t27lZWV4iU1bW/Q8suu5PT09Hr06GFjY0OdHLl79+7U9ohfC7X0pXwGTYpp6stp6qgFDA1Iv5P+5MkToVBYWVnJ4XBEIlFVVVVHvGJhYaGhoWFtbe369eubmprWr19fUVFx/PhxV1dXQoiJiUlSUhK1hEVfX5/2BTfANBiDAaBTc3Mz1WnE5Ya6MXDgwPr6emNjYyMjI/GwjZIS0xeXbP8iZ+wScxk5RtcveIPd32XP3mDJ5ZLm5ubc3Nzs7Oxr167l5OSUlJRER0f/9/2npKTcu3cvNDRUVlbW09PT3d19/fr11dXViYmJNjY25ubm7fEmoKvAGAwAnWRlZc3NzV/+4BYvr3n8+PGdO3eociMrKytuM+Jmo6OjQ1N2kGaysrI2NjY2NjZBQUHvt4eioiJ1dXUFBYWwsLDr16+HhYVpamqeOHFCX1+fuvDhhQsXqMsJqampBQYGtvc7AOmHBgPARIaGhoaGhv369Wu7saqqiqoyjx8/vnbt2vHjxwsKCmpqatqO04j7DS41B50sPT39xo0bvr6+hoaGU6dOLSsr27lzp4KCgr29vb+/v6amJiFk9erV4sfjnyj8R/gHBMAa6urq6urq9vb2bTc2NTU9fvyYajYPHz5MTEykKo6Ojs7LAzYqKir0xQfpUVxcLCsrq6mpefDgwTNnzsybN8/Z2fn8+fPUIWmEkO3bt4sPafbz86M7L0gnNBgAdpOTk3vlPFRxcbH4MKiYmBjqBpfLfaHTGBsbv9/BHT4+Pv7+/suXL2+n9wGMRp3i1s7Ornfv3t9++21qauratWs1NTXNzMyWLFnSs2dPQsiiRYvEj8cZWaAToMEASCfq2A1nZ+e2G6urq8XzUDdv3oyKiiooKKioqHh5EsrY2FhGRuYN+6+pqYmIiEhLS1u8ePELl0wCVisrKxMImg0NDWNiYvbv3z98+PCQkJCkpKSioiIvLy9CyLJly8QFBX/1QCMciwTQ1bW0tIjnodrS1NR8eR5KfPawvn37Uod86+vr+/v7L1y4EMciSYG/vr0feXfhokULhg4dmp6eLhAI7Ozs3txlAeiCMRiArk5GRsbMzMzMzOyF7SUlJeI2c/HiRfF5+agqI35YcXHxoUOHrl27tnTpUkKYfrw3vBmHwzl16hSXSwghL6y4AmAaNBgAeDU9PT09Pb2+ffu23VhbW0tNQlHLNinNzc3p6emfffZZsMPPdCQFgK4IDQYA3oGKioqtre2yZcvabuTz+bq6uiYmJrgCMAB0GjQYAHhnAoFAJBLJy8vr6ekZGhr6+fl5enpqa2tv/yKH7mgA0FWgwQDAO+PxeG5ubv7+/q6urgYGBnTHAYCuCA0GAN7ZiRMn6I4AAF0dl+4AAADw/xQXFxUVF7bdsu6Hb2bNnkxfIgAmQoMBAGCQx4UFoZNGZGbebbtRUUlJURFHqgP8P5hFAgD4l0gkos7URxehQPDyiUYXzPuMpjgAzIUGAwC0efKkZOefv6akJD59Wtetm2noxGl+vkOpLw0PHrho4ZcJCXHJKQlKSsrDg0Z/OOUTQkhjY2PYT+suX44nhPTq1WfenKVxF87+vuPnQweidHX1CCHp6TcvxsfMnbOY2s+WsLUpqYkH90cSQo6f+Ofvw3vLyp7o6xv6Dho6ftxkOTm56uqqkFF+s2YuvJ+dmZh4wcrK5qew8DdkLix6vH37j9dvpPL5MoP9h2Vm3fUZODh4xJj5Cz9WkFdY/8NW6mGH/t6zbfuPZ04lUifgf+VLv/xeRET04bQxhJBvv1v2LSFDhgQt+/ybCaFBJSXF9va9f/5xJ7Xzs2ej9h34s7CwQEtLe1jgyA9Cp3G53PvZmfMXfLRuzU+/h/+ck5Olp2cw85MFHh7eHfx3CEAbzCIBAG0EQkFGxp3gEWNmz1ykqqq2es3Kexl3xF9d98PXlpY9wrbs8PcL3PXX9uTkBELI/gN/RkdHjhkdOnPGgpqaagUFBW9vP0JI4uWL1LNOnzlx9lxUc3MzIaS1tfVSQpz3AD9CyK6/fv99x0+DfAZ/tvSrgd5+h/7evWnLavFr7d27U1/PYNPGbXPnLHlD4IqK8gULP75+PXXc2MmzZy4qeJx/8+b1t77N1730y+9FS1N7xfJVhJBpU2f9FBY+KfQjQsiSxSutLHuI9xYdHbn2h6+trGz+t3LNQG//P/78bd/+P6kvNTU1ffv9sjGjQ8M2/66vZ7BqzYrq6qr3+psBYAGMwQAAbQwNjHb9cZiatQkICB452i8x8YKtjR311cCA4A9CpxFCLC2so05FpF5N6t/fs6i4UEFBIXTiVD6fPywwhBCipqZubWVz+fLFkSHjGhoaLlw8V19fH38p1s936M1b1ysrK7y9/crKSvft/2PlitXeA3ypnWtp6WwJWztv7lLqbs+eDtM/nvvWwAcP7S4vL/tl666etvaEkH79PEJG+b35KW946ZffCyHE2sqGEGJiYubg4EhtcXHuf/jw3obGBmqSK/yPXxwcHFcuX0UIGeA1qLa25uChv0aPmkg9eP68zwb5DCaETJ8+b+asSTdvXR/gNei9/nIAmA5jMABAp+ycrBX/Wzxm3NDJH44UCoUVFeXiL8nLK1A3eDyejo5ueVkpIcTPN6CxsfGLZfNzc7PFj/T29ku7ea2uru5i/HlCiJ/v0KioY4SQixfP6+np97S1v3YtRSAQrF6zcvBQN+q/n7duIISUlT6h9uDk5CpJ2us3Uq2tbKj6IqE3vPQr38ubFRTkl5WVti0lLi5u9fX1BY/zqbsKz79penoGVH+SPCoAu2AMBgBoc/3GlS+Wze/j6Pz5Z18rKSp99c1nraLWVz6Sz+MLW4WEkH6u7mvX/Lhte9jHn0wYFhiyaOEyPp/v7e23I3xrckrCqdPH/f0Cg4aN+mRmaH5+XvylWH+/QEJIeUUZIWTN6jBdHb22uzU0NH76tK5tW3qz2toaKyubd3qPb3hpc3PLl9/Lm/dW97SOEKKurineoqKiSvUhHd3/t38ZvgwhpLVV+E5pAVgEDQYAaLNnT7ihofGa1WHUT24FyWpEP1d3F+f+R44e+PW3LXp6BpMnfWxkaGxtZXPkyP6MzLsL539hYWFla2v/w4ZvqSkk8Y95anbmvwTW0tIpf82oxuuOYHrzS7/8Xt4cgKpBbVe3VFZWtH0VgK4Ds0gAQJvqmipLC2uqvjQ3N9c31Le2vnoMRoxaosvlcseO+UBbW+f+/Qxqu7e3X0bmXTu7XhYWVoSQ4OFj7t69TU0hEUL69HHhcDjHIg6J99PQ0PAegXtY22Zk3s16/qJtqatpUMMtlOLnp6R7w0u/8r3IyckTQl7Xk7S0tPX1DFJTE8VbLl48Ly8vb9lmqS9AF4ExGACgjaOjc3T0yVOnj6uqqB0+sq+2tibvQc6bz8hy9NjBxMsX/f0Cy8tLy8pKe/ToSW2nJpKCh4+h7g4c6P/Lb5upo5AIIcZG3UaNnHDk6IHlKz/19BhYXl4WcfzvtWt+tH7HKaHx46acOn186Wdzxo75QEdHNzX1svhLLi5ul7bE/X14r6Oj8+XLF6NORbz1pV/5XnR19QwNjP7+Z6+8gkJNTfWokROo47HFpn44c936bzZs/N7Fxe369dSExAsfTpmhoCDR8BWANEGDAQDafDR1dkV52c9bN6ioqAYNGzVuzKTNYWtupF116uPyuqcYGhq3NDf/tm2LkpLyqFETxo97dq59I0Pjvk6u1JwRIUROTi5g6AjxXULI3DmLdXX1jh07dOVKkpaWtpenj4627rsG1tc32PDDL9t+/3HP3nAVFdV+rh7iLwUMHVFQkH/w0O49e8MHePmOGztJfJDz6176le+Fw+GsXLlm/YZvt/6yUVdX32fgYH39/3ftzCFDghqbGg//s+/suShtLZ0Zn8yfMH7Ku74RACnAefnkjwAA72f7Fzljl5jLyNF5TtvORJ0Nb9HCZcEjxtCdpX3s/i579gZLLtYXABtgDAYA4F91dXUTPwh65ZdmzlgYNGxkpycCgFdDgwEA+JeiouLv2/e/8kuqKmqdHgcAXgsNBgDgX1wu10DfUMIHq6mpx8Vc7eBEAPBqmO0EAAAA9kGDAQAAAPZBgwEAAAD2QYMBAAAA9kGDAQAAAPZBgwEAAAD2QYMBAAAA9kGDAQAAAPZBgwEAAAD2QYMBgHajqS+HiwKymrahPMHVfoEl8GEDAO1GIGitLm+mOwW8p9rKlsZ6AZdHdw4AyaDBAEC76WatVFshoDsFvKeashZTWyW6UwBICg0GANqNx3Cti4eL6E4B7yn+SLFboBbdKQAkxRGJMOcJAO2moU64f12+/xQjDT1ZurOApGoqWs7+9XjMgm4qmphDAtZAgwGAdlZfI4yPKHtwu87cQbm6vIXuOO1JKBTyeFL1M15NW/ZBeq2pjZL7cC01bRm64wC8AzQYAOgQghZRWWFTq1CqPmFmz579008/ychIz096Ho+rqS8rI8ehOwjAO+PTHQAApBNfhqNvKk93inZmZqNmZKHI5+OTE4B+GIMBAAAA9sGxSAAAkrp+/Tp+6wNgCDQYAABJzZs3r7kZp+wDYAQ0GAAASU2YMEHKjkUCYC+sgwEAAAD2wRgMAICkrly50traSncKACBoMAAA72DhwoUtLVJ1jj4A9kKDAQCQ1LBhw7AOBoAhsA4GAAAA2AdjMAAAkoqLi8M6GACGQIMBAJDUihUrsA4GgCHQYAAAJDVo0CCsgwFgCKyDAQAAAPbBGAwAgKROnTolFArpTgEABA0GAOAdrFq1SiAQ0J0CAAgaDADAO8D5YACYA+tgAAAAgH0wBgMAIKnz58/jfDAADIExGAAASbm7u8fFxcnJydEdBAAwBgMAIDEPDw+sgwFgCIzBAAAAAPtgDAYAQFJXrlzBOhgAhkCDAQCQ1IoVK3A+GACGQIMBAJCUuro6h8OhOwUAEKyDAQAAAFbCGAwAgKQaGhrojgAAz6DBAABIytfXt6mpie4UAEDQYAAAAICVsA4GAAAA2AdjMAAAksI6GADmQIMBAJAU1sEAMAcaDACApCwsLLhcfGwCMALWwQAAAAD74JcJAABJ3b9/H7/1ATAEGgwAgKQ+/PDD5uZmulMAAEGDAQB4B1gHA8AcWAcDAAAA7INfJgAAJJWbm4vf+gAYAg0GAEBSkyZNwjoYAIZAgwEAkJS1tTXWwQAwBNbBAAC8Rd++fTkcDnVbJBJxOByRSDRy5MiVK1fSHQ2g68IvEwAAb2Fqaiq+TVUZQ0PDGTNm0BoKoKtDgwEAeIuhQ4eKx2AoPj4+urq69CUCADQYAIC3mThxorGxsfiugYFBaGgorYkAAA0GAOBtVFRUhg4dSt0WiUTe3t76+vp0hwLo6tBgAADebsKECdQwjLGx8aRJk+iOAwBoMAAAElBTUwsMDCSEeHl5YQAGgAlwNDUAdIaKkpbMqzW1lYKa8ha6s7yn1tbWgoICI0NDHp9Pd5b3pKYtq6TKs+ytrGsiR3cWgP8KDQYAOtz9G3VpF6oNLRV1jOW5bP3pLxWE5MnjxtJHjRa9lOzdVelOA/CfoMEAQMfKvFZ7/8ZT77GYeWGQhKMlxtYKDh4oMcBiWAcDAB2ourQlPbEG9YVpPEfp5d56Wva4ie4gAO8PDQYAOlD2zTotI3m6U8Ar6HSTv59WR3cKgPeHBgMAHai2SqDTDQ2GiXSM5esqhXSnAHh/aDAA0IHqKgUcCR4GnY/L49SUN9OdAuD9ocEAAAAA+6DBAAAAAPugwQAAAAD7oMEAAAAA+6DBAAAAAPugwQAAAAD7oMEAAAAA+6DBAAAAAPugwQAAAAD7oMEAAAAA+6DBAAAAAPugwQAAAAD7oMEAABBCyKnTx0NG+ZWUFL/1kXfvpTc1NbXvq+fmZo8I9klIvNC+uwWQYmgwAACEECIrK6ekpMzlvuVT8Uz0ybnzpjY2NrTvq/P5fGVlFT6P3767BZBi+L8FAIAQQvx8h/r5Dn3rw9579EUkEnE4nNd91cTEbP++E++3Z4CuCQ0GABiksbEx7Kd1ly/HE0J69eozb85SfX2D27fT9uwNv52eRgix6WE3a9aiHta2TU1NY8cH9HN1X7F8FfXctLRrny6ZuXZ1WP/+nkXFhb/+uvna9RRZWTlrK5uPPppj06PnG1533fpvoqMjCSHnopP5fP7Kr5Z0Mzbl8/mRUccELS39+3suXLBMWVn5TPTJsB/XEUJCRvkRQr74/OuhQ4YTQm6kXd0RvjUnJ0tDQ7OPo8v0j+dqaWkTQqZ9PK67mYWZmcXRYwebmhonjP9w11/bd+860q2bKfW6ny6e2dBQHxIy7of13xJCNqz/xblvP+r7EL7zl5jYM83NTd2MTceNmzzIZ/CBg3/9vuPnQweidHX1CCHp6TcvxsfMnbOY2tWWsLVPSkvWrg7r+L8lAEbALBIAMMj+A39GR0eOGR06c8aCmppqBQUFQkhxcWFTc9PkSdM/nDKjuLhw2ZcLGhsb5eTkBvsPS0i8UF9fTz333PlTenr6rq7u5eVl8xd8VFNbPW/u0pkzFrS0tCxcNP3Bg5w3vO6okRP8/QPbbvn78N7i4sI1q8PmzV164eL5vft2EkL6uXqMGzuJELJ2ddhPYeH9XD0IIdeup37+xTwzU/OlS/43bsykW7euL146q7GxkdrPlStJGZl31qza8v13m4JHjOHz+edjTlNfKikpTrt5bfjw0X0cXWZ8Ml/80q2trStWfpqUFP9B6LRPFy23tOzx/arlp04f9/b2I4QkXr5IPez0mRNnz0U1NzdTT7mUEOfs1K+9/0IAmAtjMADAIEXFhQoKCqETp/L5/GGBIdRGP78Acb3o0aPn4iWzbqenuTj3Hx406sjRA5cuxQ4ZEtTU1BR/KWb8uClcLnfP3nANdc1NG37j8/mEEH+/wElTQiJPHZs/d+nrXtfaysbM1LztFmNjk+Vffs/hcGxt7OITYq9cTZo1c6GGhqahoTEhxNbWXk1NnXrkz1s3DA8atWD+59RdZ+f+H04bc+VqkpenDyGEx+f/b8UaqooRQjw9Bp4/f3ra1FmEkPMxp5WVlX0HDZWXl+/dy0n80vGXYm/dvnFg30ltbR1qequhof7I0QOBAcHWVjaXL18cGTKuoaHhwsVz9fX18Zdi/XyH3rx1vbKywsnJtb3/QgCYCw0GABjEzzcgJubMF8vmz52zxNzcktrI4XAuJcT9fXjvw4cPFBUVCSGVFeWEEFPT7g4OjudjTg8ZEpR4+WJjY2NgQDAhJCUl8UlpSWCQl3i3LS0tpU9K3imJvJy8eNmKnp5BevrNVz6suLjo4cMHjx8/iow61nb7k+cvZ2trL64vhJCgoFFLP5uTnn7T3r732XNR/v7D5OXlX9hncnKCQCAInTRCvEUoFCopKRNCvL39/ty1ra6uLiExjio3UVHH/HyHXrx4Xk9Pv3t3i3d6jwCshgYDAAzSz9V97Zoft20P+/iTCcMCQxYtXMbn83fvCf9z17bRoybOmD6/vKLs2++WtYpaqccPHzZq3fpvysvLzp0/5ekxUFNTixBSUVnu5uY1Y/r8tnumGsD7keHLtLYKX/mlyspyQsiHU2YM8BrUdrumpjZ1Q0Feoe12pz4uRkbdzsec5svI5Ofnffv1+lfuU0tLe/PGbW038vh8qsHsCN+anJJw6vRxf7/AoGGjPpkZmp+fF38p1t8v8OVdAUgxNBgAYJZ+ru4uzv2PHD3w629b9PQMxo2dtP/An8MCQ+bNXdJ2bIMyYIDvz79sPHrs4JUrSRvW/0JtVFFRra6uMjEx67iQIpGIuqGsrEIIaWpqlPDlOBzOsMCQg4d2i0SiXr36mJmZv/wYFRXVqqpKPT0DOTm5F75kZGhsbWVz5Mj+jMy7C+d/YWFhZWtr/8OGbysrK6hVMgBdB1byAgCDUOtSuVzu2DEfaGvr3L+f0djY0NTUZG1tSz2guqaKWrhK3ZWTk/P3Dzxw8C8jo259HJ2pjU5OrunpNzOz7ol329DQbqdvocZUyspKqbvGxiZ6evqnz5wQv4RAIGhpaXnDHgKGjqivf3oy8uiI4WNe+QAnJ1ehUHji5D+vzO/t7ZeRedfOrpeFhRUhJHj4mLt3b+vp6fe0tW+ntwjADhiDAQAGOXrsYOLli/5+geXlpWVlpT169FRTUzc3tzx67KCmptbTurq/dv/O5XJzc7PFTxk+bNTRoweHB40Sb/lwyozk5ITPPp87buwkDQ3N1NTLwlbhqu82tUtCO/vePB5v668bA4aMaGpuGjF89Nw5S776+rO586eOGD6mVSiMPhvp7x84ZnTo6/agrq7h6THwRtrVFyaexPz9Ak9GHt22/cei4kJrK5vs7KyExLhdf/xDrZihJpKCn7efgQP9f/lts/cADMBAl4MxGABgEEND45bm5t+2bYk6FTFq1ITx4yYTQv63Yo2CvMJ333956PCe2bM/nTzp4+jok+JxDjMzc+e+/QYPDhLvxMjQeOtPf9jZ9dq3/49fft1UVV3p5xvQXgmNDI2XLF7x6NHDrb9svHDhHCHEy9Nn7eowGb7ML79u2r03XE/PoFebA4teKShoVGBAsIyMzCu/KiMjs+GHX4KGjYyNjd68Zc31G6kjho+hjquiAvR1chXPGcnJyQUMHYEpJOiCOOLZXACAdhe5o8i8t2q3Hkp0B4EXPclvTIstG73QmO4gAO8Js0gA0FUsWDT9wYPsl7e7u3t/+cW3dCQCgPeHBgMAXcVXK9e2CF6xxvaFA54BgBXQYACgq6BOcQsA0gEreQEAAIB90GAAAACAfdBgAAAAgH3QYAAAAIB90GAAAACAfdBgAAAAgH3QYAAAAIB90GAAAACAfdBgAAAAgH3QYACgA/H4HC6HQ3cKeBUO4cvy6A4B8P7QYACgA8krcetqXnEpIqDd02qBnCLKJbAYGgwAdCAdY/mnVQK6U8Ar1Ja36JvJ050C4P2hwQBAB7J3V825VVNfgxLDLC1NremXKx291ekOAvD+OCKRiO4MACDN6muFJ3cUuQXpaujJ0p0FCCGktrLl0pGSwI/0VTT4dGcBeH9oMADQ4RqfCs/8VVJXLTA0V2xtpTtNF8aX4T7OqVNU5vlN1FPRRH0BdkODAYBOUlHcXFbY3PiUxTNKmzdvXrBgAZ/P1p/9coo8LQM5bUMMhoE0QIMBAJCUu7t7XFycnJwc3UEAACt5AQAAgIXQYAAAAIB90GAAACSlpqbGwSmGAZgBDQYAQFLKysp0RwCAZ9BgAAAk9fjxYxz9AMAQaDAAAJJSUVHBLBIAQ6DBAABIqra2FmMwAAyBBgMAAADsgwYDACCpHj16YBYJgCHQYAAAJJWZmYlZJACGQIMBAJCUrq4uxmAAGAINBgBAUk+ePMEYDABDoMEAAAAA+6DBAABIqlevXnRHAIBn0GAAACR169YtuiMAwDNoMAAAAMA+aDAAAJLq3bs33REA4Bk0GAAASd28eZPuCADwDBoMAAAAsA8aDACApBwcHHBGOwCGQIMBAJDU7du3cUY7AIZAgwEAAAD2QYMBAJCUpaUl3REA4Bk0GAAASWVnZ9MdAQCeQYMBAAAA9kGDAQCQlIaGBo5FAmAINBgAAElVVlbiWCQAhkCDAQCQlJGREcZgABgCDQYAQFKPHz/GGAwAQ6DBAAAAAPugwQAASArXpgZgDjQYAABJ4drUAMyBBgMAIClNTU2s5AVgCDQYAABJVVRUYCUvAEOgwQAAAAD7oMEAAEjKwMAAs0gADIEGAwAgqaKiIswiATAEGgwAgKRMTEwwBgPAEGgwAACSKi0tpTsCADyDBgMAIKmGhgbMIgEwBAf/NwIAvJmTk5N48kgkElG3vb29N2/eTHc0gK4LYzAAAG9haWnJeY7L5XI4HH19/dmzZ9OdC6BLQ4MBAHgLNzc3LvffT0uRSOTk5GRlZUVrKICuDg0GAOAtxo0bZ2hoKL6rr68/efJkWhMBABoMAMDbGBkZeXh4ULdFIlGfPn2sra3pDgXQ1aHBAAC83fjx442MjKgBmClTptAdBwDQYAAAJGBiYuLu7k6tgMEADAAT4GhqAKBBq5Dk3K6rKm1uqG2lO4uknj59GhMT4+3traamRncWSSmocNW0ZMztlPlyOJUwSBs0GADobEUPGs/tLdE0kNMzVSAEH0EdiMPlPnlYX1Xa7DFC29RWke44AO0JDQYAOlVxXmNSVIVvqCEHk9idKGZ/obOfhrGVAt1BANoNPkIAoPO0CsmRnwv8JqG+dDbfUMMzfxU31AnpDgLQbvApAgCd52Z8Vc/+6nSn6KJsXdVuxlfRnQKg3aDBAEDnKS9q0jbCRAY9NA3lK4tb6E4B0G7QYACg89RVCWXlcVAMPeQUuLXVArpTALQbNBgAAABgHzQYAAAAYB80GAAAAGAfNBgAAABgHzQYAAAAYB80GAAAAGAfNBgAAABgHzQYAAAAYB80GAAAAGAfNBgAAABgHzQYAAAAYB80GAAAAGAfNBgAkEK5udkjgn0SEi9Qd+vq6rLuZ9Ad6pm799Kbmprabln3wzezZk+mLxEAK6HBAIAU4vP5ysq6YRmRAAASQElEQVQqfB6fujt9xoTTp4/THYoQQs5En5w7b2pjY0PbjYpKSoqKSvSFAmAlPt0BAADak0gk4nA4JiZm+/edEG9sbm6mNdS/Xhh9oSyY9xkdWQDYDWMwAMBQIpFo+IiBGzetEm/5csWi6uoq6nZ5edkgP5cz0Serq6t8fJ0P/b1n1ZqVAcM8F376yZnokz6+zj6+zlevpRBCJoQGVVZWRBw/7OPrPCE0iHp6Y2Pj1l82jRztP2z4gFmzJ8fGnX1rnv0Hdo2bEBgwzHP+wo+vXU+lNhYVF/7vq6WBQV4ho/w+/2JeRuZd8eNv305b+tmcwCCvwCCvL1csyrqfcSb6ZNiP6wghIaP8fHydz0SfpOL5+DrPX/gx9SyBQLAjfOuYcUP9h/SfPmOieCLsnyP758ybGnfh3KTJIQHDPBcsmp6fn9d+32wA9kGDAQCG4nA47h7el5PiW1tbCSElJcUpKYnUT31CyMX4GB6P5+7uTd3du3envp7Bpo3b5s5Z0sfRZcYn88X7+ebr9Soqql6ePj+FhX/z9XpCSGtr64qVnyYlxX8QOu3TRcstLXt8v2r5qTdOM127nrojfGuvXk6LFy3X1zNoqK+nWtT8BR/V1FbPm7t05owFLS0tCxdNf/AghxBy5Wryp0tm1tbWzJq5aMYnC1qFQqFA0M/VY9zYSYSQtavDfgoL7+fqQQhZsnillWUP8Qtt3LTq0N97goaNXLF8lb6+4f++Wnrr1g3qS/fupf/9954lS1Z+9+3G0icla3/4ukO+7wAsgVkkAGCugQP8zp6Nunv3tr197zPRJ0UiUWTUsfHjJhNCLsafd3JyVVVRpUZlevZ0mP7xXPETe/dyEt+26dGTz+draWk7ODhSW+Ivxd66fePAvpPa2jqEED/foQ0N9UeOHggMCH5dkuLiQkLIyOBxdna9/P0DqY179oZrqGtu2vAbn88nhPj7BU6aEhJ56tj8uUu3/rJRX9/w55/+kJWVJYSEBI+lnmJoaEwIsbW1V1NTp7a4OPc/fHhvQ2MDISQ/Py/6bOSUydOnfjiTEOI9wHfSlJG7/tq+edM26sGrV23R1NQihIwaNeHX37ZU11Srqap1wDcegAXQYACAuZyd+ysrKyckXrCz6xUdfXJYYMjpMyfS0q5162Z6+3ba5599JX6kk5Or5LtNTk4QCAShk0aItwiFQiUl5Tc8pX8/TxUV1TVr/zd/3mf9+3tSG1NSEp+UlgQGeYkf1tLSUvqkpKi4MD8/b/rHc6n6Irmbt64TQjw9fai7HA7Hxbn/ufOnxA+Ql1egbujpGRBCystK0WCgy0KDAQDmkpGRcXMbkHj5oqur+5PSkg+nzKiuroo6daxnz15tp5Da/miXRGVluZaW9uaN29pu5PHf9HmopaW99ac/fvlt85crFtnb9/5q5VodHd2KynI3N68Z0+e3faSSkvKTJ8WEEF0dvXd5r4QQ8vRpHSFEQ11TvEVVVa2+vv7p06cvPFKGL0MIEbYK3/UlAKQGGgwAMNrAAX7nzp3aEb7V3W2Ajo7u8OGjV/5v8cOHD6gpJMn3IxKJxLdVVFSrqir19Azk5OQk34OJidkPa3+6fuPKV18v/WH9Nxs3/KqiolpdXWViYvbCI6kiUlFZLkmYtrS1dQkhNTXV1PQWIaSiopzP58vLy0ueE6CLwEpeAGA0Z+f+SkpKGRl3hg8fTa0a0dXRu5+d6TPQX/KdKMgrlJeXie86ObkKhcITJ/8Rb2loaHjNU/9FHZLt1Melf38v6vx4Tk6u6ek3M7PuvbCfbt1MdXR0o89GCgQCartIJKLWIyvIKxBCyspKX/kStrb2HA4nOSVB/IrJKQl2dr14PJ7kbxagi8AYDAAwmqysrJvbgLt3bzv37UctDQkKGrXzj1/bTiG9lYNDn5jYM/sP7FJRUbXr2cvfL/Bk5NFt238sKi60trLJzs5KSIzb9cc/bxjquJdx59vvvggJHqegoJiaetmmR09CyIdTZiQnJ3z2+dxxYydpaGimpl4WtgpXfbeJw+HM+GTB6jUr586bOmTIcC6Xe/Zc1Mjgcf7+gXb2vXk83tZfNwYMGdHU3DRi+Oi2r2JkaDxkcNCuv7YLhUJDQ+OoqGMVFeXLv/z+v30LAaQTGgwAMN3AAX6WFtYcDoe6GzB0xJ07t95pCmnmjAUVFWV79oarq2nMmbPY3Nxyww+/7Aj/OTY2OjLyqLGxyYjhY/hvXAcjKyNratJ9//4/RSJRb8e+C+Z9ThWOrT/98dv2sH37/+BwOFZWNiNDxlOP9/MdKi8vv3v3jt+2bVFTU7e2tjUyNqGesmTxivCdv2z9ZaOVlc0LDYYQsmjhMiUl5WMRh2pra7qbWaxZtcWpj8u7f88ApB/nddOxAADtLuLXQtv+6oYWinQH6YpKCxqvni0b96kx3UEA2gfGYAAAntkRvrXt4hgxVRW1fXsZcVklABBDgwEAeGbcuMlBQaNe3s7l4KAHAMZBgwEAeEZNVQ0niANgC/xiAQAAAOyDBgMAAADsgwYDAAAA7IMGAwAAAOyDBgMAAADsgwYDAAAA7IMGAwAAAOyDBgMAAADsgwYDAAAA7IMGAwAAAOyDBgMAnUdZndfS1Ep3ii6qualVRQNXkgHpgQYDAJ1HU1+2tKCR7hRdVPnjJg1dGbpTALQbNBgA6Dy9vdQzr1bTnaKLyrxa3ctTne4UAO0GDQYAOg9PhhM8y+j83kK6g3Q5MfuL/CbqKqry6A4C0G44IpGI7gwA0LUU5jSc3VeiZ6Kga6LA4dCdRrpxyJOHDZVPmt0CNc3slOhOA9Ce0GAAgAatQnL/Rm1VWcvTagHdWd7BuXPnBg0axOOxZiRDWZWvqiVj3ktJVh4j7iBt0GAAACTl7u4eFxcnJydHdxAAwDoYAAAAYCE0GAAAAGAfNBgAAElZWVlxsPYYgBnQYAAAJHX//n2sHQRgCDQYAABJ8Xg8jMEAMAQaDACApIRCIcZgABgCDQYAQFIaGhoYgwFgCDQYAABJVVZWYgwGgCHQYAAAJNW7d2+6IwDAM2gwAACSunnzJt0RAOAZNBgAAABgHzQYAABJKSoqYiUvAEOgwQAASKq+vh4reQEYAg0GAEBSZmZmGIMBYAg0GAAASeXl5WEMBoAh0GAAAACAfdBgAAAkZW9vj1kkAIZAgwEAkFR6ejpmkQAYAg0GAAAA2AcNBgBAUriqAABzoMEAAEgKVxUAYA40GAAAAGAfNBgAAEk5OjrSHQEAnkGDAQCQVFpaGt0RAOAZNBgAAABgHzQYAABJ9ejRA2e0A2AINBgAAEllZmbijHYADIEGAwAAAOyDBgMAICkej4dZJACGQIMBAJCUUCjELBIAQ6DBAABIysHBge4IAPAMGgwAgKRu375NdwQAeAYNBgAAANgHDQYAQFJqampYyQvAEGgwAACSqq6uxkpeAIZAgwEAkJSdnR3GYAAYAg0GAEBSd+7cwRgMAEOgwQAASMrBwQFjMAAMgQYDACCp27dvYwwGgCHQYAAAJKWjo0N3BAB4hoPfJwAA3szJyYkQwuH8vw/Mvn377tixg9ZcAF0axmAAAN7CwMCAy+VyOBzuc7q6urNmzaI7F0CXhgYDAPAWffv2bW1tbbulR48effv2pS8RAKDBAAC8zcSJEw0MDMR3tbW1p0yZQmsiAECDAQB4G1tbW0dHR/FdGxsbDMAA0A4NBgDg7SZOnKivr08NwEyaNInuOACABgMAIAF7e3sHBweRSNSzZ09nZ2e64wAA4dMdAACgQzQ1tD6tFtTXCBueCluaWiV4xlv4uU4tf6Dg5xpyN7nmv+9NRo4rr8RTVOEpqfLllfDLJMA7w/lgAECqVD1peXDnaeb1utZWbkNtC1+OJyMvw8APOg6X29LQImgWKCjLcEirlaOSuYOypr4M3bkAWAMNBgCkRF2VIP5oWV2tSMTlK2spKmnI051IUvVVTXVlT0UCgYIiGTBKW10HPQbg7dBgAEAaJJ6suJdSrWuppaqnRHeW91f7pL40t8LSUXnASC26swAwHRoMALDevnWPVPTUVPVZ3F3aqi15Wp5fOWWFKZdHdxQABsPyMQBgMUGz6JfF2ZrdtaWmvhBCVPSUDHrq/fZZdlNDOyxABpBWGIMBALYStoj++CbP0sOEw6E7SsfISSoI/dxYQRlDMQCvgDEYAGCrv1bnmzoZSmt9IYSY9jXYs/oh3SkAGApjMADAStF7SluIgrK2At1BOlZ9VZPwac3w6fp0BwFgHIzBAAD75GfUF+c3S319IYQoqstVl4uyrtfSHQSAcdBgAIB94iPKdS016U7RSXStNBNOlNOdAoBx0GAAgGVybtUpqMorqMrSHaSTyCrwNfSV76W2w6UMAKQJGgwAsMzdlFoZRTm6U7zad+uD/jm+rt13K6OicCcJE0kA/w8aDACwTH7GUxVd6Tn7iySUNeWfPGoUNOPAC4B/ocEAAJvkZzRoGSlJ8RHUr6Ntopx3t57uFAAMwqc7AADAOygvauLwO+qDKzv32qlzvxYWZ6koa1p2dw7wn62qok0IWbnad/TwL9LvXbibmaggr9zfZeRgn+nUU4RC4fkLO5OvRjQ3N1iY921paeygbITHL33caOnYtQafAN4AYzAAwCa1VQKeTIeco/Z+zpUduxfo6XYfF7JigHtobt6NbX/ObW5+1kgOHv3WUN96zsfbnHoHnI3dcTczkdp+LHLDuQs7bazdRwYtlZWRb2jsqNUqMnK8uiphB+0cgI0wBgMAbFJXJeDLKXbEniOiNvV3HjkyaCl119qy34afxmdmJzv0HEgIcXUa4es9lRBiqG+deu14VnZyzx4eBYUZyVeP+XpPC/CbRQhx7jMs58H1jshGCOHL8euqMYsE8C80GABgEw6Hy+O3/+BxRWVRSemDsopHyVcj2m6vqi6hbsjKPjt7Ho/HU1PVra4pJYTcvnuBEDLAfWLbeO2e7dnr8rkiXtdb/gPwemgwAMAmsvKchhpBu++2tq6cEOLvM71XT5+221VUtF9+MJfLb20VEkKqqorl5ZWVFNXaPc/LWhoFfBk0GIB/ocEAAJsoq/PKy9q/wSjIqxBCWlqadHXMJH+WkpJGY2Ndi6BZht/hp9draRJo6OITG+BfWMkLAGyioSPL7YDPLR1tE3U1/SvXTzY1N1BbhEKBQNDy5mcZG9kQQm7cim7/QC8TEU39rnIaYgBJoMEAAJsYWymUP2r/4304HE5w4Kc1tWU/b/84MeWfS0mHftr+8eXUf978rN52fro6ZkeOrztx+sdraaePnFxfU1va7tko1UW1RhbSfyVLAMmhwQAAmyiq8pTV+Q01Te2+Z4eeAz+atJnHkzlxasv5C39oaOibm/V581N4PN70yWHWlv2SrhyJjP6Zy+EqKaq3ezBCSHO9gMslGnoyHbFzAJbiiEQ4TTUAsMm1mMq8+yIt085YP8sQlY9r9fRb3YO6yuW4ASSBdWEAwDJOPhpJUdlvaDAPHqbt3Lvk5e0K8iqvO+Nc0JD5/Z1D2ivhvczEff989fJ2kUhEiOiVR1x/MiXMtJvD63b4JLsiYOI7LDEG6AowBgMA7JMaXfEwu1XHXOOVX21paaKOjn6BSERed0ElRQU1efl2O2F/c3Nj3dOKl7e3traKRCIe7xXnFFZR0X7dAU3lD6t19Vq9Rr7iuG6ArgxjMADAPq5DNHNuFbQKRdxXneRNRkZOU8OQjlzPyMrKa8q2W4CGqnqPGcbttTcAqYGVvADASn6hOnlXH9OdosM9vFboM0arIw4gB2A7/G8BAKykYyTnFqj5OL2E7iAdqOhuaW8vVSNLHEQN8ApYBwMALJZ3tyHhZJVxL126g7S/x3dKXXxVrft0yGUsAaQAxmAAgMXMeio4DVTKu/KYSNfvYvk3Cu37KaC+ALwBxmAAgPXKHjfFHCrjK8prmXbICeU6U8Wj6saqep8x2gbm8nRnAWA0NBgAkBLJpyqux1Ya9NBS1JCXU2LZ6Wub6wVPKxueZFfY9Vd1H6GNpbsAb4UGAwDSQ9Asuh5bdS+1RiAg6oYqhHD4cjwZeT6H+5rzwNBIJGpuEAiahISIqotrOURk46LaZ6C6vBLKC4BE0GAAQApVlbYU3K8vL2qpqxK0NIvqawR0J3qRspoMV4Yoq/G09GWNLBVw3WmAd4UGAwAAAOyD4UoAAABgHzQYAAAAYB80GAAAAGAfNBgAAABgHzQYAAAAYB80GAAAAGCf/wOSPGaAp+h2FgAAAABJRU5ErkJggg==\n",
            "text/plain": [
              "<IPython.core.display.Image object>"
            ]
          },
          "metadata": {}
        }
      ],
      "source": [
        "from langchain_core.messages import get_buffer_string\n",
        "\n",
        "# Search query writing\n",
        "search_instructions = SystemMessage(content=f\"\"\"You will be given a conversation between an analyst and an expert.\n",
        "\n",
        "Your goal is to generate a well-structured query for use in retrieval and / or web-search related to the conversation.\n",
        "\n",
        "First, analyze the full conversation.\n",
        "\n",
        "Pay particular attention to the final question posed by the analyst.\n",
        "\n",
        "Convert this final question into a well-structured web search query\"\"\")\n",
        "\n",
        "def search_web(state: InterviewState):\n",
        "\n",
        "    \"\"\" Retrieve docs from web search \"\"\"\n",
        "\n",
        "    # Search query\n",
        "    structured_llm = llm.with_structured_output(SearchQuery)\n",
        "    search_query = structured_llm.invoke([search_instructions]+state['messages'])\n",
        "    print(\"### Search Tavili ####\")\n",
        "    # Search\n",
        "    search_docs = tavily_search.invoke(search_query.search_query)\n",
        "\n",
        "     # Format\n",
        "    formatted_search_docs = \"\\n\\n---\\n\\n\".join(\n",
        "        [\n",
        "            f'<Document href=\"{doc[\"url\"]}\"/>\\n{doc[\"content\"]}\\n</Document>'\n",
        "            for doc in search_docs\n",
        "        ]\n",
        "    )\n",
        "\n",
        "    return {\"context\": [formatted_search_docs]}\n",
        "\n",
        "def search_wikipedia(state: InterviewState):\n",
        "\n",
        "    \"\"\" Retrieve docs from wikipedia \"\"\"\n",
        "\n",
        "    # Search query\n",
        "    structured_llm = llm.with_structured_output(SearchQuery)\n",
        "    search_query = structured_llm.invoke([search_instructions]+state['messages'])\n",
        "    print(\"### Search Wikipedia ####\")\n",
        "    # Search\n",
        "    search_docs = WikipediaLoader(query=search_query.search_query,\n",
        "                                  load_max_docs=2).load()\n",
        "\n",
        "     # Format\n",
        "    formatted_search_docs = \"\\n\\n---\\n\\n\".join(\n",
        "        [\n",
        "            f'<Document source=\"{doc.metadata[\"source\"]}\" page=\"{doc.metadata.get(\"page\", \"\")}\"/>\\n{doc.page_content}\\n</Document>'\n",
        "            for doc in search_docs\n",
        "        ]\n",
        "    )\n",
        "\n",
        "    return {\"context\": [formatted_search_docs]}\n",
        "\n",
        "\n",
        "def search_scholar(state: InterviewState):\n",
        "\n",
        "    \"\"\" Retrieve docs from scholar \"\"\"\n",
        "    # Search query\n",
        "    structured_llm = llm.with_structured_output(SearchQuery)\n",
        "    search_query = structured_llm.invoke([search_instructions]+state['messages'])\n",
        "    results = google_scholar.run(search_query.search_query)\n",
        "\n",
        "    print(\"### Search Semantic Scholar ####\")\n",
        "    docs = chain2.invoke({\"publications\":results})\n",
        "\n",
        "    docums= []\n",
        "    for item in docs.documents:\n",
        "\n",
        "\n",
        "      doc = f'<Document source=\"{item.title}\"\\n Abstract=\"{item.abstract}\",\\n authors: {item.autors}\\n</Document>'\n",
        "      docums.append(doc)\n",
        "\n",
        "    text = \"\\n\\n---\\n\\n\".join(\n",
        "            [\n",
        "\n",
        "              str(doc) for doc in docums\n",
        "            ]\n",
        "    )\n",
        "\n",
        "    return {\"context\": [text]}\n",
        "\n",
        "def search_pubmed(state: InterviewState):\n",
        "\n",
        "    \"\"\" Retrieve docs from pubmed \"\"\"\n",
        "    structured_llm = llm.with_structured_output(SearchQuery)\n",
        "    search_query = structured_llm.invoke([search_instructions]+state['messages'])\n",
        "    print(\"### Search Pubmed ####\")\n",
        "    pubmed_docs = retriever.invoke(search_query.search_query)\n",
        "    docs_pubmed= []\n",
        "    for item in pubmed_docs:\n",
        "      doc = f'<Document source Pubmed=\"{item.metadata.get(\"uid\")}\" \\n Title :\"{item.metadata.get(\"Title\")}\"/>\\n, Abstract: {item.page_content}\\n</Document>'\n",
        "      docs_pubmed.append(doc)\n",
        "\n",
        "    texto = \"\\n\\n---\\n\\n\".join(\n",
        "      [\n",
        "\n",
        "          str(doc) for doc in docs_pubmed\n",
        "      ]\n",
        "    )\n",
        "    return {\"context\": [texto]}\n",
        "\n",
        "answer_instructions = \"\"\"You are an expert being interviewed by an analyst.\n",
        "\n",
        "Here is analyst area of focus: {goals}.\n",
        "\n",
        "You goal is to answer a question posed by the interviewer.\n",
        "\n",
        "To answer question, use this context:\n",
        "\n",
        "{context}\n",
        "\n",
        "When answering questions, follow these guidelines:\n",
        "\n",
        "1. Use only the information provided in the context.\n",
        "\n",
        "2. Do not introduce external information or make assumptions beyond what is explicitly stated in the context.\n",
        "\n",
        "3. The context contain sources at the topic of each individual document.\n",
        "\n",
        "4. Include these sources your answer next to any relevant statements. For example, for source # 1 use [1].\n",
        "\n",
        "5. List your sources in order at the bottom of your answer. [1] Source 1, [2] Source 2, etc\n",
        "\n",
        "6. If the source is: <Document source=\"assistant/docs/llama3_1.pdf\" page=\"7\"/>' then just list:\n",
        "\n",
        "[1] assistant/docs/llama3_1.pdf, page 7\n",
        "\n",
        "skip the addition of the brackets as well as the Document source preamble in your citation.\n",
        "\n",
        "add authors of the documents if possible\"\"\"\n",
        "\n",
        "def generate_answer(state: InterviewState):\n",
        "\n",
        "    \"\"\" Node to answer a question \"\"\"\n",
        "\n",
        "    # Get state\n",
        "    analyst = state[\"analyst\"]\n",
        "    messages = state[\"messages\"]\n",
        "    context = state[\"context\"]\n",
        "    print(\"### Generate Answer ####\")\n",
        "    # Answer question\n",
        "    system_message = answer_instructions.format(goals=analyst.persona, context=context)\n",
        "    answer = llm.invoke([SystemMessage(content=system_message)]+messages)\n",
        "\n",
        "    # Name the message as coming from the expert\n",
        "    answer.name = \"expert\"\n",
        "\n",
        "    # Append it to state\n",
        "    return {\"messages\": [answer]}\n",
        "\n",
        "def save_interview(state: InterviewState):\n",
        "\n",
        "    \"\"\" Save interviews \"\"\"\n",
        "\n",
        "    # Get messages\n",
        "    messages = state[\"messages\"]\n",
        "\n",
        "    # Convert interview to a string\n",
        "    interview = get_buffer_string(messages)\n",
        "\n",
        "    # Save to interviews key\n",
        "    return {\"interview\": interview}\n",
        "\n",
        "def route_messages(state: InterviewState,\n",
        "                   name: str = \"expert\"):\n",
        "\n",
        "    \"\"\" Route between question and answer \"\"\"\n",
        "\n",
        "    # Get messages\n",
        "    messages = state[\"messages\"]\n",
        "    max_num_turns = state.get('max_num_turns',2)\n",
        "    print(\"### Routing Messages ####\")\n",
        "    # Check the number of expert answers\n",
        "    num_responses = len(\n",
        "        [m for m in messages if isinstance(m, AIMessage) and m.name == name]\n",
        "    )\n",
        "\n",
        "    # End if expert has answered more than the max turns\n",
        "    if num_responses >= max_num_turns:\n",
        "        return 'save_interview'\n",
        "\n",
        "    # This router is run after each question - answer pair\n",
        "    # Get the last question asked to check if it signals the end of discussion\n",
        "    last_question = messages[-2]\n",
        "\n",
        "    if \"Thank you so much for your help\" in last_question.content:\n",
        "        return 'save_interview'\n",
        "    return \"ask_question\"\n",
        "\n",
        "section_writer_instructions = \"\"\"You are an expert technical writer.\n",
        "\n",
        "Your task is to create a short, easily digestible section of a report based on a set of source documents.\n",
        "\n",
        "1. Analyze the content of the source documents:\n",
        "- The name of each source document is at the start of the document, with the <Document tag.\n",
        "\n",
        "2. Create a report structure using markdown formatting:\n",
        "- Use ## for the section title\n",
        "- Use ### for sub-section headers\n",
        "\n",
        "3. Write the report following this structure:\n",
        "a. Title (## header)\n",
        "b. Summary (### header)\n",
        "c. Sources (### header)\n",
        "\n",
        "\n",
        "\n",
        "4. Make your title engaging based upon the focus area of the analyst:\n",
        "{focus}\n",
        "\n",
        "5. For the summary section:\n",
        "- Set up summary with general background / context related to the focus area of the analyst\n",
        "- Emphasize what is novel, interesting, or surprising about insights gathered from the interview\n",
        "- Create a numbered list of source documents, as you use them\n",
        "- Do not mention the names of interviewers or experts\n",
        "- Aim for approximately 400 words maximum\n",
        "- Use numbered sources in your report (e.g., [1], [2]) based on information from source documents\n",
        "\n",
        "6. In the Sources section:\n",
        "- Include all sources used in your report\n",
        "- Provide full links to relevant websites or specific document paths\n",
        "- Separate each source by a newline. Use two spaces at the end of each line to create a newline in Markdown.\n",
        "- link the Sources to the authors and titles of the documents.\n",
        "- It will look like:\n",
        "\n",
        "### Sources\n",
        "[1] Link or Document name, Authors\n",
        "[2] Link or Document name, Authors\n",
        "\n",
        "7. Be sure to combine sources. For example this is not correct:\n",
        "\n",
        "[3] https://ai.meta.com/blog/meta-llama-3-1/\n",
        "[4] https://ai.meta.com/blog/meta-llama-3-1/\n",
        "\n",
        "There should be no redundant sources. It should simply be:\n",
        "\n",
        "[3] https://ai.meta.com/blog/meta-llama-3-1/\n",
        "\n",
        "8. Final review:\n",
        "- Ensure the report follows the required structure\n",
        "- Include no preamble before the title of the report\n",
        "- Check that all guidelines have been followed\"\"\"\n",
        "\n",
        "def write_section(state: InterviewState):\n",
        "\n",
        "    \"\"\" Node to answer a question \"\"\"\n",
        "\n",
        "    # Get state\n",
        "    interview = state[\"interview\"]\n",
        "    context = state[\"context\"]\n",
        "    analyst = state[\"analyst\"]\n",
        "    print(\"### Writting Section ####\")\n",
        "    # Write section using either the gathered source docs from interview (context) or the interview itself (interview)\n",
        "    system_message = section_writer_instructions.format(focus=analyst.description)\n",
        "    section = llm.invoke([SystemMessage(content=system_message)]+[HumanMessage(content=f\"Use this source to write your section: {context}\")])\n",
        "\n",
        "    # Append it to state\n",
        "    return {\"sections\": [section.content]}\n",
        "\n",
        "# Add nodes and edges\n",
        "interview_builder = StateGraph(InterviewState)\n",
        "interview_builder.add_node(\"ask_question\", generate_question)\n",
        "interview_builder.add_node(\"search_web\", search_web)\n",
        "interview_builder.add_node(\"search_wikipedia\", search_wikipedia)\n",
        "interview_builder.add_node(\"search_scholar\", search_scholar)\n",
        "interview_builder.add_node(\"search_pubmed\", search_pubmed)\n",
        "interview_builder.add_node(\"answer_question\", generate_answer)\n",
        "interview_builder.add_node(\"save_interview\", save_interview)\n",
        "interview_builder.add_node(\"write_section\", write_section)\n",
        "\n",
        "# Flow\n",
        "interview_builder.add_edge(START, \"ask_question\")\n",
        "interview_builder.add_edge(\"ask_question\", \"search_web\")\n",
        "interview_builder.add_edge(\"ask_question\", \"search_wikipedia\")\n",
        "interview_builder.add_edge(\"ask_question\", \"search_scholar\")\n",
        "interview_builder.add_edge(\"ask_question\", \"search_pubmed\")\n",
        "interview_builder.add_edge(\"search_web\", \"answer_question\")\n",
        "interview_builder.add_edge(\"search_wikipedia\", \"answer_question\")\n",
        "interview_builder.add_edge(\"search_scholar\", \"answer_question\")\n",
        "interview_builder.add_edge(\"search_pubmed\", \"answer_question\")\n",
        "interview_builder.add_conditional_edges(\"answer_question\", route_messages,['ask_question','save_interview'])\n",
        "interview_builder.add_edge(\"save_interview\", \"write_section\")\n",
        "interview_builder.add_edge(\"write_section\", END)\n",
        "\n",
        "# Interview\n",
        "memory = MemorySaver()\n",
        "interview_graph = interview_builder.compile(checkpointer=memory).with_config(run_name=\"Conduct Interviews\")\n",
        "\n",
        "# View\n",
        "display(Image(interview_graph.get_graph().draw_mermaid_png()))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 104,
      "id": "50f382f1-6e93-48d0-a44a-1094d26ccb1e",
      "metadata": {
        "id": "50f382f1-6e93-48d0-a44a-1094d26ccb1e",
        "outputId": "e91157b7-b064-4e77-86f8-03f05a24fc49",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "Analyst(affiliation='PharmaGen Research Labs', name='Dr. Lisa Nguyen', role='Pharmaceutical Research Scientist', description='Dr. Nguyen is involved in the development of new drugs for rare pediatric diseases. Her focus is on the challenges of creating effective treatments given the small patient populations and the high costs associated with drug development. She is motivated by the potential to bring innovative therapies to market that can significantly improve the quality of life for affected children.')"
            ]
          },
          "metadata": {},
          "execution_count": 104
        }
      ],
      "source": [
        "# Pick one analyst\n",
        "analysts[2]"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "3750ac4f-f458-4b2d-8bad-32ce34895758",
      "metadata": {
        "id": "3750ac4f-f458-4b2d-8bad-32ce34895758"
      },
      "source": [
        "Here, we run the interview passing an index of the llama3.1 paper, which is related to our topic."
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "topic"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 35
        },
        "id": "nqcD_yvuafvP",
        "outputId": "d197deb9-e079-4d13-b57a-2c19fb64761e"
      },
      "id": "nqcD_yvuafvP",
      "execution_count": 105,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "'Rare diseases in children'"
            ],
            "application/vnd.google.colaboratory.intrinsic+json": {
              "type": "string"
            }
          },
          "metadata": {},
          "execution_count": 105
        }
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 106,
      "id": "b2242d4e-8430-4de9-8cf7-3ad2f9a22b28",
      "metadata": {
        "id": "b2242d4e-8430-4de9-8cf7-3ad2f9a22b28",
        "outputId": "e9865683-cad8-43ad-fe23-765dbedba2f8",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Generate Question ####\n",
            "QUESTION: Hello, my name is Alex Thompson, and I'm an analyst researching the development of new drugs for rare pediatric diseases. I'm particularly interested in understanding the challenges and innovative approaches in this field. Dr. Nguyen, could you share some specific challenges you face when developing treatments for rare pediatric diseases?\n",
            "### Search Tavili ####\n",
            "### Search Wikipedia ####\n",
            "### Search Pubmed ####\n",
            "### Search Semantic Scholar ####\n",
            "### Generate Answer ####\n",
            "### Routing Messages ####\n",
            "### Generate Question ####\n",
            "QUESTION: Thank you for sharing those insights, Dr. Nguyen. Could you provide a specific example of a rare pediatric disease you've worked on and how you approached these challenges in its drug development?\n",
            "### Search Tavili ####\n",
            "### Search Pubmed ####\n",
            "### Search Wikipedia ####\n",
            "### Search Semantic Scholar ####\n",
            "### Generate Answer ####\n",
            "### Routing Messages ####\n",
            "### Generate Question ####\n",
            "QUESTION: That's fascinating, Dr. Nguyen. Could you elaborate on how computational methods are used in drug repurposing for neuroblastoma? What specific tools or techniques are involved?\n",
            "### Search Tavili ####\n",
            "### Search Wikipedia ####\n",
            "### Search Pubmed ####\n",
            "### Search Semantic Scholar ####\n",
            "### Generate Answer ####\n",
            "### Routing Messages ####\n",
            "### Writting Section ####\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<IPython.core.display.Markdown object>"
            ],
            "text/markdown": "## Overcoming Challenges in Developing Therapies for Rare Pediatric Diseases\n\n### Summary\n\nThe development of new drugs for rare pediatric diseases presents unique challenges due to the small patient populations and high costs associated with drug development. These challenges are compounded by the need for innovative therapies that can significantly improve the quality of life for affected children. Dr. Nguyen's work focuses on addressing these challenges and bringing effective treatments to market.\n\nRare pediatric diseases often lack sufficient patient populations to conduct robust clinical trials, making it difficult to gather the necessary data for drug approval. This scarcity of data can hinder the development of effective treatments and delay the introduction of potentially life-saving therapies. Additionally, the high costs associated with drug development for rare diseases can deter pharmaceutical companies from investing in research and development, further limiting treatment options for patients [1].\n\nOne novel approach to overcoming these challenges is the use of drug repurposing, which involves finding new therapeutic uses for existing drugs. This strategy can accelerate the availability of treatments by leveraging known safety profiles and reducing development costs. Drug repurposing has shown promise in treating conditions like neuroblastoma, a challenging pediatric malignancy with limited treatment options [2]. By repurposing existing drugs, researchers can bring effective therapies to market more quickly, improving patient outcomes and quality of life.\n\nAnother innovative strategy is the use of international data partnerships to share information and resources across borders. The International Childhood Cancer Data Partnership, for example, aims to combine data from multiple countries to address complex challenges in pediatric cancer research. This collaborative effort can help answer research questions that would be difficult to tackle with limited data from individual countries [3].\n\nDespite these promising approaches, significant challenges remain. The transition of children with rare diseases from pediatric to adult care is one such challenge, as it requires careful coordination and planning to ensure continuity of care. The lack of standardized recommendations and protocols for this transition can lead to gaps in treatment and care, potentially impacting patient outcomes [4].\n\nIn conclusion, the development of therapies for rare pediatric diseases requires innovative approaches and collaborative efforts to overcome the inherent challenges. By leveraging strategies like drug repurposing and international data partnerships, researchers can accelerate the development of effective treatments and improve the quality of life for children affected by these conditions.\n\n### Sources\n[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143853/  \n[2] Pubmed: 39258785, \"Advances in the approaches used to repurpose drugs for neuroblastoma.\"  \n[3] Pubmed: 39799506, \"Making the Case for an International Childhood Cancer Data Partnership.\"  \n[4] \"The transition of children with rare diseases from pediatric to adult care\", M. Molnár, Judit Cs Sági, L. Szabó, Z. Grosz"
          },
          "metadata": {},
          "execution_count": 106
        }
      ],
      "source": [
        "from IPython.display import Markdown\n",
        "messages = [HumanMessage(f\"So you said you were writing an article on {topic}?\")]\n",
        "thread = {\"configurable\": {\"thread_id\": \"1\"}}\n",
        "interview = interview_graph.invoke({\"analyst\": analysts[2], \"messages\": messages, \"max_num_turns\": 3}, thread)\n",
        "Markdown(interview['sections'][0])"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "3b739e87-68bb-4e96-a86a-704e84240a6c",
      "metadata": {
        "id": "3b739e87-68bb-4e96-a86a-704e84240a6c"
      },
      "source": [
        "### Parallelze interviews: Map-Reduce\n",
        "Map-reduce operations are essential for efficient task decomposition and parallel processing. This approach involves breaking a task into smaller sub-tasks, processing each sub-task in parallel, and aggregating the results across all of the completed sub-tasks.\n",
        "\n",
        "\n",
        "https://langchain-ai.github.io/langgraph/how-tos/map-reduce/\n",
        "\n",
        "\n",
        "\n",
        "We parallelize the interviews via the `Send()` API, a map step.\n",
        "\n",
        "We combine them into the report body in a reduce step.\n",
        "![image.png](data:image/png;base64,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)\n",
        "### Finalize\n",
        "\n",
        "We add a final step to write an intro and conclusion to the final report."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "6a0042f9-5b9f-441a-9e8d-7d8189f44140",
      "metadata": {
        "id": "6a0042f9-5b9f-441a-9e8d-7d8189f44140"
      },
      "outputs": [],
      "source": [
        "import operator\n",
        "from typing import List, Annotated\n",
        "from typing_extensions import TypedDict\n",
        "\n",
        "class ResearchGraphState(TypedDict):\n",
        "    topic: str # Research topic\n",
        "    max_analysts: int # Number of analysts\n",
        "    human_analyst_feedback: str # Human feedback\n",
        "    analysts: List[Analyst] # Analyst asking questions\n",
        "    sections: Annotated[list, operator.add] # Send() API key\n",
        "    introduction: str # Introduction for the final report\n",
        "    content: str # Content for the final report\n",
        "    conclusion: str # Conclusion for the final report\n",
        "    final_report: str # Final report"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 107,
      "id": "c2224592-d2ff-469d-97bd-928809f896d7",
      "metadata": {
        "id": "c2224592-d2ff-469d-97bd-928809f896d7",
        "outputId": "9148c307-7084-400e-b77e-e144b31f570b",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        }
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "image/png": "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\n",
            "text/plain": [
              "<IPython.core.display.Image object>"
            ]
          },
          "metadata": {}
        }
      ],
      "source": [
        "from langgraph.constants import Send\n",
        "\n",
        "def initiate_all_interviews(state: ResearchGraphState):\n",
        "    \"\"\" This is the \"map\" step where we run each interview sub-graph using Send API \"\"\"\n",
        "\n",
        "    # Check if human feedback\n",
        "    human_analyst_feedback=state.get('human_analyst_feedback')\n",
        "    print(\"### INITIATE ALL INTERVIEWS ####\")\n",
        "    if human_analyst_feedback:\n",
        "        # Return to create_analysts\n",
        "        return \"create_analysts\"\n",
        "\n",
        "    # Otherwise kick off interviews in parallel via Send() API\n",
        "    else:\n",
        "        topic = state[\"topic\"]\n",
        "        return [Send(\"conduct_interview\", {\"analyst\": analyst,\n",
        "                                           \"messages\": [HumanMessage(\n",
        "                                               content=f\"So you said you were writing an article on {topic}?\"\n",
        "                                           )\n",
        "                                                       ]}) for analyst in state[\"analysts\"]]\n",
        "\n",
        "report_writer_instructions = \"\"\"You are a technical writer creating a report on this overall topic:\n",
        "\n",
        "{topic}\n",
        "\n",
        "You have a team of analysts. Each analyst has done two things:\n",
        "\n",
        "1. They conducted an interview with an expert on a specific sub-topic.\n",
        "2. They write up their finding into a memo.\n",
        "\n",
        "Your task:\n",
        "\n",
        "1. You will be given a collection of memos from your analysts.\n",
        "2. Think carefully about the insights from each memo.\n",
        "3. Consolidate these into a crisp overall summary that ties together the central ideas from all of the memos.\n",
        "4. Summarize the central points in each memo into a cohesive single narrative.\n",
        "\n",
        "To format your report:\n",
        "\n",
        "1. Use markdown formatting.\n",
        "2. Include no pre-amble for the report.\n",
        "3. Use no sub-heading.\n",
        "4. Start your report with a single title header: ## Insights\n",
        "5. Do not mention any analyst names in your report.\n",
        "6. Preserve any citations in the memos, which will be annotated in brackets, for example [1] or [2].\n",
        "7. Create a final, consolidated list of sources and add to a Sources section with the `## Sources` header.\n",
        "8. List your sources and authors in order and do not repeat.\n",
        "\n",
        "[1] Source 1\n",
        "[2] Source 2\n",
        "\n",
        "Here are the memos from your analysts to build your report from:\n",
        "\n",
        "{context}\"\"\"\n",
        "\n",
        "def write_report(state: ResearchGraphState):\n",
        "    # Full set of sections\n",
        "    sections = state[\"sections\"]\n",
        "    topic = state[\"topic\"]\n",
        "    print(\"### WRITE REPORT ####\")\n",
        "    # Concat all sections together\n",
        "    formatted_str_sections = \"\\n\\n\".join([f\"{section}\" for section in sections])\n",
        "\n",
        "    # Summarize the sections into a final report\n",
        "    system_message = report_writer_instructions.format(topic=topic, context=formatted_str_sections)\n",
        "    report = llm.invoke([SystemMessage(content=system_message)]+[HumanMessage(content=f\"Write a report based upon these memos.\")])\n",
        "    return {\"content\": report.content}\n",
        "\n",
        "intro_conclusion_instructions = \"\"\"You are a technical writer finishing a report on {topic}\n",
        "\n",
        "You will be given all of the sections of the report.\n",
        "\n",
        "You job is to write a crisp and compelling introduction or conclusion section.\n",
        "\n",
        "The user will instruct you whether to write the introduction or conclusion.\n",
        "\n",
        "Include no pre-amble for either section.\n",
        "\n",
        "Target around 100 words, crisply previewing (for introduction) or recapping (for conclusion) all of the sections of the report.\n",
        "\n",
        "Use markdown formatting.\n",
        "\n",
        "For your introduction, create a compelling title and use the # header for the title.\n",
        "\n",
        "For your introduction, use ## Introduction as the section header.\n",
        "\n",
        "For your conclusion, use ## Conclusion as the section header.\n",
        "\n",
        "Here are the sections to reflect on for writing: {formatted_str_sections}\"\"\"\n",
        "\n",
        "def write_introduction(state: ResearchGraphState):\n",
        "    # Full set of sections\n",
        "    sections = state[\"sections\"]\n",
        "    topic = state[\"topic\"]\n",
        "    print(\"### WRITE INTRODUCTION ####\")\n",
        "    # Concat all sections together\n",
        "    formatted_str_sections = \"\\n\\n\".join([f\"{section}\" for section in sections])\n",
        "\n",
        "    # Summarize the sections into a final report\n",
        "\n",
        "    instructions = intro_conclusion_instructions.format(topic=topic, formatted_str_sections=formatted_str_sections)\n",
        "    intro = llm.invoke([instructions]+[HumanMessage(content=f\"Write the report introduction\")])\n",
        "    return {\"introduction\": intro.content}\n",
        "\n",
        "def write_conclusion(state: ResearchGraphState):\n",
        "    # Full set of sections\n",
        "    sections = state[\"sections\"]\n",
        "    topic = state[\"topic\"]\n",
        "    print(\"### WRITE CONCLUSION ####\")\n",
        "    # Concat all sections together\n",
        "    formatted_str_sections = \"\\n\\n\".join([f\"{section}\" for section in sections])\n",
        "\n",
        "    # Summarize the sections into a final report\n",
        "\n",
        "    instructions = intro_conclusion_instructions.format(topic=topic, formatted_str_sections=formatted_str_sections)\n",
        "    conclusion = llm.invoke([instructions]+[HumanMessage(content=f\"Write the report conclusion\")])\n",
        "    return {\"conclusion\": conclusion.content}\n",
        "\n",
        "def finalize_report(state: ResearchGraphState):\n",
        "    \"\"\" The is the \"reduce\" step where we gather all the sections, combine them, and reflect on them to write the intro/conclusion \"\"\"\n",
        "    # Save full final report\n",
        "    content = state[\"content\"]\n",
        "    print(\"### FINALIZE REPORT ####\")\n",
        "    if content.startswith(\"## Insights\"):\n",
        "        content = content.strip(\"## Insights\")\n",
        "    if \"## Sources\" in content:\n",
        "        try:\n",
        "            content, sources = content.split(\"\\n## Sources\\n\")\n",
        "        except:\n",
        "            sources = None\n",
        "    else:\n",
        "        sources = None\n",
        "\n",
        "    final_report = state[\"introduction\"] + \"\\n\\n---\\n\\n\" + content + \"\\n\\n---\\n\\n\" + state[\"conclusion\"]\n",
        "    if sources is not None:\n",
        "        final_report += \"\\n\\n## Sources\\n\" + sources\n",
        "    return {\"final_report\": final_report}\n",
        "\n",
        "# Add nodes and edges\n",
        "builder = StateGraph(ResearchGraphState)\n",
        "builder.add_node(\"create_analysts\", create_analysts)\n",
        "builder.add_node(\"human_feedback\", human_feedback)\n",
        "builder.add_node(\"conduct_interview\", interview_builder.compile())\n",
        "builder.add_node(\"write_report\",write_report)\n",
        "builder.add_node(\"write_introduction\",write_introduction)\n",
        "builder.add_node(\"write_conclusion\",write_conclusion)\n",
        "builder.add_node(\"finalize_report\",finalize_report)\n",
        "\n",
        "# Logic\n",
        "builder.add_edge(START, \"create_analysts\")\n",
        "builder.add_edge(\"create_analysts\", \"human_feedback\")\n",
        "builder.add_conditional_edges(\"human_feedback\", initiate_all_interviews, [\"create_analysts\", \"conduct_interview\"])\n",
        "builder.add_edge(\"conduct_interview\", \"write_report\")\n",
        "builder.add_edge(\"conduct_interview\", \"write_introduction\")\n",
        "builder.add_edge(\"conduct_interview\", \"write_conclusion\")\n",
        "builder.add_edge([\"write_conclusion\", \"write_report\", \"write_introduction\"], \"finalize_report\")\n",
        "builder.add_edge(\"finalize_report\", END)\n",
        "\n",
        "# Compile\n",
        "memory = MemorySaver()\n",
        "graph = builder.compile(interrupt_before=['human_feedback'], checkpointer=memory)\n",
        "display(Image(graph.get_graph(xray=1).draw_mermaid_png()))"
      ]
    },
    {
      "cell_type": "markdown",
      "id": "1b64ba9a-2b5e-40e1-a778-0f635aa3f6d0",
      "metadata": {
        "id": "1b64ba9a-2b5e-40e1-a778-0f635aa3f6d0"
      },
      "source": [
        "Let's ask an open-ended question about LangGraph."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 108,
      "id": "362932ee-4106-4a2d-a32d-b812eafcf9df",
      "metadata": {
        "id": "362932ee-4106-4a2d-a32d-b812eafcf9df",
        "outputId": "1af6b41d-1904-48e3-a017-816000f09f23",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Name: Dr. Emily Carter\n",
            "Affiliation: Children's Rare Disease Research Institute\n",
            "Role: Pediatric Geneticist\n",
            "Description: Dr. Carter focuses on the genetic underpinnings of rare diseases in children. Her primary concern is identifying genetic markers that can lead to early diagnosis and potential gene therapies. She is motivated by the potential to improve early intervention strategies and enhance the quality of life for affected children.\n",
            "--------------------------------------------------\n",
            "Name: Mr. John Thompson\n",
            "Affiliation: National Health Policy Center\n",
            "Role: Health Policy Analyst\n",
            "Description: Mr. Thompson analyzes the impact of health policies on the availability and accessibility of treatments for rare diseases in children. He is concerned with policy gaps that may hinder research funding and access to care. His motive is to advocate for policies that support comprehensive care and research funding for rare pediatric diseases.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Aisha Khan\n",
            "Affiliation: Global Pediatric Health Organization\n",
            "Role: Epidemiologist\n",
            "Description: Dr. Khan studies the prevalence and distribution of rare diseases in children globally. Her focus is on identifying patterns and risk factors associated with these diseases. She is motivated by the need to inform public health strategies and improve global awareness and resource allocation for rare pediatric diseases.\n",
            "--------------------------------------------------\n",
            "Name: Ms. Laura Bennett\n",
            "Affiliation: Rare Disease Advocacy Network\n",
            "Role: Patient Advocate\n",
            "Description: Ms. Bennett works closely with families affected by rare diseases in children. Her focus is on raising awareness and providing support to families navigating the healthcare system. She is driven by the desire to empower families and ensure their voices are heard in research and policy discussions.\n",
            "--------------------------------------------------\n"
          ]
        }
      ],
      "source": [
        "# Inputs\n",
        "max_analysts = 4\n",
        "#topic = \"The benefits of adopting a healthy life style to prevent cardiovascular conditions\"\n",
        "thread = {\"configurable\": {\"thread_id\": \"1\"}}\n",
        "\n",
        "# Run the graph until the first interruption\n",
        "for event in graph.stream({\"topic\":topic,\n",
        "                           \"max_analysts\":max_analysts},\n",
        "                          thread,\n",
        "                          stream_mode=\"values\"):\n",
        "\n",
        "    analysts = event.get('analysts', '')\n",
        "    if analysts:\n",
        "        for analyst in analysts:\n",
        "            print(f\"Name: {analyst.name}\")\n",
        "            print(f\"Affiliation: {analyst.affiliation}\")\n",
        "            print(f\"Role: {analyst.role}\")\n",
        "            print(f\"Description: {analyst.description}\")\n",
        "            print(\"-\" * 50)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 109,
      "id": "ac521a5f-5a4f-44f9-8af9-d05228e20882",
      "metadata": {
        "id": "ac521a5f-5a4f-44f9-8af9-d05228e20882",
        "outputId": "d06099c7-dd0c-4652-bda8-15558c891a27",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### INITIATE ALL INTERVIEWS ####\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'configurable': {'thread_id': '1',\n",
              "  'checkpoint_ns': '',\n",
              "  'checkpoint_id': '1efd9098-7602-6e63-8002-0ca76c8e39cc'}}"
            ]
          },
          "metadata": {},
          "execution_count": 109
        }
      ],
      "source": [
        "# We now update the state as if we are the human_feedback node\n",
        "graph.update_state(thread, {\"human_analyst_feedback\":\n",
        "                                \"Add somebody with Pharmaceutical reasearch Background   \"}, as_node=\"human_feedback\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 110,
      "id": "a3be311f-62ee-49e7-b037-75c53d8960a8",
      "metadata": {
        "id": "a3be311f-62ee-49e7-b037-75c53d8960a8",
        "outputId": "dd9c3484-c4de-4460-ab98-98780739c351",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Name: Dr. Emily Carter\n",
            "Affiliation: Children's Rare Disease Research Institute\n",
            "Role: Pediatric Geneticist\n",
            "Description: Dr. Carter focuses on the genetic underpinnings of rare diseases in children. Her primary concern is identifying genetic markers that can lead to early diagnosis and potential gene therapies. She is motivated by the potential to improve early intervention strategies and enhance the quality of life for affected children.\n",
            "--------------------------------------------------\n",
            "Name: Mr. John Thompson\n",
            "Affiliation: National Health Policy Center\n",
            "Role: Health Policy Analyst\n",
            "Description: Mr. Thompson analyzes the impact of health policies on the availability and accessibility of treatments for rare diseases in children. He is concerned with policy gaps that may hinder research funding and access to care. His motive is to advocate for policies that support comprehensive care and research funding for rare pediatric diseases.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Aisha Khan\n",
            "Affiliation: Global Pediatric Health Organization\n",
            "Role: Epidemiologist\n",
            "Description: Dr. Khan studies the prevalence and distribution of rare diseases in children globally. Her focus is on identifying patterns and risk factors associated with these diseases. She is motivated by the need to inform public health strategies and improve global awareness and resource allocation for rare pediatric diseases.\n",
            "--------------------------------------------------\n",
            "Name: Ms. Laura Bennett\n",
            "Affiliation: Rare Disease Advocacy Network\n",
            "Role: Patient Advocate\n",
            "Description: Ms. Bennett works closely with families affected by rare diseases in children. Her focus is on raising awareness and providing support to families navigating the healthcare system. She is driven by the desire to empower families and ensure their voices are heard in research and policy discussions.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Emily Carter\n",
            "Affiliation: Children's Hospital Research Institute\n",
            "Role: Pediatric Geneticist\n",
            "Description: Dr. Carter focuses on the genetic underpinnings of rare diseases in children. Her primary concern is identifying genetic markers that can lead to early diagnosis and intervention. She is motivated by the potential to improve patient outcomes through personalized medicine.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Raj Patel\n",
            "Affiliation: National Institute of Health\n",
            "Role: Epidemiologist\n",
            "Description: Dr. Patel studies the prevalence and distribution of rare diseases in pediatric populations. His work involves analyzing data to identify patterns and potential environmental or genetic risk factors. He aims to inform public health strategies and policy decisions to better address these diseases.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Sarah Thompson\n",
            "Affiliation: Global Rare Disease Foundation\n",
            "Role: Patient Advocate and Policy Advisor\n",
            "Description: Dr. Thompson advocates for children with rare diseases and their families. She focuses on improving access to care, raising awareness, and influencing policy to support research funding. Her motivation is to ensure that patients receive the necessary support and resources.\n",
            "--------------------------------------------------\n",
            "Name: Dr. Michael Lee\n",
            "Affiliation: PharmaGenix\n",
            "Role: Pharmaceutical Researcher\n",
            "Description: Dr. Lee is involved in the development of new treatments for rare pediatric diseases. His research focuses on drug discovery and development, aiming to bring innovative therapies to market. He is driven by the challenge of addressing unmet medical needs and improving quality of life for affected children.\n",
            "--------------------------------------------------\n"
          ]
        }
      ],
      "source": [
        "# Check\n",
        "for event in graph.stream(None, thread, stream_mode=\"values\"):\n",
        "    analysts = event.get('analysts', '')\n",
        "    if analysts:\n",
        "        for analyst in analysts:\n",
        "            print(f\"Name: {analyst.name}\")\n",
        "            print(f\"Affiliation: {analyst.affiliation}\")\n",
        "            print(f\"Role: {analyst.role}\")\n",
        "            print(f\"Description: {analyst.description}\")\n",
        "            print(\"-\" * 50)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 111,
      "id": "0af41f54-88d9-4597-98b0-444c08322095",
      "metadata": {
        "id": "0af41f54-88d9-4597-98b0-444c08322095",
        "outputId": "082711a4-3543-4e57-e56d-b6c487d87e77",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### INITIATE ALL INTERVIEWS ####\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "{'configurable': {'thread_id': '1',\n",
              "  'checkpoint_ns': '',\n",
              "  'checkpoint_id': '1efd9099-b1be-6122-8004-48e4aa48a1ae'}}"
            ]
          },
          "metadata": {},
          "execution_count": 111
        }
      ],
      "source": [
        "# Confirm we are happy\n",
        "graph.update_state(thread, {\"human_analyst_feedback\":\n",
        "                            None}, as_node=\"human_feedback\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 112,
      "id": "37123ca7-c20b-43c1-9a71-39ba344e7ca6",
      "metadata": {
        "id": "37123ca7-c20b-43c1-9a71-39ba344e7ca6",
        "outputId": "dd70c3af-6326-4af5-da7d-c5a87d8f8669",
        "colab": {
          "base_uri": "https://localhost:8080/"
        }
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "### Generate Question ####\n",
            "### Generate Question ####\n",
            "### Generate Question ####\n",
            "### Generate Question ####\n",
            "QUESTION: Hello, my name is Emily Carter, and I'm a health journalist focusing on pediatric health issues. I'm particularly interested in the work you're doing on rare diseases in children. Could you share some insights into how you identify patterns in the prevalence of these diseases? Are there any surprising trends you've discovered in your research?\n",
            "QUESTION: Hello, I'm Alex Thompson, a science journalist focusing on medical advancements. I'm thrilled to have the opportunity to speak with you, Dr. Carter. To start, could you share an example of a rare disease in children where identifying genetic markers has significantly improved early diagnosis and intervention?\n",
            "QUESTION: Hello, I'm Alex Carter, a health and science journalist. I'm currently working on an article about rare pediatric diseases and the innovative treatments being developed to address them. Dr. Lee, could you share what initially drew you to focus on rare pediatric diseases in your research?\n",
            "QUESTION: Hello, I'm Alex Carter, a journalist focusing on healthcare and policy issues. I'm really interested in learning more about your work with the Global Rare Disease Foundation. Could you share some specific examples of how you've successfully improved access to care for children with rare diseases?\n",
            "### Search Wikipedia ####\n",
            "### Search Pubmed ####\n",
            "### Search Tavili ####\n",
            "### Search Tavili ####\n",
            "### Search Wikipedia ####\n",
            "### Search Pubmed ####\n",
            "### Search Tavili ####\n",
            "### Search Pubmed ####\n",
            "### Search Wikipedia ####\n",
            "### Search Tavili ####\n",
            "### Search Semantic Scholar ####\n",
            "### Search Wikipedia ####\n",
            "### Search Pubmed ####\n",
            "### Search Semantic Scholar ####\n",
            "### Search Semantic Scholar ####\n",
            "### Search Semantic Scholar ####\n",
            "### Generate Answer ####\n",
            "### Generate Answer ####\n",
            "### Routing Messages ####\n",
            "### Generate Question ####\n",
            "QUESTION: That's fascinating, Dr. Patel. Could you elaborate on how environmental factors might interact with genetic predispositions in these rare diseases? Are there any specific examples where you've seen this interaction play a significant role?\n",
            "### Routing Messages ####\n",
            "### Generate Question ####\n",
            "### Search Wikipedia ####\n",
            "### Generate Answer ####\n",
            "### Search Tavili ####\n",
            "### Search Pubmed ####\n",
            "QUESTION: That's fascinating, Dr. Carter. Could you elaborate on how these genetic markers are identified? What technologies or methods are primarily used in your research to pinpoint these markers in children?\n",
            "### Search Wikipedia ####\n",
            "### Search Semantic Scholar ####\n",
            "### Search Tavili ####\n",
            "### Search Pubmed ####\n",
            "### Search Semantic Scholar ####\n",
            "### Generate Answer ####\n",
            "### Routing Messages ####\n",
            "### Generate Question ####\n",
            "### Routing Messages ####\n",
            "### Generate Question ####\n",
            "QUESTION: That's fascinating, Dr. Lee. Could you provide an example of a specific rare pediatric disease that you are currently working on, and what makes it particularly challenging to develop a treatment for?\n",
            "### Search Wikipedia ####\n",
            "### Search Tavili ####\n",
            "### Search Pubmed ####\n",
            "QUESTION: Thank you for sharing those examples. I'm curious, could you provide a specific instance where your advocacy work directly influenced policy changes that benefited children with rare diseases?\n",
            "### Search Tavili ####\n",
            "### Search Wikipedia ####\n",
            "### Search Pubmed ####\n",
            "### Search Semantic Scholar ####\n",
            "### Generate Answer ####\n",
            "### Search Semantic Scholar ####\n",
            "### Generate Answer ####\n",
            "### Routing Messages ####\n",
            "### Writting Section ####\n",
            "### Generate Answer ####\n",
            "### Generate Answer ####\n",
            "### Routing Messages ####\n",
            "### Writting Section ####\n",
            "### Routing Messages ####\n",
            "### Writting Section ####\n",
            "### Routing Messages ####\n",
            "### Writting Section ####\n",
            "--Node--\n",
            "conduct_interview\n",
            "--Node--\n",
            "conduct_interview\n",
            "--Node--\n",
            "conduct_interview\n",
            "--Node--\n",
            "conduct_interview\n",
            "### WRITE REPORT ####\n",
            "### WRITE INTRODUCTION ####\n",
            "### WRITE CONCLUSION ####\n",
            "--Node--\n",
            "write_conclusion\n",
            "--Node--\n",
            "write_introduction\n",
            "--Node--\n",
            "write_report\n",
            "### FINALIZE REPORT ####\n",
            "--Node--\n",
            "finalize_report\n"
          ]
        }
      ],
      "source": [
        "# Continue\n",
        "for event in graph.stream(None, thread, stream_mode=\"updates\"):\n",
        "    print(\"--Node--\")\n",
        "    node_name = next(iter(event.keys()))\n",
        "    print(node_name)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 113,
      "id": "f8f66ad8-80fd-4eb2-96b6-6ae9dffd060c",
      "metadata": {
        "id": "f8f66ad8-80fd-4eb2-96b6-6ae9dffd060c",
        "outputId": "a3e9d946-f673-4cd1-d824-c2ea5d9bd1f7",
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        }
      },
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "<IPython.core.display.Markdown object>"
            ],
            "text/markdown": "# Unraveling the Complexities of Rare Pediatric Diseases\n\n## Introduction\n\nRare diseases in children present a unique set of challenges, demanding early diagnosis and intervention to improve patient outcomes. This report delves into the genetic intricacies of these conditions, highlighting Dr. Carter's work on genetic markers and early testing. It explores groundbreaking studies, such as those in Saudi Arabia, that reveal novel genetic variants and underscore the importance of early intervention. Dr. Patel's research further illuminates the role of genetic and environmental factors, while Dr. Thompson advocates for equitable healthcare access. Finally, innovative therapies and personalized medicine offer new hope, bridging gaps in treatment and care for affected children.\n\n---\n\n\n\nThe landscape of rare diseases in children is marked by complex genetic underpinnings, unique challenges in diagnosis and treatment, and significant disparities in healthcare access. Recent advancements in genetic research and personalized medicine offer promising avenues for early diagnosis and intervention, which are crucial for improving patient outcomes. Genetic testing, such as whole exome and genome sequencing, has revolutionized the diagnostic process by identifying pathogenic variants and informing personalized treatment plans [1][5]. Early intervention is pivotal, as it reduces the time to diagnosis and enables more effective treatment strategies, ultimately improving the quality of life for affected children [3][4].\n\nResearch highlights the significant role of genetic factors in the manifestation of rare diseases, with approximately 80% of these conditions having genetic origins and half manifesting in childhood [2]. Studies, such as those conducted in Saudi Arabia, have expanded the spectrum of known genetic variants, underscoring the importance of genetic screening in early diagnosis [1]. Additionally, the interaction between genetic predispositions and environmental factors plays a crucial role in disease manifestation, necessitating comprehensive treatment plans that consider both influences [4].\n\nThe development of innovative therapies is a critical area of research, driven by the need to address unmet medical needs. Personalized medicine, guided by genetic testing, has enabled the development of targeted therapies, such as vosoritide for achondroplasia, improving treatment efficacy and minimizing side effects [1]. Innovative clinical trial designs are essential for accommodating small patient populations, accelerating the approval of new therapies, and ensuring timely access for patients [2].\n\nAdvocacy and policy development are vital in addressing the disparities in healthcare access and outcomes for children with rare diseases. Global inequalities, such as those seen in the treatment of spinal muscular atrophy, highlight the need for international collaboration and policy reform to ensure equitable access to life-saving therapies [1]. The integration of genomics into healthcare, as demonstrated by initiatives like the Australian Genomics program, offers promising advancements for rare disease diagnosis and treatment [3].\n\nThe transition from pediatric to adult care poses additional challenges, requiring coordinated efforts to ensure seamless care and support for patients as they age [3]. Public health policies and regulatory frameworks play a crucial role in facilitating drug development for rare pediatric diseases, with recent efforts focusing on patient-centered outcomes and increased patient engagement in clinical trials [4].\n\nIn conclusion, the insights gathered from recent studies and expert opinions emphasize the importance of genetic testing, early intervention, innovative therapies, and comprehensive advocacy in managing rare pediatric diseases. By addressing these challenges, the scientific and medical communities can work towards improving outcomes and quality of life for children with rare diseases.\n\n\n---\n\n## Conclusion\n\nThis report underscores the critical importance of early diagnosis and intervention in managing rare pediatric diseases, as highlighted by Dr. Carter's research on genetic markers. The studies from Saudi Arabia and other regions emphasize the role of genetic testing in identifying novel variants, which is crucial for timely intervention. Dr. Patel's work further illuminates the genetic and environmental factors influencing these diseases, advocating for genetic counseling and comprehensive healthcare strategies. Dr. Thompson's advocacy highlights the disparities in access to care and the need for policy reform. Finally, advancements in innovative therapies and personalized medicine offer hope for improved outcomes, bridging gaps in treatment and care for affected children.\n\n## Sources\n\n[1] Monogenic interferon-mediated diseases: novel phenotype and genotype characteristics from a Saudi population, Alhanouf Al-Saleem, Shahad A. Alansari, Mohammed Almuhaizea, Sulaiman M Al-Mayouf  \n[2] Intractable and rare diseases research, W. Tang, M. Makuuchi  \n[3] https://www.tgen.org/patients/center-for-rare-childhood-disorders/stories/early-intervention-is-crucial-for-better-outcomes-for-children-with-rare-diseases/  \n[4] https://fdna.com/health/resource-center/rare-genetic-syndromes-and-their-impact-on-child-development/  \n[5] https://www.nature.com/articles/s41390-024-03728-w  \n[6] Whole-genome sequencing reveals contribution of rare and common variation to structural kidney and urinary tract malformations, M. Chan, O. Sadeghi-Alavijeh, C. Voinescu, et al.  \n[7] Evaluating Anaemia Treatment in Associated Diseases in Children in Port Harcourt, Nigeria, Chijioke-Nwauche In, Origbo Cc  \n[8] https://fdna.com/health/resource-center/the-5-most-common-rare-diseases-in-children/  \n[9] https://pmc.ncbi.nlm.nih.gov/articles/PMC3647367/  \n[10] Pubmed: Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability.  \n[11] Pubmed: The psychosocial impact of childhood dementia on children and their parents: a systematic review.  \n[12] Pubmed: Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare.  \n[13] Pubmed: Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.  \n[14] \"Consensus Guidelines for the Use of Vosoritide in Children with Achondroplasia in Australia,\" Pubmed.  \n[15] \"Innovative strategies for trial design,\" Authors: B. Feldman.  \n[16] \"[The transition of children with rare diseases from pediatric to adult care],\" Authors: M. Molnár, Judit Cs Sági, L. Szabó, Z. Grosz.  \n[17] \"Development of Medicines for Rare Pediatric Diseases - PMC,\" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143853/."
          },
          "metadata": {},
          "execution_count": 113
        }
      ],
      "source": [
        "from IPython.display import Markdown\n",
        "final_state = graph.get_state(thread)\n",
        "report = final_state.values.get('final_report')\n",
        "Markdown(report)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "id": "808bd094",
      "metadata": {
        "id": "808bd094"
      },
      "outputs": [],
      "source": []
    }
  ],
  "metadata": {
    "kernelspec": {
      "display_name": "Python 3 (ipykernel)",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.12.1"
    },
    "colab": {
      "provenance": [],
      "include_colab_link": true
    }
  },
  "nbformat": 4,
  "nbformat_minor": 5
}